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Abstract
Cancer is a leading cause of death worldwide. Chemotherapy is the main approach used 
currently for the treatment and management of this disease especially disseminated 
malignant tumours. Traditional anticancer drugs have a limited selectivity as they target 
mainly DNA synthesis or cell proliferation leading to severe side effects. However, the 
newer anti-cancer drugs are more selective in targeting certain aberrant signalling 
pathways in cancer cells.
In the first part of this work, a series of benzimidazole and indole analogues of a potent 
antitumour benzothiazole lead compound were synthesised to enhance its pharmaceutical 
properties. Their antitumour activity was tested against different human cancer cell lines. 
In most cases, these analogues did not display any significant activity except for some of 
the N-substituted ones with p-toluenesulfonyl group, which yielded submicromolar GI50  
values.
The second part of the work focuses on the design and synthesis of antitumour agents 
targeting the Wnt signalling pathway. The aberrant activation of this signalling pathway 
has been implicated in a wide spectrum of cancers. Disheveled PDZ domain is an 
essential protein-protein interaction mediator in the Wnt signalling pathway. Novel 
anti tumour agents were designed using molecular modelling approaches to selectively 
inhibit the PDZ domain and hence abolish tumouregenic effects associated with the 
aberrant activation of Wnt signalling. Biochemical binding assays showed that one of the 
hits obtained through high-throughput docking binds specifically to the Disheveled PDZ 
domain. Structural optimisation studies of this hit were also carried out in order to 
improve activity.
Part 1
The synthesis and biological 
evaluation of novel benzimidazole and 
indole based antitumour compounds
Chapter One
1. INTRODUCTION
Introduction
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Chapter One Introduction
1.1. Cancer
Cancer is a group of diseases characterised by unregulated growth and abnormal division 
of cells, which attain the ability to invade adjacent tissues or spread from their site of 
origin to other sites and anatomical parts in the body.1 Cancer is considered a leading 
cause of death worldwide. According to the World Health Organization (WHO), cancer 
accounted for 7.6 million (13%) of all deaths worldwide in 2005.2 Moreover, these 
figures are expected to continue rising to reach an estimated 9 million (2015) and 11.4 
million (2030) cancer-related deaths.2 It is also expected that cancer rates could increase 
from 10 million new cases globally in 2000 to 15 million new cases in 2020.2While 
various factors may well contribute to this estimated sharp increase in new cases, the 
worldwide steadily ageing population is recognised as the chief factor.3
The tissue of origin confers cancer distinct characteristics and features and therefore, over 
one hundred cancer types have been classified which can be divided into the following 
main categories.
Carcinomas: this class originates from epithelial cells and represents the most 
widespread group of cancers (85%) including the common forms of breast, lung, prostate 
and colon cancer.
Sarcomas: these type of cancers are derived from the connective tissue cells which 
originate from embryonic mesoderm such as bone, cartilage, fat, muscle and blood 
vessels.
Lymphomas: cancers of the lymphatic system, which often arise in the lymph nodes. 
Leukaemia: cancer of the blood or bone marrow.
Blastoma: these cancers are most common in children and are derived from primitive or 
incompletely differentiated cells. Most common examples in this class include 
nephroblastoma (kidneys), medulloblastoma (cerebellum) and retinoblastoma (retina). 
Germ cell tumours: tumours derived from germ cells and the most common cancers of 
this group are ovarian and testicular cancers.
2
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1.2. Causes and risk factors
The massive research endeavour in the pathology and molecular biology of cancer over 
the past few decades has established that this disease develops due to abnormalities at the 
genetic level with mutations or alterations of mainly two gene classes; oncogenes and 
tumour suppressor genes.4 Alterations to DNA sequences of these two gene classes 
trigger a rather complicated series of events at the cellular level leading to the multistage 
formation of tumour cells. These alterations can occur as a result of a combination of 
genetic factors and external factors which can be divided into three main categories 
including; physical, chemical and biological carcinogens (cancer causing substances or 
agents).
1.2.1. Physical carcinogens: examples include ultraviolet (UV) and ionizing radiation, 
which can damage cellular DNA causing formation of tumour cells. The primary source 
for UV radiation is sunlight and prolonged exposure is associated with increased risk of 
developing melanoma and skin cancers. Ionizing radiation particles (a and p particles) as 
well as X-ray and y-rays are known to cause DNA fragmentation through the formation 
of free radicals.3
1.2.2. Chemical carcinogens: examples include but not limited to; asbestos, components 
of tobacco smoke and anatoxins.6*8 While prolonged exposure to the microscopic fibers 
of the insulating material asbestos is linked particularly to mesothelioma, tobacco 
smoking is a known cause of many forms of cancer and mainly lung cancer (90% of 
cases). Aflatoxins are potent carcinogens, which are produced by many fungus species 
and can gain entry to the body through contaminated food. Once ingested, these 
carcinogens can get metabolized to the highly reactive epoxide intermediates, which can 
cause DNA damage and ultimately lead to a tumour.
IJ23. Biological carcinogens: examples include certain bacterial and viral infections, 
which are estimated to account for up to 20% of all cancers.9For bacterial infections, the 
most prominent example is the finding that chronic infection with Helicobactor pylori is
3
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the main leading cause for developing gastric cancers.10 On the other hand, viruses are 
linked to a variety of human malignancies including the role of Epstein Barr virus (EBV) 
in Burkitfs lymphoma, the human papillomavirus (cervical carcinoma) and hepatitis B 
and hepatitis C (liver cancer).9
Nevertheless, the aforementioned causes do not represent by any means an exhaustive 
list; indeed, only a selection are presented and more causes and risk factors are still being 
identified by research studies. In most cases, it is the combination between these factors 
that lead to developing cancer, as it is a multifactorial disease. It is also worthy to note 
that while most cancers are generally not inherited, an increased predisposition to certain 
types of cancer have been linked to inheritance of some genes. For instance, inherited 
mutations in the genes BRCA1 and BRCA2 have been closely associated with breast and 
ovarian cancers.11
13. Hallmarks of cancer
The underlying cellular and molecular routes involved in the carcinogenesis process 
differ between cancer types but the end result is the same since all cancers share certain 
characteristics and features. In 2000, Hanahan and Weinberg defined and described six 
common hallmarks for most cancers: self-sufficiency in growth signals, insensitivity to 
anti-growth signals, apoptosis (programmed cell death) evasion, limitless replicative 
potential, sustained angiogenesis and metastasis (Figure 1).12
13.1.Self-sufficiency in growth signals: normal cells require mitogenic growth signals, 
which are transmitted into the cell from their normal tissue microenvironment by 
transmembrane receptors to move from a quiescent state into the active proliferative 
state. On the other hand, tumour cells develop the ability to generate their own growth 
signals. Three main strategies are used by tumour cells to acquire growth signal 
autonomy. These strategies involve the overexpression of extracellular growth factor 
(GF) receptors, alterations in components of the downstream cytoplasmic circuitry and
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alterations of extracellular matrix receptors (integrin). For instance, HER2/neureceptor is 
upregulated in stomach and mammary carcinomas. 13Oncogenes activate cellular 
proliferation, leading to unregulated cell growth and differentiation. Most of these 
oncogenes are derived from a non-mutant version of genes known as proto-oncogenes, 
which are usually involved in normal cellular growth. Examples of oncogenes include 
ras, which is known to be mutated in up to 15% of all cancer, myc and abl.14
13.2. Insensitivity to growth inhibitory signals: normal cells also require anti-growth 
signals, which operate to maintain cellular quiescence and tissue homeostasis. These anti­
growth signals can block cell proliferation by forcing cells into the quiescent state (Go of 
cell cycle) or by inducing their terminal differentiation to enter a postmitotic state where 
they are no longer able to re-enter the cell cycle. Cancer may arise from inactivation or 
malfunction of genes that normally suppress cell proliferation. This inhibitory signalling 
is mediated by ligands acting on cellular receptors such as transforming growth factor 
beta (TGF-p), and its receptor (TGF-P receptor) to transduce signals to the nucleus via 
secondary messengers.15 These pathways involve mainly proteins such as retinoblastoma 
protein (Rb), cyclins, cyclin-dependent kinases (CDK) and their inhibitors (CDKi) to 
finely control the cell cycle clock.15 Aberrant activation of these inhibitory pathways is 
associated with tumourgenesis. For instance, loss of Rb or members of the CDKi family 
and overexpression of certain cyclins and CDK have been implicated in a range of 
tumours.16
133. Evading apoptosis: the number of cells is maintained relatively constant through 
means of cell death and division. It follows that there is a continuous process of assessing 
the balance of anti-apoptotic(survival) and pro-apoptotic (death) signals received by 
cells.In normal cells, cell cycle arrestoccurs as a result of DNA damage to enable the 
potential repair. However, once damage exceeds the cell repair capacity, the balance of 
anti- and pro-apoptotic signals is lost and cells undergo programmed cell death 
(apoptosis) to avoid the risk that mutations are carried through the replicative process. 
Therefore, apoptosis represents a very powerful barrier to the development of cancer.
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Nonetheless, cancer cells can sustain DNA damage by directing the balance of 
intracellular pro-apoptotic and anti-apoptotic molecules in favour of inhibition of 
apoptosis. Indeed, the tumour suppressor gene p53 and the oncogene bcl-2 which are two 
of the best characterised cancer-associated genes are crucially involved in apoptosis.17,18
13.4. Limitless replicative potential: normal cells have a limited and a finite number of 
cell divisions, which can they undergo before they enter a replicative senescence. This is 
a period of permanent growth arrest. The process is driven by the inability of cells to 
fully replicate the ends of their chromosomes (the telomeres) at each division and as 
subsequently, telomeres get progressively shorter. On the other hand, cancer cells acquire 
the ability to maintain the length of their telomeres mostly through upregulation of the 
enzyme complex telomerase. Telomerase consists of two main components; an RNA 
template (hTR) and a reverse transcriptase (hTERT).19-21 This latter uses the RNA 
template as a guide in the resynthesis of the telomere DNA sequence which enables 
tumours to rebuild any lost telomere parts occurring at each round of cell division.
133. Sustained angiogenesis: in normal tissue, the process of angiogenesis which is the 
growth of new blood vessels is well controlled by a balance between the positive pro- 
angiogenic and the negative anti-angiogenic signals. Examples of pro-angiogenic signals 
include vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
(bFGF), acidic fibroblast growth factor (aFGF), transforming growth factors alpha and 
beta (TGF-a, TGF-P), platelet-derived growth factor (PDGF) and tumour necrosis factor 
alpha (TNF-a).22,23 On the other hand, anti-angiogenic signals include angiostatin, 
endostatin, interleukins (IL-ip, IL-12, IL-18) and anti-thrombin III.22,23Solid tumours 
acquire the ability to grow new blood vessels to ensure a sustained supply of oxygen and 
nutrients by subverting the controlled balance between the positive and negative 
angiogenic signals. It follows therefore that the production of pro-angiogenic proteins is 
upregulated while the anti-angiogenic proteins production is down-regulated by cancer 
cells.
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13.6. Tissue Invasion and metastasis: this is the process by which cancer spreads from 
its primary site where it first originated to distant parts of the body.24 It is very common 
in the late stages of the disease and accounts for 90% of cancer deaths. Metastasis 
involves a series of biological processes, which include the following:
• Detachment from immediate surrounding tissue at the local site mediated by the 
enzymatic digestion of the extracellular matrix.
• Specific directional motility and entry to blood or lymphatic vessels.
• Survival in the circulation until arrival at the metastatic site that may be chosen 
on the basis of provision of a favourable supply of appropriate growth factors.
• Adherence to the blood vessels endothelium at its destination and extravasation 
from the vessel.
• Proliferation and invasion of the new location.
• Angiogenesis initiation to ensure growth.
Research studies have established that metastasis is not a random process but rather 
driven by expression of specific chemokine receptors by tumour cells that allow them to 
find a suitable environment for colony establishment.25
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Figure I: The six hallmarks o f cancer (adapted from reference 12).
1.4. C urrent treatment for cancer
There are several approaches for cancer treatment and management, which include 
mainly surgery, radiotherapy, photodynamic therapy and chemotherapy. It is the case that 
most often more than one approach is used depending on the nature and stage o f the
8
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cancer. The treatment also depends on the patient’s general health condition, age and 
lifestyle.
1.4.1. Surgery: is the first modality used successfully in the treatment of cancer 
especially by removal of some common solid tumors. However, it is usually used in 
combination with chemotherapy and/or radiotherapy. The administration of 
chemotherapy and radiotherapy can be carried out either before surgery to shrink the 
tumour which facilitates its removal or most commonly after to ensure absence of any 
metastases or local infiltration. A large area of the surrounding normal tissue is also often 
removed during the process with the aim of achieving total eradication of cancer cells.
1.4.2. Radiotherapy: it is estimated that around 40% of cancer patients will receive 
radiotherapy at some point either as a form of treatment or to manage symptoms.26 The 
principal goal of this approach is to locally deliver a tumouricidal dose of ionizing 
radiation in the form of X-ray or y-rays to the cancer site without affecting the 
surrounding healthy tissue. The success of radiotherapy depends on the difference in 
radiosensitivity between tumour and normal tissue. Radiotherapy is usually categorized 
into three main types depending on method of delivery and position of radiation source: 
external beam radiotherapy (teletherapy, radiation source is outside the body), internal 
beam therapy (brachytherapy, radioactive source is placed in site of treatment) and 
systemic radioisotope therapy (radioisotopes administered by infusion or given orally). In 
this latter category, targeting can be achieved by attaching the radioisotope to an antibody 
or by exploiting the chemical properties of the isotope to achieve specific absorption at a 
given target site such as the use of iodine-131 (13,I) in the treatment of thyroid cancer.
In terms of side effects, radiotherapy is associated with acute complications which are 
often limited to the area being treated but systemic ones may occur which include fatigue, 
skin reactions, GI toxicity, oropharyngeal mucositis and myelosuppression. Long-term 
complications may occur months or years after treatment as a result of damage to blood 
vessels and connective tissue, which include an increased risk of developing both 
secondary leukaemia and solid tumours.
9
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1.43. Photodynamic therapy (PDT): PDT centers around the use of a radiation light of 
an appropriate wavelength to induce formation of cytotoxic free radicals in the targeted 
cancer cells.28 As well as a radiation source, PDT requires the use of a photosensitiser, 
which is selectively administered to the target tissue. A photosensitiser is a chemical 
compound (e.g. Photoffin), which can move from its ground state to an excited singlet 
state upon exposure to a light of a specific wavelength leading to the formation of 
reactive oxygen species. These free radicals undergo a series of rapid reactions with 
nearby biomolecules leading to damage and ultimately destruction of tumour cells 
through apoptosis and necrosis. Massive research efforts are currently undergoing in this 
area of cancer treatment especially in applying nanotechnology to photosensitisers.29
1.4.4. Chemotherapy: systemic chemotherapy is the main approach used currently for 
the treatment of disseminated malignant tumours. Traditional chemotherapy drugs can be 
grouped into alkylating agents, antimetabolites, anthracyclines, plant alkaloids and 
topisomerase inhibitors. While these classes of drugs affect mainly cell division or DNA 
synthesis, newer anti-cancer drugs are more selective in targeting certain aberrantly 
activated pathways in cancer cells. Examples of some current and prospective modalities 
of cancer treatments are listed in Table 1.
10
Category Function Examples
Antimetabolites Interfere with intermediary metabolism of proliferating cells Methotrexate, 5-Fluorouracil
Monoclonal Antibodies Target cancer cells that express specific antigen Herceptin, Zevalin
Mitosis Inhibitors Target microtubules and proteins required in cell division Taxol
Steroid hormones Block steroid and hormone-dependent growth of certain tumours Tamoxifen, Flutamide
Alkylating / cross-linking 
agents
Causes death of growing cells by damaging DNA Endoxan, Cisplatin, Cyclophosphamide
Signal-transduction agents Modulate communications between cells Gleevec, Tarceva, Iressa
Angiogenesis inhibitors Block blood vessel formation to tumour Avastin
Histone-deacetylase inhibitors Disrupts transcription of genes SAHA
Telemorase inhibitors Affect telomere maintenance required for tumour growth BIBR1532
Antitumour antibiotics Bind DNA to prevent DNA and/or RNA tsynthesis Doxorubicin, Etoposide
Table 1: Examples of some current and prospective modalities of cancer chemotherapy treatment (modified from reference 30).
11
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1.5. Cancer and drug discovery
The main focus of cancer drug discovery has traditionally been on targeting cell division 
and DNA synthesis leading to the identification of different anti-cancer drugs such as 
antimetabolites, alkylating, cross-linking and antimitotic agents. While such drugs have 
been proven to be effective, their selectivity for tumour cells over normal cells is limited 
leading to severe side effects.
Driven by the massive advances of cancer molecular and cellular biology, cancer drug 
discovery has become dominated by the target-driven approach in both academia and 
industry.31 It is argued that drugs discovered through this approach would achieve more 
selectivity to the molecular target and hence overcome the limitations experienced with 
most conventional chemotherapies which are based on DNA targeting and their immense 
adverse effects. Typically, in this approach, the identification and validation of a 
substantial target, which plays a major role in the formation of tumour is the first and 
most important step. The screening of small compound libraries comes next in order, a 
process that can be achieved through high throughout screening tools. Then, the 
identified hit molecule can be developed to a drug-like lead compound which may also 
require further optimisation to achieve some desired pharmaceutical properties before 
becoming a clinical drug candidate. Undoubtedly, the development of imatinib (Gleevec, 
Figure 2) which is used mainly for the treatment of chronic myelogenous leukemia 
(CML) through this approach and its success pushed more research groups to adopt this 
methodology of drug discovery.32
12
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Figure 2: Chemical structure of imatinib (Gleevec)
On the other hand, chemistry-driven drug discovery which can be considered as 
conducting the drug discovery process in a reverse manner is emerging as another 
approach in cancer drug discovery.33Unlike the targeted approach, small molecules not 
targets are the main focus and potential compound leads are selected based on their 
induction of particular phenotypic responses in cellular environment. These phenotypic 
changes can be analysed by screening tools such as the NCI-60 panel. The approach is 
best illustrated by the discoveiy of the novel antitumour agent Phortress.
1.5.1. Phortress: A novel, potent and selective antitumour agent.
Phortress is an experimental antitumour agent with potent and selective activity against 
human-derived carcinomas of breast, ovarian and renal origin. It is currently in Phase 1 
clinical trials in the Northern Institute for Cancer Research at Newcastle University. The 
discovery of this clinical antitumour agent is the result of iterative interactions between 
medicinal chemistry and pharmacology research groups.
13
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The start of the Phortress development was based on the observation that the compound 
2-(4-aminophenyl)benzothiazole (CJM 126, Figure 3) inhibited growth in the human 
derived breast cancer cell line MCF-7 at submicromolar concentrations. Subsequent 
structural optimisation studies led to the identification of the compound DF203 (2-(4- 
amino-3-methylphenyl)benzothiazole) with a remarkable differential activity in vitro and 
in vivo against a spectrum of tumour types including breast, ovarian, renal and colon 
cancers despite its simple structure.34 However, DF203 exhibited a unique biphasic dose- 
response relationship in sensitive cell lines. At low nanomolar concentration of this 
compound, cell growth inhibition occurs but this was followed by a second growth phase 
in that a proliferative response was noticed at higher (low micromolar) concentrations. It 
was found that at higher concentrations, DF203 metabolism led to the production of a 
hydroxylated derivative (2-(4-amino-3-methylphenyl)-6-hydroxybenzothiazole), which 
inactivated the bio-activating enzyme, cytochrome P450 (CYP1A1).35,36 In order to 
overcome this deactivating metabolism, fluorine substituents were introduced to the 
benzothiazole ring leading to the optimised compound (5F203 as shown in Figure 3).35,36 
However, one major limitation to the application of 5F203 in the clinic was its inherent 
lipophilicity and poor aqueous solubility. Therefore, to enhance pharmaceutical 
properties of 5F203, its lysyl amide prodrug (Phortress) was prepared in which activity 
and selectivity are retained.37
CcV0 -nh* — -
DF203
CJM 126
5F2A3L yiyiia ld t pradng (PfcortrtM)_________________________________________________
Figure 3:The chemical structures of intermediates in the discovery process of Phortress.
14
Chapter One Introduction
Phortress is readily absorbed and hydrolysed to 5F203. Mechanistic studies have 
established now that the mechanism o f  action o f  this compound lies in its interaction with 
the arylhydrocarbon receptor (AhR) to selectively induce expression o f the cytochrome 
P450 CYP1A1 in breast and ovarian cancer cell lines (Figure 4).34
Phortress
CYP1A1 
DNA addu<
Cell
death
5F 203
Extracellular
Intracellular
CYP1A1-* Metabolite 
_______________ I
Inherently resitant tumor cell 
(e.g. MDA-MB-435)
Sensitive tumor cell 
(e.g. MCF-7)______________________________________________ _ _ J
Figure 4: the proposed mechanism o f action o f  Phortress (adapted from reference 34).
Moreover, as a continuation to exploring this chemistry-driven approach, a closely 
related benzothiazole based analogue; 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole 
(GW 610, Figure 5) otherwise known as PMX610 (being developed in Pharminox 
laboratories; a UK based pharmaceutical company) has been found to have potent (sub-
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nanomolar GI50) and selective in vitro antitumor properties in colon and non-small cell 
lung cancer cell line.38,39 Despite its structural similarities to 5F203, this new 
benzothiazole antitumour agent (PMX 610) is proven to have a different mechanism of 
action though it still not well understood as yet.39
Figure 5: The chemical structures of PMX610.
1.6. Aims and objectives
PMX610 has a very potent antitumour activity with profound selectivity in colon and 
non-small cell lung cancer cell lines but in vivo studies of this compound using standard 
aqueous formulations were compromised by its high lipophilicity (logP 4.2). Therefore, 
this project aims to explore and evaluate the antitumour activity of other benzothiazole- 
related heterocycle analogues namely benzimidazole and indole congeners which are 
likely to have superior pharmaceutical properties. Promising results were obtained when 
this hypothesis was tested on another structurally-related heterocycle the benzoxazole 
ring by our group and more details of this work have already been published (reference 
40).
The benzimidazole and indole nucleus provide a versatile scaffold in medicinal chemistry 
for the design of new therapeutic agents, and a number of substituted benzimidazoles 
possessing a range of biological activities have been reported.41 Amongst the range of 
biological activities ascribed to benzimidazole derivatives have been antitumour, 
antiparasitic, antiviral and antimicrobial activity.41 Of particular interest have been
16
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reports of antitumour benzimidazoles with activity against cancer drug targets of current 
interest, as exemplified for example by a benzimidazole-based inhibitor of polo-like 
kinase 1,2-arylbenzimidazole-4-carboxamides as PARP-1 inhibitors and the thioredoxin- 
inhibitory antitumour quinols including benzimidazole derivatives 42-44On the other hand, 
anti-cancer agents containing the indole nucleus have been widely reported especially in 
the area of tubulin polymerisation inhibiton 45
Initial work will focus on optimising conditions for the synthesis of 2-substituted 
benzimidazole and indole congeners of PMX610 and a particular consideration will be 
drawn toward fluorinated ones. Once a robust synthetic route is established, small 
libraries with focused analogues will be prepared. Then, depending on the biological 
properties, the work may be extended to generate larger libraries with a wide variety of 
substituents.
17
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2. The synthesis and antitumour evaluation of 
(substituted) 2-phenylbenzimidazoles
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2.1. Chemistry
(Substituted) 2-phenylbenzimidazoles are most commonly synthesised via two main 
approaches as illustrated in Figure 1. One involves a condensation-dehydration of o- 
phenylenediamines with carboxylic acids or their derivatives (nitriles, imidates or 
orthoesters) while the other consists of a condensation with aldehydes under oxidative 
conditions.1 In most cases, the first approach requires harsh conditions such as the use of 
strong acidic medium at elevated temperatures.2 In addition to the relatively milder 
conditions, the use of the second approach has the advantage of having a wide range of 
differently substituted aldehydes commercially available.3 Therefore, this latter approach 
was our first choice for the preparation of the 2-phenylbenzimidazole based analogues of 
PMX610.
NHI
R
Figure l:The two main approaches for the synthesis of (substituted) 2- 
phenylbenzimidazoles.
2.1.1. The synthesis of 2-phenylbenzimidazoles
2.1.1.1. The use o f indium triflate In(OTf)3:
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The use of the mild Lewis acid In(OTf)3hasrecently been reported for the convenient 
synthesis of 2-arylbenzimidazoles in a one-pot procedure (Scheme l).4 It is also 
worthwhile to note that another triflate agent ytterbium triflate(Yb(OTf)3)was also 
reported previously for the synthesis of 2-arylbenzimidazole under similar conditions.5
C c
OMe
— - r r v r S —.
NHf ^  Jj
Reagents and conditions: In(OTf)3 5 mol%, PCM, RT, 12hr.______
Scheme 1
This synthetic route involves the condensation of o-phenylenediamines and aldehydes in 
the presence of catalytic amounts of the commercially available In(OTf)3 (5mol%) at 
room temperature. However, when attempting this procedure, a mixture of several 
components was obtained with the diamine compound (N,N-Bis-(3,4-dimethoxy- 
benzylidene)-benzene-1,2-diamine) being the major isolated one as illustrated below 
(Scheme 2).
•NH* O H C ^ ^ ^ O M e  , /rvw \ItKO TO ^
NHj OMd
Reagents and condltIons:ln(OTf)3 5mol%, PCM, RT, 12hr.
Me
OMd
OMe
Scheme 2
This particular side reaction has been previously reported to occur during the synthesis of 
benzimidazoles through the condensation of o-phenylenediamines and aldehydes.6,7It 
follows that each amino group of the phenylenediamine molecule reacts with a molecule 
of the aldehyde leading to the formation of this diamine.Therefore, it was anticipated that 
by maintaining a minimum concentration of the aldehyde in the reaction mixture
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(dropwise addition), the formation of this byproductwould be prevented or limited. 
However, even with this modified protocol, there were no significant improvements in 
the overall yield and hence, efforts were turned into exploring alternative synthetic 
methods with different reagents.
2.1.1.2, Using sodium metabisulfite (NajSjOs):
There are several reported examples of the use of inorganic oxidizing reagents in the 
preparation of 2-arylbenzimidazoles which include, NaHSOj,8 Oxone®9 and Na2S2 0 5 10. 
Of these reagents, 2-arylbenzimidazoles synthesis using Na2S20s proceeds at relatively 
mild conditions with good yields.11 Moreover, this reaction is amenable to microwave- 
assisted synthesis which usually affords excellent product yields and also meets with our 
research group interests in exploring the use of microwave-assisted synthesis for 
improving chemical reactions.
The preparation of 2-arylbenzimidazoles with this synthetic method involves the use of 
the inorganic oxidative reagent Na2S2 0 s to promote the condensation of o- 
phenylenediamine and substituted aldehydes in refluxing DMF (Scheme 3). Compared to 
the previous procedure (use of In(OTf)3), the preparation of 2-(3,4-dimethoxyphenyl)- 
/ //-benzimidazole using Na2S20s (Scheme 3) afforded relatively good yields ( > 55%) of 
the desired compound. Moreover, once the reaction is completed (TLC monitoring), the 
compound can be precipitated out by the addition of H2O. The precipitated product is of 
high purity and any further purification desired can mostly be achieved by a simple 
recrystallisation from aqueous methanol.
OH*
R
R: H,Me 
R,: Ht F
R
Reagents andConditions: Na2S20 5 , DMF, Reflux, 2.5 hr.
Scheme 3
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Because of the mild conditions, ease of synthesis and purification as well as the overall 
good yields obtained, this synthetic method was used for the preparation of several 
substituted 2-phenylbenzimidazole based analogues to PMX610 as shown in Figure 2.
Figure 2: Some of the substituted 2-phenylbenzimidazolebased analogues to PMX610 
synthesised using Na2S2 0 s
2,1.1.3. Using piperonyloyl chloride as a starting material:
The preparation of compounds such as 2-(3,4-methylenedioxyphenyl)-l//-benzimidazole 
is important to further unravel the importance of the methoxy groups for the biological 
efficacy of these seriesof benzimidazoles. However, due to difficulties in obtaining 
piperonyl aldehyde commercially (certificate from the Home Office is required to permit 
its purchase), an alternative synthetic procedure using piperonyloyl chloride as a starting 
material was used.12
The preparation of 2-(3,4-methylenedioxyphenyl)-l//-benzimidazole from
phenylenediamine and piperonyloyl chloride involves two consecutive synthetic steps
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(Scheme 4).lt follows that an amide intermediate is formed first from the condensation of 
the aniline and acyl chloride. This intermediate has to be heated under reflux in acetic 
acid for prolonged periods to generate the benzimidazole in its oxidized form.
NH.
NH NH
Reagents and conditions: (A) TEA, THF, Q°C, lhr. (B) AcOH, reflux, 7hr.
Scheme 4
Nevertheless, the amide intermediate once isolated by the evaporation of the solvent 
(THF) in vacuo, was used directly in the following step without any purification. 
However, a column chromatography was necessaiy to obtain the final product 
(substituted) (2-(3,4-methylenedioxyphenyl)benzimidazole) in analytically pure form. 
Despite the harsh conditions employed and the need for column chromatography 
compared to the previous synthetic route (synthesis of 2-phenylbenzimidazoles using 
Na2S20s), the yields obtained were comparable (50-60%). The 2-phenylbenzimidazoles 
prepared through this approach are shown in Figure 3.
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i
M l
___________________________ 9________________________________________
Figure 3: The 2-phenylbenzimidazole based analogues to PMX610 synthesised using 
piperonyloyl chloride as a starting material.
2.1.1.4. The isolation o f 2-(3,4-dimethoxyphenyl)-5-fluoro-l//-benzimidazoIe
(4)isomers:
The fluorinated 2-phenylbenzimidazole products (2, 4, 7), resulting from the reaction of 
4-fluro-1,2-benzenediamine, although represented here as 5-fluorobenzimidazole 
products, are actually a rapidly equilibrating mixture of the formal 5-and 6-substituted 
products due to tautomerism of the benzimidazole N-proton (Figure 4).
" C O -
H
-  _  H
“5-fluoro”-isomer “6-fluoro”-isomer
Figure 4: N-l / N-3 proton tautomerisation of the fluorinated 2-phenylbenzimidazole 
products.
To investigate this observation further, it was anticipated that the deprotonation and 
substitution of the benzimidazole N-proton would prevent this rapid tautomerism and 
lead to aseparable mixture of 5- and 6-substituted products. Hence, the fluorinated 2- 
phenylbenzimidazole product (4) was treated with p-toluenesulfonyl chloride in pyridine, 
leading to the formation of a mixture of products, which were separated using column
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chromatography to give the pure N-substituted 5-fluoro- and 6-fluoro-benzimidazole 
products 10 and 11 respectively (Scheme 5).
T* 11
Reagents and conditions: p-toluenesulfonoylchloride, pyridine, RT, 16hr.
For the characterisation of the individual isomeric products, NOESY (2D-NMR) 
experiment was performed. It uses the dipolar interaction of spins (the nuclear 
Overhauser effect, NOE) to establish correlation of protons.13 The correlation between 
two protons depends on the distance between them. Hence, the cross-peaks in the 
resulting 2D spectrum connect resonance from protons that are close in space.
In this example, characterisation was carried out by observing the NOE between tosyl 
proton(H-6” ) and the benzimidazole proton (H-7), allowing the H-7 proton to be 
characterised and identified for each particular fluorinated isomer on the basis of its *H 
NMR splitting pattern (Figure 5). The fluorine position is then defined by measuring 
coupling constants (JHz) since fluorine-hydrogen (F-H) coupling is larger than hydrogen- 
hydrogen (H-H) coupling. Therefore, for the first isomer 2-(3,4-dimethoxyphenyl)-5- 
fluoro-N-tosylbenzimidazole (10), H-7 appears as a doublet of doublet with a meta 
coupling constant of 5.0 Hz; a typical 3J  (meta coupling) between H and F (Figure 5, 
Figure 6). NMR spectra of2-(3,4-dimethoxyphenyl)-5-fluoro-l-tosylbenzimidazole and 
2-(3,4-dimethoxyphenyl)-6-fluoro-l-methylbenzimidazole are represented in Figure 6 
and Figure 7 respectively.
Scheme 5
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Figure 5: N-l / N-3 proton tautomerisation and nOe effects in products lOand 11.
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1st isomer: 2-(3.4-t>m«ttKMcypheny«)-5-nuoro-l -metfYyiben/lmld*7ot« (10)
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Figure 6:NMR of2-(3,4-Dimethoxyphenyl)-5-fluoro-1 -methylbenzimidazole
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2nd isomer:2-(3,4-D»mettK>xypheny1)-6-fluoro-l-methylbenzlmklazo»e (11)
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2.2. Biology
The new benzimidazole compounds were tested for in vitro antitumour activity in the 
human breast carcinoma cell lines MCF-7 (ER +ve) and MDA 468 (ER -ve) using the 
well-established MTT assay.14
The biological test assays for these series of PMX610 benzimidazole based analogues 
were carried out in the laboratories of our collaborators at the University of Nottingham 
under the supervision of Dr Tracey Bradshaw, who was involved in the earliest 
development of PMX610. The following is a summary of the protocol followed to 
conduct the MTT assays.
2.2.1. Protocol for MTT assays: Compounds were prepared as 10 mM top stocks, 
dissolved in DMSO, and stored at 4 °C, protected from light for a maximum period of 4 
weeks. Human derived cell lines (MCF-7 (ER+), MDA 468 (ER-) breast carcinoma) were 
routinely cultivated at 37 °C in an atmosphere of 5% CO2 in RPMI 1640 medium 
supplemented with 2 mM L-glutamine and 10% fetal calf serum and subcultured twice 
weekly to maintain continuous logarithmic growth. Cells were seeded into 96-well 
microtiter plates at a density of 5 x 103 per well and allowed 24 h to adhere before drugs 
were introduced (final concentration 0.1 nM -100 mM, n = 8). Serial drug dilutions were 
prepared in medium immediately prior to each assay. At the time of drug addition and 
following 72 hours exposure, l-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) 
was added to each well (final concentration 400 mg/mL). Incubation at 37 °C for 4 h 
allowed reduction of MTT by viable cells to an insoluble formazan product. Well 
contents were aspirated and formazan solubilized by addition of DMSO:glycine buffer 
(pH 10.5) (4:1). Absorbance was read on an Anthos Labtec systems plate reader at 550 
nm as a measure of cell viability; thus cell growth or drug toxicity was determined.
2.2.2.Results:
Table 1 lists the results (GI50 values) of the antitumour evaluation studies and includes 
the data previously obtained using the same method for PMX610.14
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Compound Mean GI50 / pM MCF-7
Mean GI50 / pM 
MDA 468
PMX 610 <0.0001 <0.0001
6 59.8 >100
4 85.7(15.6) 94.4 (6.9)
5 90.3 (8.5) 84.2 (19.8)
1 50.8 (0.2) 43.6 (7.9)
2 53.4 (4.5) 39.8 (3.8)
3 >100 >100
7 70.6 (4.4) 43.2 (0.5)
8 49.4 (8.4) 26.3 (21.4)
9 72.4 (2.5) 79.3 (16.2)
10 6.82 (0.07) 5.19 (1.09)
11 6.40 (0.28) 4.55 (0.40)
Table 1 Jn vitro antitumour activity of the synthesised benzimidazoles against the MCF-7 
and MDA 468 breast cancer cell lines (standard deviations in brackets).
The MCF-7 and MDA 468 cell lines were chosen here since they were previously shown 
to be exquisitely sensitive to the lead benzothiazole PMX 610. Inspection of Table 1 
reveals that the new 2-phenylbenzimidazole derivatives prepared in this study do not 
display antitumour activity at the sub-nanomolar GI50 level seen for PMX 610, for the 
two breast cancer cell lines examined. In most cases, growth inhibitory values were in the 
micromolar range. This point is illustrated by comparison of the lead benzothiazole 
(PMX 610; MCF-7 GI50 = <0.0001 pM) with its direct benzimidazole analogue (4,MCF- 
7 GIso = 85.7 pM). Notable observations were that the presence of a fluorine atom in the 
benzimidazole ring did not lead to substantial enhancement of antitumour activity
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(compare 4 versus 6, or 2 versus 1 for example). Also noteworthy was that the N- 
methylated compounds 5,3 and 9 were essentially inactive with GIsovalues > 50 pM.
The most potent and interesting compounds from this new series were the two isomeric5- 
fluoro- and 6-fluoro-benzimidazoles (10 and 11) where the benzimidazole nitrogen bears 
an electron-withdrawing group (p-toluenesulfonyl). These two compounds displayed an 
antitumour activity in the low micromolar range in the cell lines used. In these cases low 
micromolar GI50 values were obtained, suggesting that there is space for further drug 
design and potential for the installation of other electron-withdrawing groups in this 
position in order to further optimise activity.
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3. The synthesis and antitumour evaluation of 
(substituted) 2-phenylindoles
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3.1.Chemistry
The synthesis of indoles has been a major area of focus in organic synthesis for the past 
decades due to their structural diversity and biological activity.1 Thus, numerous 
procedures and well-established synthetic routes have been devised for the formation of 
the indole ring. Examples of the well-known classical methodologies include the Fischer 
indole synthesis, the Bischler indole synthesis, the Gassman synthesis from N-halo- 
anilines, the Madelung cyclisation of N-acyl-o-toluidines and the Batcho-Leimgruber 
indolesynthesis from o-nitrotoluenes and dimethylformamide acetals.2 Moreover, novel 
methodologies are still emerging to overcome limitations of these classical procedures 
and to enable a wide range of substitution patterns of the indole nucleus.
Nevertheless, in recent years, the use of transition metals in the synthesis of indoles has 
become very popular because such catalysed reactions are generally tolerant to various 
chemical functionalities compared to the classical methodologies.3 Of particular interest 
are the palladium or copper complex-catalysed reactions of 2-haloanilines and terminal 
alkynes for the synthesis of 2-subsituted indoles since these starting materials are 
commercially available or readily accessed through well-established synthetic routes.
3.1.1. The synthesis of substituted 2-phenylindoles
3.1.1.1. The use of palladium-catalysed reactions of o-iodoanilines and terminal 
alkynes
Initial efforts focused on establishing a suitable synthetic route toward substituted 2- 
phenyl indoles via the palladium-catalysed reactions of o-haloanilines and terminal 
alkynes. Therefore, our first objective was to ensure access to these starting materials 
either commercially or via robust synthetic procedures.
A. Access to terminal alkynes
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The terminal alkyne; 3,4-dimethoxyphenylethyne is not commercially available and 
hence, it was essential to explore a reliable procedure for its preparation which can also 
be extended to the preparation of any other required terminal alkynes.
Terminal alkynes can be prepared via different synthetic routes from various substrates. 
Amongst the reported procedures, the one based on the use of aldehydes was considered 
the most suitable since several aldehydes bearing different substituents with desired 
substitution pattern have already been used in the synthesis of the benzimidazole series 
(Chapter 2) and were still available in good quantities.
A. L The preparation o f 3,4-dimethoxyphenylethyne through Corey-Fuchs reaction
The synthesis of terminal alkynes from aldehydes using the Corey-Fuchs reaction 
proceeds over two steps with a relatively good yield (>65%) (Scheme l).4In the first step, 
the reaction of carbon tetrabromide (CBr4) with triphenylphosphine (PI13P) leads to the in 
situ generation of a highly reactive ylide which quickly undergoes a Wittig reaction with 
3,4-dimethoxybenzaldehyde forming the intermediate (2,2-dibromo-l-(3,4- 
dimethoxyphenyl)ethene). This intermediate is isolated and purified before using it in the 
next step where it undergoes lithium-halogen exchange with butyllithium (n-BuLi) 
followed by alpha-elimination of the other bromide to form olefinic carbene that rapidly 
rearranges to the more stable form 3,4-dimethoxyphenylethyne (13).
.Br-
CHO
MaO MftO
OM» OAto
Reagents andconditions:A; CBr4, Ph3P, DCM, RT, 1 hr.B; n-BuLi, THF,-78°C, 1 hr,
H20. ________________________________
Scheme 1
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Overall, while this synthetic route affords relatively good yields (> 60%) of the desired 
terminal alkynes from its corresponding aldehydes, laborious work is needed for each 
step and more importantly the harsh conditions required (mainly the use of the strong 
base n-BuLi) may compromise the procedure’s compatibility with some aldehydes 
bearing base sensitive functional groups.
A. 2. The preparation o f 3, 4, 5-trimethoxyphenylethyne in a one-pot procedure
Recently, an alternative one-pot procedure was reported for the synthesis of terminal 
alkynes from aldehydes as illustrated in Scheme 2.5In this reaction, dimethyl-2- 
oxopropylphosphonate reacts with p-toluenesulfonylazideto form dimethyldiazo- 
oxopropylphosphonate; otherwise known as Bestmann's reagent,which in the presence of 
potassium carbonate leads to the in situgeneration of dimethyl (diazomethyl)phosphonate. 
This latter reagent catalyses the formation of the desired terminal alkyne (3, 4, 5- 
trimethoxyphenylethyne in this case(14).
O ^ H
x X &
Oftto CM*
14
Reagents and conditions: Dimethyl-2-oxopropylphosphonate,p-toluenesulfonylazide,
CH3CN, RT, 2 h; MeOH, RT, 24 h.
Scheme 2
This procedure enables the easy preparation of the desired terminal alkynes in one step 
under mild conditions, which makes it more compatible with a wide range of functional 
groups compared to the previous synthetic route (Scheme 1). However, as described in 
the original paper, once aldehydes bearing electron donating groups are used, reactions 
do not go to completion resulting in low yields which was the case in this example 
(40%).6Attempts to improve the yield by employing higher concentrations of the reagent 
(up to 3 eq) and running the reaction for longer times resulted in no major improvements.
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B, Preparation o f o-iodoanilines
One of the major limitations of the metal catalysed reaction between the o-haloanilines 
and terminal alkynes is that it fails to give good yields of the desired indoles when 2- 
bromo- or 2-chloroanilines are employed and requires the use of iodoanilines which are 
most often not commercially available.7
B. 1. Synthesis o f 4-fluoro-2- iodoaniline
2-Iodoanilines can be obtained via a selective o-iodination of the readily available 
anilines. Scheme 3 illustrates the first attempt to synthesise 4-fluoro-2- iodoaniline(15).
Reagents and conditions: NaI0 4 , KI, NaCl, AcOHrfkO (9:1), RT, 6 hr.
Scheme 3
This procedure was recently reported to achieve the selective monoiodination of aromatic 
compounds using a reagent system consisting of NalCU/KI/NaCl in aqueous acetic acid 
in excellent yields.8 It is thought that the reaction proceeds via in situ generation of iodine 
monochloride which acts as the electrophile for the iodination.8 However, when 
employing this procedure for the iodination of 4-fluoroaniline,very low yields of the 
desired product were obtained because ofdifficulties in its purification asseveral other 
byproducts were formed. Therefore, it was important to explore an alternative iodination 
methodology with better yields and fewer byproducts.
In a new attempt for the synthesis of 4-fluoro-2-iodoaniline, a procedure which is based 
on the use of molecular iodine (I2) in an aqueous media was chosen (Scheme 4).9The 
iodination reaction proceeds efficiently to form the product; 4-fluoro-2-iodoaniline,which
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wasobtained in good yields (64%) with high purity via an extraction with diethyl ether 
and subsequentremoval of the solvent.
Xx^ — -
15
Reagents and conditions: NaHCC>3, H20, RT, 3 hr.
X T .
Scheme 4
This procedure was also used for the preparation of 4,5-difluoro-2-iodoaniline(16)in a 
good yield (69%) as shown in Scheme 5.
'XX ------ -
Reagents and conditions:^, NaHC03, H20, RT, 3 hr.
XX
16
Scheme 5
Generally speaking, the palladium-catalysed annulation of o-iodoanilines with alkynes 
usually proceeds via aSonogashira coupling to form an alkynylaniline intermediate, 
which is isolated and subsequently treated with a strong base to promote its cyclisation to 
the corresponding indole. This methodology was significantly improved by Yamanaka et 
al who reported that treatment of terminal alkynes with o-iodo-TV-mesylanilides under 
Sonogashira conditions could directly afford indole products in a single step through a 
coupling-cyclisation process using catalytic amounts of both palladium and copper.10 
Scheme 6 illustrates the preparation of 5-fluoro-3,4-dimethoxyphenyl-N-tosyl-indole 
(17)using this procedure.
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Reagents and conditions:PdCl2(PPh3)2 , Cul, TEA, THF,reflux, 6 hr.
Scheme 6
Following this procedure, the indole product was obtained but only in low yields (25%) 
since some other byproducts were also isolated. The byproducts, which were successfully 
characterised include the uncyclised form of the indole product and the dimer of the 
terminal alkyne formed through Glaser coupling; a side reaction which is often 
encountered in the presence of copper (I) (Figure 1). It follows therefore that halting 
these side reactions would significantly improve the yield of the desired indoles.
ftteO OMft
- ~ Q  — M O ~0M*
Product of the Glaser dimerisation
ilia
NHI
Ta
The uncyclised intermediate
Figure 1: The main isolated side products during the preparation of 5-fluoro-
3,4dimethoxyphenyl-N-tosy 1-indole.
Recently, a copper-free modified protocol of this procedure via palladium catalyzed 
tandem Sonogashira coupling 5-endo-dig cyclisation at room temperature under 
ultrasonic irradiation was reported for the synthesis of 2-substituted indoles.11 It was 
therefore anticipated, greater chemoselectivity would be achieved by using this copper- 
free procedure since the dimerisation of terminal alkyne molecules (Glaser reaction) is 
minimised and this would ultimately improve the overall yield of indole product.
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Following the modified protocol (Scheme 7), it was noticed that the dimerisation of the 
terminal alkyne was reduced as it was expected. However, this was at the expense of the 
cyclisation of the alkynylaniline intermediate, since uncyclisedalkynyl aniline was the 
major isolated compound. This in turn signifies the importance of copper for the 
cyclisation step as Yamanaka et al mentioned in the original paper, that both palladium 
and copper are important for the indole ring formation although the exact role of each is 
not determined. 10
Reagents and conditions:2 mol% Pd(OAc)2, BmNOAc, CH3CN, somcation, 6  hr.
Scheme 7
Nevertheless, as a further attempt, it was thought that the dropwise addition of the 
terminal alkyne to the reaction mixture (would minimise the formation of the alkyne 
dimer since at low alkyne concentration, Sonogashira coupling and subsequent 
cyclisation would be favored over Glaser coupling. Employing this modified procedure, 
the yield improved to 35%.
Another limitation that remained with this procedure is that the obtained indole product is 
still bearing the tosyl group at position 1. Therefore, the next step was to work out an 
easy procedure for the removal of this group. This was achieved by refluxing the product 
in THF with tetrabutylammonium fluoride (TBAF) as illustrated in scheme 8 .,2The NH- 
free indole (5-fluoro-3,4-dimethoxyphenyl-NH-indole, 18) was obtained in good yields 
(over 80%) after purification with column chromatography.
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OMe OMft
Reagents and conditions: TBAF, THF, Reflux, 70° C, 6 hr.
Scheme 8
Overall, relatively moderate yields are obtained in the synthesis of 2-substituted indoles 
via this optimised one-pot palladium-catalysed annulation of o-iodoanilines with terminal 
alkynes. However, several operative steps are required in this synthetic route including 
the preparation of both starting materialsand removal of tosyl group at the end of the 
reaction. Therefore, it was imperative to explore other synthetic routes, which enable the 
fast preparation of the desired 2 -substituted indole analogues.
3.1.1.2. The use of domino copper-catalysedcoupling-cyclisation of o-iodoanilines 
with terminal alkynes
Cacchi and coworkers reported that the copper complex([Cu(phen)(PPh3)2]-NC>3) can be 
efficiently used to catalyse the preparation of 2-aryl-NH-indoles from the 
iodotrifluoroacetanilide and terminal alkynesbearing both electron-donating and electron- 
withdrawing groups (EWG) in a one-pot procedure through a domino copper- 
catalysedcoupling-cyclisation reaction. 13 Scheme 9 shows the synthesis of 4,5-difluoro- 
2(3,4,5-trimethoxyphenyl)indole employing this procedure.
COCF*
Reagents and conditions: [Cu(phen)(PPh3)2]-N0 3 , K3PO4, toluene, reflux, 12hr.
Scheme 9
46
Chapter Three Indole based analogues
Reaction of 3,4-difluoro-2-iodotrifluoroacetanilide with 3,4,5-trimethoxyphenylethyne in 
the presence of 10 mol % [Cu(phen)(PPh3)2]-N0 3 afforded 4,5-difluoro-2-(3,4,5- 
trimethoxyphenyl)-NH-indolein 30 % yield. It is worthwhile to note that the uncyclised 
intermediate is noticed while the dimerisation of the alkyne was very low since it was 
added dropwise.
Nevertheless, this procedure gives comparable yields to the previous one starting from 
the same substrates with the main advantage being the formation of the NH free indole 
products at the end of the reaction. However, this synthetic route still requires prior 
optimisation of the starting materials and the synthesis of the copper reagent [Cu 
(phen)(PPli3)2]-N0 3 (for a detailed synthesis of this reagent,refer to Experimental section; 
Chapter 5).
3.1.13. The use of the intramolecular Heck cyclisation of 2-chloroanilines and 
acetophenones
Nazare et al reported a mild, one-step palladium catalysed synthesis of 2-substituted 
indoles from 2-chloroanilines and acetophenones. 14 The main advantage of this procedure 
as compared to the previous ones is that both substrates can be obtained from commercial 
sources with a wide range of substituents overcoming the limitations of the previously 
attempted procedures.
The procedureis based on the use of the commercially available catalyst [Pd(tBu3P)2] 
with a base (K3PC>4)and MgSCU to catalyse the coupling reaction of 2 -chloroanilines and 
acetophenonesin dimethylacetamide (DMAC) at 140°C in a pressure tube under inert gas 
conditions. It is also reported that the addition of low amounts of acetic acid is necessary 
for a highly selective reaction toward the formation of the desired indole product 
otherwise various byproducts are formed. 14 However, whenattempting the synthesis of 2- 
(3,4-dimethoxyphenyl)NH-indole using this procedure (Scheme 10), many side products 
were detected and the 3,4-(dimethoxyphenyl)-NH-indole (20) was isolated in very low 
yield (15%).
47
Chapter Three Indole based analogues
Oil* OMft
Reagents and conditions: [Pd(tBu3P)2], K3PO4, MgS0 4 , DM AC, 145 °C, 24hr.
Scheme 10
At first it was thought that the low yield of this particular reaction was due to the 
electron-donating effect of the methoxy substituents of the 3,4-dimethoxyacetophenone 
since EWG substrates are generally preferred for the Heck coupling. However, no major 
improvements in the yield were noticed when using an acetophenone bearing electron- 
withdrawing group (P-NO2 acetophenone, yield 19% only). A better explanation for the 
low yields of the isolated products lies in the instability of the palladium reagent (Pd 
(tBu3P)2). This limitation can be overcome by using this reagent freshly prepared prior to 
performing indole synthesis. However, this is not a convenient approach for the 
preparation of a library of indoles.
3.I.I.4. The use of Fischer indole synthesis
The Fischer indoles synthesis is a well-established classical synthetic route for the 
synthesis of indoles, which is commonly used in industry for the synthesis of different 
indole based drugs. It consists of the acid catalysed reaction of phenylhydrazines and 
acetophenones, which are both available commercially.15 Phenylhydrazines can also be 
easily prepared by the reduction of the appropriate aryl diazonium salts, which in turn are 
prepared from their corresponding anilines. The preparation of 5-difluro-2(3,4- 
dimethoxyphenyl)indole(2 Misrepresented in Scheme 11 as an example ofFischer indole 
synthesis. Generally, a phenylhydrazine is heated under reflux with an acetophenone to 
give a phenylhydrazone intermediate. After the removal of solvent in vacuo, 
polyphosphoric acid (PPA) is added to the residue obtained and the mixture is heated to 
120°C. The reaction progress is monitored by TLC and can be completed within 30 
mins-4 hrs with acetophenones bearing electron-donating groups reacting more rapidly.
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Oil*
Reagents and conditions: (A)SnCl2, NaN02, HC1, H20,RT, 4hr.(B) p-methoxy-acetophenone, 
EtOH, 80*C, reflux, lhr.(C) PPA, 125°C. 30 mins.____________________________________
Scheme 11
The crude product precipitates once the reaction mixture contents were poured into cold 
water and subsequently the product was purified by column chromatography. It was also 
noticed that better yields were obtained when acetophenones bearing electron-donating 
groups were employed.
Overall, using the Fischer indole synthesis, a small library of substituted 2-phenylindole 
analogues was generated based on the substitution pattern of PMX610 as shown in Figure 
2.On another note, the p-aminoacetophenone was first protected with a tosyl group prior 
to performing the synthesis of the desired indoles using this substrate. Interestingly, this 
protecting group was lost during the synthesis process to generate the unprotected 2-(p- 
aminophenyl)-l//-indole (21).
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Figure 2: A library of 2-phenylindoles prepared via the Fischer indole synthesis.
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3.2. Biology
The synthesised indole compounds (Figure 2) were sent this time to our collaborators in 
the Tenovus centre (Welsh School of Pharmacy, Cardiff University) where they were 
tested against the human breast carcinoma MCF-7 (ER +ve), non-small lung cancer 
A549, prostate cancer PC3 and colorectal cancer LOVO cell lines using MTT assays. 
These indole compounds were tested for in vitro antitumour activity against these four 
cell lines compared to the benzimidazole analogues which were tested only in the MCF-7 
and MDA 468 cell lines since these two cell lines were previously shown to be 
exquisitely sensitive to the lead benzothiazole PMX 610 as outlined in Chapter 2. 
Nevertheless, Table 1 lists the results (IC50 values) obtained for the indoles in the four 
cell lines.
The data obtained clearly reveals that the new 2-phenylindole derivatives prepared do not 
display a potent antitumour activity at the sub-nanomolar level (GI50 level seen for PMX 
610) as was the case with the benzimidazoles (Chapter 2). In most cases, the obtained 
values were in the micromolar range and some of these compounds can essentially be 
considered inactive (IC5o>100pM) or have no significant activity that may be considered 
for further developments. For example, the IC50 values obtained for the compound 18 
which is the direct indole analogue of PMX610 were >100pM in the four cell lines used.
The only case, which can be considered as an exception, was the indole 17 (2-(4,5- 
dimethoxyphenyl)-5-fluoro-N-tosyl-indole), which exerted a sub-micromolar activity in 
the four cell lines. Most intriguingly is the observation that this indole bears the tosyl 
group, which was the case with the most active compounds in the benzimidazole series 
(benzimidazole isomers (10, 11)). It can be said that the presence of the tosyl group in 
both series improves the antitumour activity despite the fact that this submicromolar 
activity is still far less potent than the lead compoundPMX610.
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Compound MCF7 A549 PC3 LOVO
20 50pM >100pM >100pM 50pM
18 >100pM >100pM >100pM >100pM
36 >100pM 90pM >100pM 9pM
22 >100pM >100pM >100pM 20|iM
23 >100pM >100pM lOOpM 80pM
21 >100pM >100pM >100pM >100pM
24 >100pM >100(iM >100pM >100pM
25 60pM 70pM 40pM 30pM
26 60pM 50pM 50pM 40pM
27 50pM 50pM 50pM 50|iM
29 >100pM 90pM >100pM >100pM
31 60|iM 40pM 80pM 50pM
35 >100|iM 50pM >100pM >100pM
17 0.8pM 0.9pM 0.7pM 0.6pM
Table 1: The ICsovalues for the synthesised PMX 610 based indole analogues in MCF-7
(ER +ve), A549, PC3 and LOVO cell lines.
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4. The synthesis and antitumour evaluation of 
N-substituted benzimidazole and indole analogues
of PMX610
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The in vitro cell line data obtained for the synthesised benzimidazole and indole based 
analogues of PMX-610 shows clearly that the N-substituted compounds (bearing the 
electron withdrawing group; tolyl group) display more significant antitumour activity 
than the non-substituted ones. In the cell linesused, low micromolar GIsoantitumour 
activity values were found for the 5- and 6-fluoro 2-(3,4-dimethoxyphenyl)-N- 
tosylbenzimidazole isomers (10,11) while (3,4-dimethoxyphenyl)-5-fluoro-l- 
tosylindole (17) exerted even more potent activity in the sub-micromolar range. 
Therefore, a small library of N-substituted benzimidazoles and indoles was prepared 
to further investigate this observation and study the effects of N-substitution on the 
antitumour activity. The chosen substituents were the other sulfonyl chlorides namely 
methylsulfonyl and benzenesulfonyl chloride as well as the methyl group because of 
their varying size and electron donating or withdrawing properties.
4.1. Chemistry
The chosen substituents can be introduced through substitution reactions (S n 2 )  using 
a base to deprotonate the indole or benzimidazole N-proton (NH) followed by the 
nitrogen lone pair nucleophilic attack on theelectrophile. While Sn2reactions can be 
accomplished under different conditions, the main focus was directed to finding a 
procedure, which allows access to good yields with relative ease of synthesis and 
purification.
4.1.1. The synthesis of N-substituted benzimidazoles:
4.11.1. The use o f pyridine as a base:
As outlined in Chapter 2 for the synthesis of the benzimidazoles (10,11), the reaction 
proceeds under inert conditions using pyridine (solvent and a base) at room 
temperature overnight to produce these two isomers (Scheme 1) which are then 
isolated and separated using column chromatography.1
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m
Oftto
Ti
OUt +
Reagents and conditions: pyridine, RT, 16hr.
Scheme 1
The main limitation of this synthetic route is the poor yield obtained (20%). This is 
more complicated by the fact that a relatively large amount of the crude product is 
required sincethe resulting isomers have very close R f (retardation factor) values 
causing difficulties in their separation using traditional column chromatography 
procedures. Therefore, it was necessary to investigate an alternative procedure with a 
better yield.
4.1.1.2. The use o f NaH as a base:
This synthetic route is based on the use of NaH as a base in DMF as solvent under 
inert gas conditions at room temperature as illustrated in Scheme 2. More than two­
fold yield improvement (up to 60%) was achieved by employing these reagents and 
conditions. This can be explained by the use of thestrong base (NaH), which enables 
the effective deprotonation of the mildly acidic benzimidazole proton.
+ ° T ° 's*°
Ri
R: H, F
R,: Me, Ph, 4-MePh.
Reagents and conditions:NaH, DMF, RT.
Scheme 2
The use of this procedure led to the preparation of the following derivatives (Figure 
1).
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Figure 1: The synthesised N-substituted benzimidazoles
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In addition to the synthesis of N-sulfonyl substituted benzimidazoles, 5-and 6-fluoro- 
3,4-(dimethoxyphenyl)-N-Me-benzimidazole isomers (Figure 2) were synthesised 
using this procedure (Scheme 3).
OMe
OMe
OMe
Me
OMe OMe
OMe
Me
Reagents and conditions: NaH, DMF, Mel, RT.
Scheme 3
On the other hand, the non-fluorinated counterpart 3,4-(dimethoxyphenyl)-7V-Me- 
benzimidazole (3)was previously prepared (Chapter 2) directly in a one-step from N- 
methylphenylenediamine and 3,4-dimethoxybenzaldehyde since both substrates are 
commercially available.
Figure 2: The chemical structures of 5-and 6-fluoro-3, 4-(dimethoxyphenyl)-7V-Me- 
benzimidazole isomers
Nevertheless, the characterisation of the different synthesized isomers was 
accomplished by the use of *HNMR and NOESY experiments as described in detail in 
Chapter 2.(Refer also to the experimental section, Chapter 5).
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4.1.2. The synthesis of N-substituted indoles
5-Fluoro- (3,4-dimethoxyphenyl)-l-tosyl-indole(17)was prepared via the use of Pd- 
catalysed coupling reaction as outlined in Chapter 3. However, for the synthesis of N- 
substituted indoles, the use of Sn2 conditions (NaH in DMF) was first attempted since 
the non-substituted indoles (18, 20) were already made in sufficient quantities using 
Fischer indole synthesis and this synthetic route was proved highly effective in terms 
of the obtained yields and ease of synthesis for the preparation of the N-substituted 
benzimidazoles above.
4.L2.1. The use o f NaH as a base:
The procedure described above for the synthesis of N-substituted benzimidazoles was 
applied for the preparation of the desired indoles under similar conditions. This 
synthetic method was indeed effective in the preparation of the fluorinated and non- 
fluorinated-2-(3,4-dimethoxyphenyl)-N-M?-indoles (Scheme 4) in good yields (52- 
65%).
out OM*
R = H; 53 
R = F; 52
Reagents and conditions: NaH, Mel, DMF, RT, overnight.
Scheme 4
On the other hand, when applied to the sulfonyl chlorides, it led to the formation of a 
mixture of different components including the desired N-substituted indoles. Of these 
components, the major byproduct was isolated and the NMR characterisation revealed 
that it is the 3-chloro-N-arylsulfonylindoleas illustrated in Scheme 5. These findings 
are consistent with previous reports which showed that the N-arylsulfonylation of 2- 
arylindoles with arylsylfonyl halides is accompanied by 3-halogenation with the 3- 
halogenated products being the major products.2 Moreover, it was noted that this 3-
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halogenation is more likely to occur with electron rich 2-substituents.2It follows 
therefore, that the presence of the electron donating groups (dimethoxy) of the indole 
contribute to the formation of side products.
X r v c P * ?0:f =0 -----*1
a  on*
R =H, F; R, = Me, Ph, 4-MePh.
V \
Reagents and conditions:NaH, DMF, RT.
Scheme 5
The following 3-halogenated products were obtained as shown in Figure 2.
Figure 2:Chemical structures of3-chloro-N-substituted indole side products.
The next alternative option was to employ the Pd-catalysed since the reaction 
conditions required have already been established before in the synthesis of HK32 
(Chapter 3).
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4.1.2.2. The use o f Pd -catalysed reactions
The palladium-catalysed synthetic route enables access to substituted 2-phenyl 
indoles via the Sonogashira coupling reactions of o-haloanilines and terminal alkynes 
and subsequent cyclisation to form the indole nucleus.3,4The required terminal alkyne 
(3,4-dimethoxyphenylethyne) was already prepared in a good quantity in our previous 
attempts for the synthesis of indole (17). In this synthetic route, a selective o- 
iodination is accomplished by the use of molecular iodine in aqueous media in the 
presence of sodium hydrogen carbonate (NaHCCb), the desired sulfonyl substituent 
was introduced to the iodinated aniline forming the sulfonamide.5 This sulfonamide 
is then reacted with the terminal alkyne under Sonogashira conditions followed by 
one-pot base mediated cyclisation into the desired N-substituted indole.
NHf x x : (B) XXNHI
Hi
(O
R -
Rh
H ,F
SOjMe
SOjPh
SOjPhMt
OM*
R * 1
a: H S 02Me (58)
Ik H SOjPh («•)
c: H S 0 2PhMe(61)
d: F SOjMt ( » )
e: F SOjPh (M )
f: F S02PhMe(17)
Reagents and conditions: (A) NaHCCb, H2O, RT, 3 hr.
(B) R,S02C1, Pyridine, DCM, RT, 18hr.
(C) PdCl2(PPh3) 2, Cul, TEA, THF,Reflux, 6 hr.
Scheme 5
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The use of this synthetic route enabled the synthesis of the following differently N- 
substituted indoles in average yields (45-62 %) as shown below in Figure 3.
Figure 3: N-substituted indoles synthesised using Pd catalysed coupling reactions.
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4.2.Biology
The new series of N-substituted benzimidazole and indole compounds as well as 
some of the side products (3-chloro-N-substitutedindoles) were tested for antitumour 
activity in the four different cell lines; MCF7, A549, LOVO and PC3 by our 
collaborators in Tenovus Centre, Welsh School of Pharmacy. The obtained results for 
the N-substituted benzimidazoles and N-substituted indoles are represented in Table 1 
and Table2 respectively.
Compound A549 LOVO PC3 MCF7
41 >100 50 50 50
42 >100 >100 50 70
43 10 5 5 5
50 >100 >100 >100 >100
51 >100 >100 50 >100
37 >100 >100 >100 >100
38 >100 >100 >100 >100
39 >100 50 50 50
40 >100 50 50 50
Table 1: In vitro antitumour activity (IC50) of the N-substituted benzimidazole 
analogues against cancer cell lines (MCF7, A549, LOVO and PC3).
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Compound A549 LOVO PC3 MCF7
17 0.9 0.6 0.7 0.8
58 >100 100 50 50
59 >100 >100 >100 >100
62 50 50 50 50
60 >100 50 50 >100
52 >100 50 50 >100
53 >100 50 50 50
61 5 0.5 0.5 0.5
55 >100 >100 100 90
56 5 0.5 0.5 5
57 >100 50 >100 90
54 >100 >100 >100 >100
Table2: In vitro antitumour activity (IC50) of the N-substituted indoles against cancer 
cell lines (MCF7, A549, LOVO and PC3).
Inspection of the antitumour activity data in Table 1 and Table 2 reveals that the 
prepared N-substituted benzimidazole and indole analogues do not exert antitumour 
activity at the sub-nanomolar GI50 level seen for PMX610.6
Table 1 shows clearly that in most cases, the benzimidazole compounds were devoid 
of any significant antitumour inhibitory activity (ICso> 50 pM). The only exception is 
2-(3,4-dimethoxyphenyl)-N-tosylbenzimidazole (43) which, showed low micromolar 
values in the four cell lines. Notably, this benzimidazole shows similar activity to its 
fluorinated analogues (10 and 11) where these compounds also bear the electron- 
withdrawing group, tosyl as N substituent.
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From Table 2, a similar observation can be made whereby most of the prepared N- 
substituted indoles show no significant activity except for 61 and 56. These 
compounds are also the non-fluorinated analogues of indolel7, which bear the tosyl 
substituent. This suggests that the presence of fluorine on the ring does not 
necessarily improve its antitumour activity compared to the benzothiazoles where the 
presence of fluorine was essential. The presence of chlorine at position 3 (56) reduces 
the antitumour inhibitory effects by about ten fold (compare to (61), from sub­
micromolar to low micro-molar) at MCF-7 while maintaining the same level of 
inhibitory effects at the other cell lines.
Overall, it seems that the antitumour effect is linked to the tosyl group since even the 
use of the very closely related phenylsulfonyl groups did not have much effect 
(compare 17and62 for indole series, andl, 11 and39,40 for benzimidazole series).
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5. EXPERIMENTAL
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5.1. General experimental details
Melting points were measured on a Griffin apparatus and are uncorrected. All 
commercially available starting materials used were purchased from Aldrich without 
further purification. All glassware was oven dried at 60°C for several hours or overnight.
Chromatography
Thin Layer Chromatography (TLC) was performed using precoated, aluminum backed 
silica gel plates (TLC Silica gel 60 F254-Merck) and an ultra-violet (UV) lamp was used 
for visualisation (254nm). For column chromatography, silica gel (Silica 60A particle 
size 35-70 micron, Fisher Scientific) was used.
NMR spectroscopy
’H, and ,3C NMR were recorded on a Bruker Avance 500 spectrometer with operating 
frequencies of 500, and 125 MHz respectively. The following abbreviations are used in 
the assignment of NMR signals: s (singlet), d (doublet), t (triplet), m (multiplet). J  
coupling constants were calculated on the Topspin program and are reported Hertz (Hz).
Mass Spectroscopy
Mass spectra were determined under electrospray conditions on a Bruker MicroTOF LC 
instrument at the Welsh School of Pharmacy, Cardiff, or at the Chemistry Department, 
Cardiff University.
CHN Analysis
CHN analysis was carried out by MEDAC. The data were recorded on a Carlo-Erba EA 
1108 element analyser, PC based data system, Eager 200 for Windows and a Sartorius 
Ultra Micro balance 4504MP8.
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5.2. Synthesised compounds
5.2,1, Substituted 2-phenylbenzimidazoles:
General method for the synthesis of 2-phenylbenzimidazoles:1 Sodium metabisulfite 
(0.60g, 3.16 mmol) was added to a stirring mixture of (substituted) 1,2-phenylenediamine 
(3.12 mmol) and substituted benzaldehyde (3.16 mmol) in DMF (10 mL), and the 
reaction mixture was heated under reflux for two hours. After completion of the reaction 
(monitored by TLC), the mixture was allowed to cool to room temperature. Addition of 
water (approximately 20 mL) caused precipitation of a pale yellow solid, which was 
collected by vacuum filtration and dried. The crude product was further purified by 
recrystallisation (aqueous methanol) or column chromatography (40% Hexane/ 60% 
EtOAc) to give the pure substituted 2-arylbenzimidazole as a white solid in yields 46- 
63%. The following compounds were prepared using this procedure.
2-(3,4,5-Trimethoxyphenyl)-l//-benzimidazole (1)2
OMe
C16H16N20 3, MW: 28431
Prepared from 1,2-phenylenediamine and 3,4,5-trimethoxybenzaldehyde (46% yield), 
m.p. 254-255 °C (Lit 259.9-262.1°C)2. 'H NMR (DMSO-*): 6 3.74 (3H, s, OMe), 3.91 
(6H, s, 2 x OMe), 7.20 (2H, dd, J3.0, 5.5 Hz, H-4, H-7), 7.53 (2H, s, H-2\ H-6’), 7.60 
(2H, m, H-5, H-6), 12.83 (1H, bs, NH). CHN Anal. Calcd for C, 67.59; H, 5.67; N, 9.85. 
Found, C 67.65, H, 5.71; N, 9.73%.
2-(3,4,5-Trimethoxyphenyl)-5-fluoro-l//-benzimidazole (2)
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OMe
C14H15FN20 3,MW: 30230
Prepared from 4-fluoro-1,2-phenylenediamine and 3,4,5-trimethoxybenzaldehyde (57% 
yield). m.p. 243-245 °C; 'H NMR (DMSO-rf6): 6 3.74 (3H, s, OMe), 3.91 (6H, s, 2 x 
OMe), 7.06 (1H, dt, J  2.5, 9.5 Hz, H-6), 7.40 (1H, d,79.0 Hz, Ar-H), 7.51 (2H, s, H-2’, 
H-6’), 7.59 (1H, m, Ar-H), 12.83 (1H, bs, NH). CHN Anal. Calcd for C, 63.57; H, 5.00; 
N, 9.26. Found, C 63.51, H, 5.03; N, 9.14%.
2-(3,4,5-Trimethoxyphenyl)-l-methyI-benzimidazole (3)
OMe
OMe
Me OMe
C17H18N20 3, MW: 29834
Prepared from iV-methyl-1,2-phenylenediamine and 3,4,5-trimethoxybenzaldehyde (59% 
yield). m.p. 114-116 °C, 'H NMR (CDCb): 6 3.89 (3H, s, NMe), 3.93 (3H, s, 4’-OMe),
3.94 (6H, s, 2 x OMe), 6.96 (2H, s, H-2’, H-6’), 7.31 (2H, m, Ar-H), 7.39 (1H, m, Ar-H), 
7.82 (1H, m, Ar-H). CHN Anal. Calcd for C, 68.44; H, 6.08; N, 9.39. Found: C, 68.85; 
H, 6.19; N, 9.48%.
2-(3,4-Dimethoxyphenyl)-5-fluoro-l//-benzimidazole (4)
OMe
H
C15HI3FN20 2,MW: 21221
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Prepared from 4-fluoro-1,2-phenylenediamine and 3,4-dimethoxybenzaldehyde (52% 
yield), m.p. 212-214°G, *H NMR (DMSO-d6): 6 3.83 (3H, s, OMe), 3.88 (3H, s, OMe), 
7.03 (1H, dt, J  2.5, 10.5 Hz, H-6), 7.13 (1H, d, J  8.5 Hz, H-5’), 7.36 (1H, m, Ar-H), 7.55 
(1H, m, Ar-H), 7.73 (1H, dd, J  1.5, 8.5 Hz, H-6’), 7.75 (1H, d, J  1.5 Hz, H-2’), 12.78 
(1H, bs, NH). CHN Anal. Calcd for C, 66.17; H, 4.81; N, 10.28. Found: C, 66.00; H, 
4.86; N, 10.08%.
2-(3,4-Dimethoxyphenyl)-l-methylbenzimidazole (5)3
OMe 
OMe 
Me
C16H16N20 2,MW: 26831
Prepared from A-methyl-1,2-phenylenediamine and 3,4-dimethoxybenzaldehyde (61% 
yield); m.p. 107-109 °C; *H NMR (CDCfe): 6 3.85 (3H, s, NMe), 3.95 (3H, s, OMe), 
3.96 (3H, s, OMe), 6.98 (1H, d, J  8.0 Hz, H-5’), 7.24 (1H, dd, J  2.0, 8.5 Hz, H-6’), 7.30 
(2H, m, Ar-H), 7.36 (2H, m, Ar-H), 7.79 (1H, m, Ar-H). CHN Anal. Calcd for C, 71.62; 
H, 6.01; N, 10.44. Found: C 71.85; H, 6.02; N, 10.36%
2-(3,4-Dimethoxyphenyl)-l//-benzimidazoIe (6)
OMe
OMe 
H
C15H14N2O2, MW: 254.28
Prepared from 1,2-phenylenediamine and 3,4-dimethoxybenzaldehyde (55% yield), m.p. 
231-233 °C (Lit 227-228°C)3; 'H NMR (DMSO-rf6): 6 3.84 (3H, s, OMe), 3.88 (3H, s, 
OMe), 7.13 (1H, d, J  8.5 Hz, H-5’), 7.18 (2H, dt, J  3.7, 7.0 Hz, H-5, H-6), 7.57 (2H, dd, J  
3.5, 5.0 Hz, H-4, H-7), 7.76 (1H, dd, J  2.0, 8.5 Hz, H-6’), 7.78 (1H, d, J  2.0 Hz, H-2’),
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12.84 (1H, bs, NH). CHN Anal. Calcd for C, 70.85; H, 5.55; N, 11.01. Found: C, 70.56; 
H, 5.62; N, 10.75 %.
General method for the synthesis of 2-(3,4-methylenedioxyphenyl)benzimidazoles.
Triethylamine (5.80 mL, 4 mmol) was added to a solution of (substituted)-1,2- 
phenylenediamine (0.29 g, 2.7 mmol) and piperonyloyl chloride (0.5 g, 2.7 mmol) in 
THF (10 mL) at 0°C with stirring. The reaction mixture was stirred at 0 °C for around 
one hour (until reaction was complete by TLC), then the solution was concentrated in 
vacuo. The resulting residue was further heated under reflux in acetic acid (100 °C) for 
12 hours. The solution was then neutralised (aqueous sodium hydroxide), and the product 
extracted using ethyl acetate (2 x 20 mL), then dried (MgSCU) and concentrated in 
vacuo. Purification by flash column chromatography (60% CH2Cl2-40% EtOAc) afforded 
the title compound as a white solid. This procedure was used in the preparation of the 
following compounds.
2-(3,4-Methylenedioxyphenyl)-l/f-benzimidazole (7) 4
H
C14H10N2O2,MW: 238.24
Prepared from 1,2-phenylenediamine and piperonyloyl chloride (46% yield), m.p. 242- 
244°C (Lit 245-247°C)4 ; *H NMR (DMSO-</6): 6  6.13 (2H, s, OCH2), 7.10 (1H, d, J  8 .8  
Hz, H-5’), 7.18 (2H, m, Ar-H), 7.56 (1H, m, Ar-H) 7.65 (1H, m, Ar-H), 7.69 (1H, d, J  1.5 
Hz, H-2’), 7.72 (1H, dd, J  1.5, 8.5 Hz, H-6 ’), 12.79 (1H, bs, NH). CHN Anal. Calcd for 
C, 70.58; H, 4.23; N, 11.75. Found: C, 70.31; H, 4.21;N, 11.66%.
2-(3,4-Methylenedioxyphenyl)-5-fluoro-l/f-benzimidazole (8).
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C14H,FN20 2, MW: 25623
Prepared from 4-fluoro-1,2-phenylenediamine and piperonyloyl chloride (46% yield), 
m.p. 205-207 °C; 'H NMR (DMSO-rf6): 5 6.13 (2H, s, OCH2), 7.04 (1H, dt, J  2.5, 10.0 
Hz, H-6 ), 7.10 (1H, d, J  8.0 Hz, H-5’), 7.36 (1H, m, Ar-H), 7.55 (1H, m, Ar-H) 7.66 (1H, 
d, J  2.0 Hz, H-2’), 7.70 (1H, dd, J  2.0, 8.0 Hz, H-6 ’), 12.86 (1H, bs, NH). CHN Anal. 
Calcd for C, 65.62; H, 3.54; N, 10.93. Found: C, 65.38; H, 3.56; N, 10.74%.
2-(3,4-Methylenedioxyphenyl)-l-methyl-benzimidazole (9) 5
Me
C15HuN20 2) MW: 25221
From 7V-methyl-1,2-phenylenediamine and piperonyloyl chloride (59% yield), m.p. 149- 
151 °C (Lit 157-158°C);5 'H NMR (CDCb): 8  3.84 (3H, s, NCHj), 6.05 (2H, s, OCH2),
6.94 (1H, d, J  8.0 Hz, H-5’), 7.23 (2H, m, Ar-H), 7.29 (2H, m, Ar-H) 7.36 (1H, m, Ar-H), 
7.77 (1H, m, Ar-H). CHN Anal. Calcd for C, 71.42; H, 4.79; N, 11.10. Found: C, 71.02; 
H, 4.75; N, 11.00%.
Preparation of 2-(3,4-dimethoxyphenyl)- 5 -fluoro-l-tosyl-benzimidazole and 2-(3,4- 
dimethoxyphenyl)- 6 -fluoro-l-tosyl-benzimidazole.
To a stirring solution of (4) (0.73 mmol) in pyridine (lOmL), p-toluenesulfonylchloride 
(1.1 mmol) was added in small portions under nitrogen and left stirring overnight. The 
reaction mixture was then diluted with H2O and extracted with DCM (3 x 20 mL), dried
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over MgS04 and concentrated in vacuo. The use of column chromatography (80% DCM/ 
20% EtOAc) enabled the isolation of the 2 isomers (10 & 11).
2-(3,4-Dimethoxyphenyl)-5-fluoro-l-tosylbenzimidazole (10)
OMe
Me
CmH^FNjO A  MW: 426.46
(21% yield), m.p. 123-125°C, *H NMR (CDC13): 6  2.31 (3H, s, Me), 3.81 (3H, s, OMe),
3.91 (3H, s, OMe), 6 .8 8  (1H, d, J 8.0 Hz, H-5’), 7.01 (2H, d, J  8.5 Hz, H-3” , H-5”), 7.03 
(1H, d, J2.0 Hz, H-2’), 7.08 (1H, dt, J2.5 Hz, 9.0 Hz, H-6 ), 7.17 (1H, dd, J  2.0 Hz, 8.0 
Hz, H-6 *), 7.18 (2H, d, J  8.5 Hz, H-2” , H-6 ”), 7.29 (1H, dd, J  2.5 Hz, 9.5Hz, H-4), 8.08 
(1H, dd, J  5.0 Hz, 9.5 Hz, H-7). CHN Anal. Calcd for C, 61.96; H, 4.49; N, 6.57. Found: 
C, 61.64; H, 4.46; N, 6.38%.
2-(3,4-Dimethoxyphenyl)-6-fluoro-l-tosylbenzimidazole (11)
OMe
Me
CJBLiJM 20 &  MW: 42646
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(16% yield); m.p.l29-131°C. 'H NMR (CDC13): 6  2.31 (3H, s, Me), 3.81 (3H, s, OMe),
3.91 (3H, s, OMe), 6.87 (1H, d ,J 8.5 Hz, H-5’), 7.00 (1H, d,J2.0  Hz, H-2’), 7.04 (2H, d, 
J  8.5 Hz, H-3” , H-5” ), 7.07 (1H, dt, J  2.5 Hz, 9.0Hz, H-5), 7.15 (1H, dd, J  2.0 Hz, 
8.5Hz, H-6 ’), 7.22 (2H, d, J  8.5 Hz, H-2” , H-6 ”), 7.56 (1H, dd, J  5.0 Hz, 9.5Hz, H-4), 
7.88 (1H, dd, J  2.5 Hz, 9.5 Hz, H-7). CHN Anal. Calcd for C, 61.96; H, 4.49; N, 6.57. 
Found: C, 61.65; H, 4.48; N, 6.28%.
5.2.2, Substituted 2-phenyl indoles
3 ,4-Dimethoxyphenylethyne (13)6
OMe
OMe
To a well stirred solution of carbon tetrabromide (3 g, 9 mmol) in dry DCM (20mL) at 0 
°C, triphenylphosphine (4.5g, 18mmol) was added followed by 3,4- 
dimethoxybenzaldehyde (1.5g, 9mmol). The resultant mixture was stirred for 1 hour at 
room temperature, washed with water, dried over MgSC>4, filtered and concentrated in 
vacuo to give orange residue. Purification by column chromatography eluting with DCM 
afforded 2,2,dibromo-l-(3,4-dimethoxyphenyl)ethene as a pale yellow oil (74% yield). 
'H NMR (CDCI3): 5 3.87 (6 H, s, 2 x OMe), 6.78 (1H, d, J 8.0 Hz, H-5’), 7.05 (1H, dd, 
J  2.5 Hz, 8.0 Hz, H-6 ’), 7.17 (1H, d,J2.5 Hz, H-2’), 7.36 (1H, s, H-l). 
2,2-Dibromo-l-(3,4-dimethoxyphenyl)ethene (2 g, 6.3mmol) was dissolved in dry THF 
(25mL) and the solution cooled to -78°C under inert gas conditions. w-BuLi (1.6M ) was 
added to the stirred solution dropwise over a period of 30 minutes and the mixture was 
allowed to warm to room temperature and stirred further for lhour. The reaction was 
quenched with saturated aqueous NH4CI, extracted with Et2 0 , dried over MgS0 4 , filtered 
and evaporated. The resultant residue was purified by column chromatography (eluting
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with DCM) to afford the titled compound as a white solid (79% yield). !H NMR 
(CDCI3): 6  2.94 (1H, s, H-2), 3.81 (6 H, s, 2 x OMe), 6.71 (1H, d, J  8.0 Hz, H-5’), 6.89 
(1H, d, J2.0 Hz, H-2’), 7.02 (1H, dd, J  8.0 Hz, 2.0 Hz, H-6 ’).
3 ,4 ,5-Trimethoxyphenylethyne (14)7
MeO OMe
OMe
p-Toluenesulfonylazide: a stirring solution of NaN3 (7.15g ,0.11mol) in H2O (20 mL) 
was diluted with ethanol (40mL) and a warm solution of p-toluenesulfonyl chloride 
(19.05g, 190.65mmol) in ethanol (lOOmL) is added causing a separation of NaCl and the 
mixture takes light brown color. After stirring for 3.5 hours, most of the solvent is 
evaporated and H2O (20 mL) is added to the residue where 2 layers are formed. The oily 
layer is separated, dried (MgSCU) and filtered to afford p-toluenesulfonylazide as a 
colourless oil which solidifies at low temperatures (89% yield).
Dimethyl-2-oxopropylphosphonate (0.19g, 1.2 mmol) was added to a suspension of 
K2CO3 (0.4lg, 3mmol) and p-toluenesulfonylazide (0.23g, 1 .2 mmol) in acetonitrile 
(15mL) and the mixture was stirred at room temperature. After 2 hours, 3,4,5- 
trimethoxybenzaldehyde (0.19 g, 1 mmol) dissolved in methanol (2mL) is added and 
stirring continued for 24 hours. The solvents were removed in vacuo and the resultant 
residue was extracted with EtOAc, dried (MgSC>4) and concentrated in vacuo. 
Purification with column chromatography (DCM) afforded pure 3,4,5- 
trimethoxyphenylethyne as a white solid (32% yield). !H NMR (CDCI3): 6  2.71 (1H, s, 
H-2), 3.79 (3H, s, OMe), 3.82 (6 H, s, 2 x OMe), 6 .6 8  (2H, s, H-2’, H-6 ’).
4-Fluoro-2-iodoaniline (15)8
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4-Fluoroaniline (1.12g, lOmmol) was placed in a beaker, NaHC0 3  (1.26g, 15mmol) and 
H2O (20 mL) were added and the mixture was cooled down to 0 °C using ice bath. 
Powdered iodine (2.53g, 10 mmol) was then added in small portions at 5-minute intervals 
and the mixture stirred for further 3 hours at room temperature. Once the reaction is 
completed (TLC monitoring), Na2S2 0 3  was added to the reaction mixture and the organic 
phase was extracted with Et2 0 , dried over MgS0 4  and concentrated in vacuo to give the 
title compound (64% yield). *H NMR (CDC13): 6  3.92 (2H, bs, NH2), 6.72 (1H, m, Ar- 
H), 6.95 (1H, m, Ar-H), 7.41(1H, m, Ar-H).
4 ,5-Difluoro-2-iodoaniline (16)8
Prepared from 3, 4-difluoroaniline (1.5g, 11.62mmol) by the same procedure described 
for the synthesis of 4-fluoro-2-iodoaniline (15) (6 8 % yield). *H NMR (CDCI3): 6  4.05 
(2H, bs, NH2), 6.51(1H, m, Ar-H), 7.38(1H, m, Ar-H).
N-(4-Fluoro-2-iodophenyl)-4-methylbenzenesulfonamide
To a stirring solution of 4-fluoro-2-iodoaniline (0.76g, 3.2mmol), pyridine (0.39 mL, 4.8 
mmol) in dry DCM (15 mL) under nitrogen gas was added p-toluenesulfonylchloride 
(4.8mmol in 10 mL DCM) dropwise at 0 °C. The mixture was then left to warm to room
Ts
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temperature and stirred for further 18 hours. The reaction was quenched with 6 N NaOH 
(lOOmL) and H2O (100 mL) was added to dissolve the resultant anion. The layers were 
separated and the aqueous layer washed with DCM, cooled to 0 °C and acidified (0.2M 
HC1) causing the title compound to precipitate as white solid (74% yield). 'H  NMR 
(CDCI3): 6  2.48 (3H, s, Me), 6.61 (1H, s, NH), 7.07 (1H, m, Ar-H), 7.24 (2H,d, J  8.0 Hz, 
H-3’, H-5’), 7.41 (1H, dd, J  3.0 Hz, 7.5 Hz, Ar-H), 7.61 (2H,_d, J  8.0 Hz, H-2’, H-6 ’), 
7.67 (lH,m, Ar-H).
5.2.2.I. The palladium-catalysed reaction between o-iodoanilines and terminal 
alkynes
2-(4,5-Dimethoxyphenyl)-5-fluoro-N-tosyl-indoIe (17) 9
OMe
Me
C^H^CXtS, MW: 42547
A mixture of N-(4-fluro-2-iodophenyl)-4-methylbenzenesulfonamide (0.29g, lmmol),
4,5-dimethoxyphenylethyne (0.58g, 1.5mmol), PdCl2(PPh3)2 (35mg, 5mol%), Cul (19mg, 
10mol%) and TEA (3mL) in THF (lOmL) was heated under reflux for 5 hours. After the 
removal of solvent, the residue was diluted with H2O and extracted with AcOEt, dried 
over MgSC>4 and concentrated in vacuo. Purification with column chromatography (70% 
ethyl acetate/ 30% hexane) afforded the title compound as a white solid (35% yield). 
NMR (CDCb): 6  2.22 (3H, s, Me), 3.82 (3H, s, OMe), 3.88 (3H, s, OMe), 6.38 (1H, s, 
H-3), 6.82 (2H, m, Ar-H), 6.92-7.00 (4H, m, Ar-H), 7.16 (3H, m, Ar-H), 8.19 (1H, dd, J
4.5 Hz, 9.0 Hz, H-7). ESI MS m/z 448.08 [M+Na*]. CHN Anal. Calcd for C, 64.93; H, 
4.74; N, 3.29. Found: C, 64.64; H, 4.58; N, 3.80%.
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2-(4,5-Dimethoxyphenyl)-5-fIuoro-l-tosyl-indole (17) synthesis (Copper-free 
procedure)10
To a mixture of N-(4-fluoro-2-iodophenyl)-4-methylbenzenesulfonamide (390 mg, 
1 mmol), Pd(OAc)2 (2 mmol %), and B114NOAC (2.5 mmol) in dry acetonitrile (8 mL) 
under nitrogen atmosphere was added 3,4-dimethoxyphenylethyne (178.2mg, 1.1 mmol) 
dropwise. The reaction mixture was placed in a sonicator and stirred for 6  hours with the 
progress of the reaction monitored by TLC. After completion of the reaction, acetonitrile 
was evaporated, diluted with water, and extracted with ethyl acetate. The organic layer 
was dried over MgS0 4 , filtered, concentrated in vacuo and the resultant residue was 
purified by column chromatography (70% ethyl acetate/ 30% hexane) as eluent to afford 
the titled compound (2 1 % yield).
2-(4,5-Dimethoxyphenyl)-5-fluoro-7//-indole (18)
OMe
H
C16H14FN02, MW: 271.29
To a solution of 2-(4,5-dimethoxyphenyl)-5-fluoro-l-tosyl-indole (lOOmg, 0.24 mmol) in 
THF (15mL) was added, TBAF (0.18 g, 0.7mmol), under nitrogen, and the mixture was 
heated under reflux (80 °C) for 6  hours. After the removal of solvent, the residue was 
diluted with H2O and extracted with AcOEt, dried over MgSCU and concentrated in 
vacuo. Purification with column chromatography afforded the title compound (82% 
yield). *H NMR (DMSO-*): 8  3.80 (3H, s, OMe), 3.87 (3H, s, OMe), 6.80 (1H, s, H-3),
6.90 (1H, dt, J 2.5 Hz, 9.0 Hz, H-6 ), 7.04 (1H, d, J 8.5 Hz, H-5’), 7.25 (1H, dd, J2.5 Hz,
10.0 Hz, H-4), 7.36 (1H, dd, 5.0 Hz, 9.0 Hz, H-7), 7.38 (1H, dd, J  2.0 Hz, 8.5 Hz, H- 
6 ’),7.45 (1H, d, J  2.0 Hz, H-2’), 11.51 (1H, s, NH). ,3C NMR (DMSO-*): 
6  55.55,55.56,97.81,104.22,108.87,109.06,111.86,117.86,124.74,125.30,129.05,12
9.09,133.54,139.93,148.67,156.21,158.04. ESI MS m/z 272.10 [M+H+], CHN Anal. 
Calcd for C, 70.84; H, 5.20; N, 5.16. Found: C, 70.82; H, 5.10; N, 5.17%.
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5.2.2.2. The use of domino copper-catalysed synthesis of 2-substituted indoles: 11 
Preparation o f [Cu(phen)(PPhj)]NOi:
Nitratobis(triphenylphosphine)copper(I): triphenylphosphine (24.22 g, 92.34 mmol) was 
slowly added to a boiling methanol (lOOmL). After the complete dissolution of 
triphenylphosphine, [Cu(NC>3)2.2 .5 H2 0 ] (7.16 g, 30.78 mmol) was added in small 
portions leading to the formation of a white precipitate. The mixture was stirred for 30 
minutes, after which, was cooled to room temperature. Then, it was filtered and the white 
residue was washed repeatedly with ethanol and diethyl ether. The resultant white solid 
was dried to give Cu(PPh3)NO (56% yield), m.p. 241-242°C (Lit 238-240°C)12 
Nitratobis(triphenylphosphine)copper(I) (977 mg, 1.50 mmol) was dissolved in 
chloroform (20 mL). After complete dissolution, triphenylphosphine (393 mg, 1.50 
mmol), followed by 1,10-phenanthroline (270 mg, 1.50 mmol) were added which caused 
the solution to immediately take yellow colour. After stirring for 30 mins at RT, the 
solvent was removed in vacuo to give a [Cu(phen)(PPh3)]N0 3  as a yellow solid. (65% 
yield). m.p. 198-199 C (Lit 202-204°C)12
5 ,6-Difluoro-2-(3,4,5-trimethoxyphenyl)- 1//-indole (19)
OMe
C17H15F2N03, MW: 31930
To a solution of 4,5-difluoro-iodotrifluoroacetanilide (1 mmol) in dry toluene (6 mL), [Cu 
(phen)(PPh3)]N0 3  and K3PO4 were added under nitrogen atmosphere and heated to reflux 
(110°C). 3,4,5-Trimethoxyphenylethyne (1.5mmol) was added dropwise over a period of 
1 hr. After completion of the reaction (TLC monitoring), the reaction mixture was cooled, 
extracted with EtOAc, dried over MgS0 4  and concentrated in vacuo. The obtained 
residue was purified by column chromatography (Et2 0 - Hexane) to afford the title
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compound (30% yield). *H NMR (DMSO-d«): 8  3.70 (3H, s, OMe), 3.88 (6 H, s, 2 x 
OMe), 6.93 (1H, s, H-3), 7.15 (2H, s, H-2’, H-6 ’), 7.34 (1H, dd, J  8.0 Hz, 11.5 Hz, H-4), 
7.50 (1H, dd, J 8 .0  Hz, 11.5 Hz, H-7), 11.56 (1H, s, NH). ESI MS m/z 320.10 [M+H*].
2-(4-Methoxyphenyl>- 5 ,6 -difluoro-l/f-indoIe (36)
C15HnF2NO, MW: 25925
Prepared from 3,4-difluoroaniline and p-methoxyphenylethyne using the same procedure 
described above for the synthesis of (19) (34% yield), *H NMR (DMSO-^): S 3.81(3H, 
s, OMe), 6.75 (1H, s, H-3), 7.04 (2H, d, J  7.0 Hz, H-3’, H-5*), 7.31 (1H, dd, J  7.0 Hz,
11.0 Hz, H-4), 7.46 (1H, dd, J  8.0 Hz, 11.5 Hz, H-7), 7.76 (2H, d, J  7.0 Hz , H-2’, H-6 ’),
11.61 (1H, s, NH).
5.2.2J. The intramolecular Heck annulation between chloroanilines and 
acetophenones.
2-(3,4-Dimethoxyphenyl)-i//-indole (20) 13
OMe
H
C16H15N02, MW: 25330
2-Chloroaniline (265 mg, 2mmol), 3,4-dimethoxyacetophenone (1.08g, 6 mmol), acetic 
acid (0.15mL) and MgS0 4  (120 mg, lmmol) were suspended in dimethylacetamide (12 
mL) in a pressure tube. Nitrogen was bubbled through the solution for 10 minutes. K3PO4 
(550 mg, 1.3mmol) and [Pd(tBu3P)2] ( 1 2 0  mg, 0 .1  mmol) were added to the solution, and
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nitrogen was bubbled through the mixture for an additional 5 minutes. The reaction 
mixture was heated to 145°C for 24 hours. After cooling to room temperature the reaction 
mixture was filtered, H2O (30mL) was added to the filtrate and the mixture was extracted 
with ethyl acetate. The combined organic layers were dried over MgSCU and the solvents 
were removed in vacuo. The residue was purified by column chromatography 
(EtOAc/hexane) to afford (73.9mg, 15% yield) of the title product, m.p. 190-191°C (Lit 
190°C).14 *H NMR (DMSO-*): 5 3.80 (3H, s, OMe), 3.87 (3H, s, OMe), 6.81 (1H, s, H- 
3), 6.98 (1H, t ,J  8.0 Hz, Ar-H), 7.06 (2H, m, Ar-H), 7.40 (2H, m, Ar-H), 7.45 (1H, A,J
1.5 Hz, H- 2’), 7.50 (1H, d, J  8.0 Hz, H- 5’), 11.39 (1H, bs, NH). I3C NMR(DMSO-dt): 
6  55.57, 55.64, 97.60, 108.99, 110.98, 112.18, 117.49, 119.18, 119.62, 121.04, 125.12,
128.78,136.86,137.94,148.43,149.02. ESI MS m/z 254.11 [M+H+].
S.2.2.4. The use of Fischer indole synthesis. 15
A: Phenylhydrazinespreparation
A solution of sodium nitrite (1.9g, 28.7 mmol) was added dropwise to a stirring solution 
of the substituted aniline (24.8mmol) in 6 M aqueous hydrochloric acid (lOmL) at 0°C 
and the resultant yellow mixture was stirred for 2 hours. To this mixture, a solution of 
stannous chloride (33g, 0.174 mol) in concentrated HC1 (30 mL) was added dropwise 
over 2 hours. After 1 hour of stirring, the mixture was poured into aqueous NaOH (10M) 
at 0°C causing a precipitation of a solid which was suspended in H2O and extracted with 
Et2 0 . After drying over MgSC>4, filtration and evaporation of the solvent, the 
phenylhydrazine was obtained.
B: General method for the Fischer indole synthesis o f 2-phenylindoles
Equivalent amounts of substituted phenylhydrazines (3.5mmol) and substituted 
acetophenones (3.5 mmol) were mixed in EtOH (20mL). A few drops of glacial AcOH 
were added and the solution was heated under reflux at 80°C for lhr. The solvents were 
evaporated to give a solid, which was added to PPA (30mL), slowly heated to 120°C and 
kept at this temperature until the reaction is complete (TLC monitoring). A solid was
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formed once the mixture is poured into a beaker containing cold water. This residue is 
collected, dried and purified using column chromatography (DCM/EtOAc) to give the 
pure corresponding indole (yield 18%-72%). The following compounds were prepared 
using this method.
2-(4-Methoxyphenyl)- 5-fluoro-///-indole (21)
H
C15H12FNO, MW: 241.26
Prepared from 4-fluorophenylhydrazine and p-methoxyacetophenone (42% yield). 
NMR (DMSO^fc): 6  3.81 (3H, s, OMe), 6.75 (1H, s, H-3), 6.89 (1H, dt, J  2.5 Hz, 9.0 
Hz, H-6 ), 7.04 (2H, d, J  7.5 Hz, H-3’,H-5’), 7.24 (1H, dd, J  2.5 Hz, 8.0 Hz, H-4), 7.34 
(1H, dd, J4.5Hz, 9.0 Hz, H-7), 7.79 (2H, dd, 7.5 Hz, H-2’,H-6 ’), 11,49(1H, s, NH).
2-(4-Methoxyphenyl)-if/-indole (22)
H
C15H13NO, MW: 22327
Prepared from phenylhydrazine and p-methoxyacetophenone (72% yield), m.p. 224-226 
°C (Lit 228-230 °C) . 16 'H NMR (DMSO-d*): 6  3.81 (3H, s, OMe), 6.76 (1H, s, H-3), 
6.97 (1H, dt, J  1.0 Hz, 8.0 Hz, Ar-H), 7.04 (2H, d, J  8.0 Hz, H-3’, H-5’), 7.06 (1H, dd, J
1.5 Hz, 7.0 Hz, Ar-H), 7.38 (1H, d, J  8.0 Hz, Ar-H), 7.49 (1H, d, J  7.5 Hz, Ar-H), 7.80 
(2H, d, J  8.0 Hz. H-2’, H-6 ’), 11.39 (1H, bs, NH). ,3C NMR (DMSO-rf*): 6  55.18,97.30,
111.02, 114.32, 114.32, 119.18, 119.61, 120.99, 124.88, 126.33, 126.33, 128.80, 136.90,
137.74,158.76.
2-(3,4,5-Trimethoxyphenyl)-//f-indole (23)
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OMe
OMe
OMe
C17H17N03, MW: 28332
Prepared from phenylhydrazine and 3,4,5-trimethoxyacetophenone (73% yield), m.p. 
190-191 °C. ‘H NMR (DMSO-*): 5 3.72 (3H, s, OMe), 3.90 (6 H, s, 2 x OMe), 6.93 
(1H, s, H-3), 7.02 (1H, dt, J  1.5 Hz, 8.0 Hz, Ar-H), 7.11 (1H, dt, J  1.5 Hz, 8.0 Hz, Ar-H), 
7.20 (2H, s, H-2’, H-6 ’), 7.43 (1H, dd, J  1.5 Hz, 8.0 Hz, Ar-H), 7.51(1H, d, 72.5 Hz, Ar- 
H), 11.39 (1H, s, NH). ,3C NMR (DMSO-*): 6  56.03, 56.13, 60.09, 98.63, 102.96,
111.06, 119.28, 119.85, 120.12, 121.41, 127.81, 128.64, 136.93, 137.09, 137.79, 153.25, 
153.25. ESI MS m/z 284.12 [M+H+],
2-(3,4,5-T rimethoxyphenyl)-5-fluoro-7//-indole (24)
OMe
C17H16FN03, MW: 30131
Prepared from 4-fluorophenylhydrazine and 3,4,5-trimethoxyacetophenone (43% yield), 
m.p. 210-211 °C. 'H NMR (DMSO-</«): 63.70(3H, s, OMe), 3.88 (6 H, s, 2 x OMe),
6.91 (1H, s, 3-H), 6.94 (1H, dt,72.5 Hz, 9.0 Hz, H-6 ), 7.17 (2H, s, H-2’, H-6 ’), 7.26 (1H, 
dd, 7 2.5 Hz, 10.0 Hz, H-4), 7.38 (1H, dd, 74.5 Hz, 8.5 Hz, H-7), 11.56 (1H, s, NH). ESI 
MS m/z 302.17 [M+H+]. CHN Anal. Calcd for C, 67.76; H, 5.35; N, 4.65. Found: C, 
67.16; H, 5.29; N, 5.10%.
2-(4-Methoxyphenyl)- 7-chloro-5-fluoro-l//-indoIe (25)
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X  \ y— C  /)— OMe
Cl
C15HuC1FNO, MW: 275.71
Prepared from 2-chloro-4-fluorophenylhydrazine and p-methoxyacetophenone (38% 
yield). fH NMR (DMSO-d*): 6  3.82 (3H, s, OMe), 6 .8 6  (1H, s, H-3), 7.05 (2H, d, J  7.0 
Hz, H-3’, H-5’), 7.10 (1H, dd, J 2.0 Hz, 9.0 Hz, H-4), 7.29 (1H, dd, J 2.5 Hz, 9.5 Hz, H-
6 ), 7.91 (2H, d, J  7.0 Hz, H-2*, H-6 ’), 11.52 (1H, s, NH). ESI MS m/z 276.05 [M+H+]. 
CHN Anal. Calcd for C, 65.35; H, 4.02; N, 5.08. Found: C, 64.76; H, 4.11; N, 5.20%.
2-(3,4-Dimethoxyphenyl)-7-chloro-5-fluoro-l/f-indole (26)
Ule
OMe
Cl
C16H,3C1FN02, MW: 305.73
Prepared from 2-chloro-4-fluoro-phenylhydrazine and 3,4-dimethoxyacetophenone (31% 
yield) 'H NMR (DMSO-rf«): 5 3.81 (3H, s, OMe), 3.89 (3H, s, OMe), 6.92 (1H, s, H-3),
7.04 (1H, d,y8.5 Hz, H-5’), 7.11 (1H, dd, J2.5 Hz, 9.5 Hz, H-4), 7.29 (1H, dd, J2.5 Hz,
9.5 Hz, H-6 ), 7.53 (1H, dd, J  2.0 Hz, 8.5 Hz, H-6 ’), 7.57 (1H, d, J  2.0 Hz, H-2’), 11.55 
(1H, s, NH). ESI MS m/z 306.07 [M+H*].
2-(3,4 ,5-Trimethoxyphenyl)-7-chloro-5-fluoro-l//-indole (27)
OMe
OMe
OMe
C17H15C1FN03, MW: 335.76
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Prepared from 2-chloro-4-fluoro-phenylhydrazine and 3,4,5-trimethoxyacetophenone 
(41% yield). 'H  NMR (DMSO-*): 6  3.71 (3H, s, OMe), 3.89 (6 H, s, 2 x OMe), 7.04 
(1H, s, H-3), 7.15 (1H, dd, J  2.5 Hz, 10.0 Hz, H-4 ), 7.29 (2H, s, H-2’, H-6 ’), 7.26 (1H, 
dd,y2.5 Hz, 10.0 Hz, H-6 ), 11.56 (1H, s, NH). ESI MS m/z 336.07 [M+H+],
2-(4-Nitrophenyl)-5-fluoro-l//-indole (28)
H
MW: 256.23
Prepared from 2-chloro-4-fluoro-phenylhydrazine and p-nitroacetophenone (22% yield). 
!H NMR (DMSO-</6): 6  7.08 (1H, dt, J  2.5 Hz, 9.0 Hz, H-6 ), 7.23 (1H, s, H-3), 7.41(1H, 
dd, J  2.5Hz, 10.0 Hz, H-4), 7.49 (1H, dd, J  5.0 Hz, 9.0 Hz, H-7), 8.16 (2H, d, J  8.0 Hz, 
H-2*, H-6 *), 8.37 (2H, d ,J 8.0 Hz, H-3’,H-5’), 11.99 (1H, s, NH).
2-(4-Nitrophenyl)- 7-chIoro-5-fluoro-l//-indole (29)
Cl
C14H8C1FN20 2, MW: 290.68
Prepared from 2-chloro-4-fluorophenylhydrazine and p-nitroacetophenone (19% yield). 
'H NMR (DMSO-rf«): 6  7.29 (1H, s, H-3), 7.31 (1H, dd, J  9.5 Hz, 2.5 Hz, H-4), 7.45 
(1H, dd, J  2.5 Hz, 9.0 Hz, H-6 ), 8.31 (2H, d, 8.5 Hz, H-2’, H-6 ’), 8.36 (2H, dd,72.5 Hz,
8.5 Hz, H-3’, H-5’), 11.98 (1H, s, NH).
2-(4-Aminophenyl)-l//-indole (30)
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H
C,4H,jN2 MW: 208.26
Prepared from phenylhydrazine and p-aminoacetophenone (24% yield). *H NMR 
(DMSO-tff): 6  5.27 (2H, s, NH2), 6.57 (1H, s, H-3), 6.64 (2H, d, J  8.5 Hz, H-3’, H-5’), 
6.93 (1H, dt, J  1.5 Hz, 8.0 Hz, H-6 ), 7.01 (1H, dt, J  1.5Hz, 8.5 Hz, Ar-H), 7.31 (1H, d, J
8.0 Hz, Ar-H), 7.43 (1H, d, J  7.5 Hz, Ar-H), 7.54 (2H, d, J  8.5Hz, H-2’, H-6 ’), 11.26 
(1H, s, NH). ,3C NMR (DMSO-*): 5 95.42,110.71,113.94,113.94,118.92,119.10, 
120.24,126.06,126.06,129.45,130.51,136.63,139.15,148.73.
2-(4-Aminophenyl)-5-fluoro-l//-indoIe (31)
H
CmHjFN* MW: 22625
Prepared from 4-fluoro-phenylhydrazine and p-aminoacetophenone (21% yield). *H 
NMR (DMSOw/6): 6  5.38 (2H, s, NH2), 6.57 (1H, s, H-3), 6.64 (2H, d, J  7.0 Hz, H-3’, 
H-5’), 6.82 (1H, dt, J  2.5 Hz, 10.5Hz, H-6 ), 7.16 (1H, dd, J  2.5 Hz, 10.0 Hz, H-4), 7.28 
(2H, dd, J  5.0 Hz, 9.0 Hz, H-7), 7.51 (2H, d, J  7.0 Hz, H-2’, H-6 ’), 11.27 (1H, s, NH). 
ESI MS m/z 227.10 [M+H+].
2-(4-Aminophenyl)-7-chloro-5-fluoro-///-indoIe (32)
/  \XXVv> NH2
ci H 
C14H10C1FN2, MW: 260.69
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Prepared from 2-chloro-4-fluoro-phenylhydrazine and p-aminoacetophenone (24% yield). 
*H NMR (DMSO-rf6): 55.38 ( 2 H, s, NH2), 6.64 (2H, d, J  7.0 Hz, H-3’, H-5’), 6 .6 8  
(1H, s, H-3), 7.02 (1H, did, J  2.5 Hz, 9.5 Hz, H-4), 7.21 (1H, dd, J  2.5 Hz, 9.5 Hz, H-6 ), 
7.64 (2H, d, J  7.0 Hz, H-2\ H-6 ’), 11.27 (1H, s, NH).
2-(3-Iodo-4-methoxyphenyl)-///-indole (33)
H
Cl5H12INO, MW: 349.17
Prepared from phenylhydrazine and 3-iodo-4-methoxyacetophenone (44% yield). 
NMR (DMSO-dfi): 5 3.88 (3H, s, OMe), 6.82 (1H, s, H-3), 7.00-7.11 (3H, m, Ar-H), 
7.37 (1H, d, J  8.5 Hz, Ar-H), 7.49 (1H, d, J  8.0 Hz, H-5’), 7.87 (1H, dd, J 2.5 Hz, 8.0 Hz, 
H-6 *), 8.28 (1H, d, J  2.5 Hz, H-2’), 11.46 (1H, s, NH). ,3C NMR (DMSO-</6): 6  56.52,
86.76, 98.01, 111.12, 111.89, 119.34, 119.80, 121.33, 126.50, 126.91, 128.60, 135.18,
136.03,137.00,157.19.
2-(3-Iodo-4-methoxyphenyl)-5-fluoro-l//-indole (34)
I
H
C15HnFINO, MW: 367.16
Prepared from 4-fluoro-phenylhydrazine and 3-iodo-4-methoxyacetophenone (39% 
yield). *H NMR (DMSO-d*): 6  3.88 (3H, s, OMe), 6.82 (1H, s, H-3), 6.91 (1H, td, J  
2.5Hz, 9.0 Hz, H-6 ), 7.11(1H, d, 8.5 Hz, H-5’), 7.25 (1H, dd, ./2.5Hz, 9.5 Hz, H-4), 7.35 
(1H, dd, J  4.5 Hz, 9.0 Hz, H-7), 7.85 (1H, dd, J  2.5 Hz, 8.5 Hz, H-6 ’), 8.28 (1H, d, J  2.5 
Hz, H-2’), 11.46 (1H, s, NH).
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2-(3-Fluoro-4-methoxyphenyl)-5-fluoro-i//-indole (35)
F
C15HuF2NO, MW: 25925
Prepared from 4-fluorophenylhydrazine and 3-fluoro-4-methoxyacetophenone (53% 
yield). 'H NMR (DMSO-d«): 5 3.89 (3H, s, OMe), 6.84 (1H, s, H-3), 6.92 (1H, dt.72.5 
Hz, 9.0 Hz, H-6 ), 7.26 (2H, m, H-Ar), 7.35 (1H, dd, 74.5 Hz, 9.0 Hz, H-7), 7.64 (1H, dd, 
7 2.0 Hz, 8.5 Hz, Ar-H), 7.72 (1H, dd, 7 2.5 Hz, 8.0 Hz, H-6 ’), 11.56 (1H, s, NH). ESI 
MS m/z 260.08 [M+H+]. CHN Anal. Calcd for C, 69.49; H, 4.28, N, 5.40. Found, C 
69.37, H, 4.29; N, 5.51%.
5.2.3, N-substituted benzimidazoles:
General method for the synthesis of N-substituted 2-phenylbenzimidazoles: NaH
(53mg, 2.2 mmol) was added to a solution of the 2-phenylbenzimidazole (0.75 mmol) in 
DMF (lOmL) at 0°C under nitrogen gas and stirred for 0.5 hour. Iodomethane or the 
sulfonyl chloride (1.5mmol) was then added and the solution left to be stirred at room 
temperature for 12 hours. The reaction mixture was diluted with H2O (30 mL) and 
extracted with DCM (3 x 30mL). The organic phases were collected, dried over MgS0 4  
and concentrated in vacuo to give a solid residue, which was purified by column 
chromatography (70%EtOAc/30% Hexane) to provide the desired N-substituted 
benzimidazole. The following compounds were prepared using this procedure.
2-(3,4-Dimethoxyphenyl)-5-fluoro-l-methylsu!fonylbenzimidazole (37)
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OMe
0 * \
Me
C16H15FN20 4S, MW: 35036
Prepared from (4) and methanesulfonyl chloride (48 % yield), !H NMR (CDCI3): 6  2.96 
(3H, s, Me), 3.97 (3H, s, OMe), 3.98 (3H, s, OMe), 7.01(1H, d ,J 8.5 Hz, H-5’), 7.18 (1H, 
dt, J 2.5 Hz, 9.0 Hz, H-6 ), 7.36 (1H, d, J  2.5 Hz, H-2’), 7.42 (1H, dd, J 2.0, 8.5 Hz, H-6 ’), 
7.53 (1H, dd, J2.5, 9.5 Hz, H-4), 8.02(1H, dd, J  4.5Hz, 9.0 Hz, H-7). CHN Anal. Calcd 
for C 54.85; H, 4.32; N, 7.99. Found: C, 54.52; H, 4.28; N, 8.22%.
2-(3,4-Dimethoxyphenyl)-6-fluoro-l-methylsulfonylbenzimidazole (38)
OMe
Me
C16H15FN20 4S, MW: 35036
Prepared from (4) and methanesulfonyl chloride (39% yield), *H NMR (CDCI3): 6  2.98 
(3H, s, Me), 6  3.97 (3H, s, OMe), 3.99 (3H, s, OMe), 6.99 (1H, d, J  8.0 Hz, H-5’), 7.21 
(1H, dt, J  2.5 Hz, 9.0 Hz, H-5), 7.35 (1H, d, J2.0 Hz, H-2’), 7.41 (1H, dd, J  2.0, 8.0 Hz, 
H-6 ’), 7.78(2H, m, H-4, H-7). Calcd for C 54.85; H, 4.32; N, 7.99. Found: C, 54.32; H, 
4.18; N, 8.02%.
2-(3,4-Dimethoxyphenyl)-5-fluoro-l-phenylsulfonylbenzimidazole (39)
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OMe
C21HI7FN20 4S, MW: 412.43
Prepared from (4) and phenylsulfonyl chloride (35% yield), !H NMR (CDCI3): 6  3.88 
(3H, s, OMe), 3.98 (3H, s, OMe), 6.94 (1H, d ,J 8.0 Hz, H-5’), 7.13 (1H, d, J2.0 Hz, H- 
2’), 7.18 (1H, dt, J 9.0 Hz, 2.5 Hz, H-6 ), 7.22 (1H, dd, J2.0 Hz, 8.5 Hz, H-6 '), 7.28-7.53 
(5H, m, H-Ar), 8.17 (1H, dd, J  9.0, 4.5 Hz, H-7). CHN Anal. Calcd for C, 61.16; H, 
4.15; N, 6.79. Found: C, 60.95; H, 3.99; N, 6.65%.
2-(3,4-Dimethoxyphenyl)-6-fluoro-l-phenylsulfonylbenzimidazole (40)
OMe
C21H17FN20 4S, MW: 412.43
Prepared from (4) and phenylsulfonyl chloride (39 % yield), *H NMR (CDCI3): 6  3.88 
(3H, s, OMe), 3.99 (3H, s, OMe), 6.95 (1H, d, J  8.5 Hz, H-5’), 7.08 (1H, d, J  2.0 Hz, H- 
2’), 7.15 (1H, dt, J  9.0 Hz, 2.5 Hz, H-5), 7.20 (1H, dd, J  2.0 Hz, 8.5 Hz, H-6 '), 7.32-7.55 
(5H, m, H-Ar), 7.65 (1H, dd, J5.0 Hz, 9.0 Hz, H-4), 7.98 (1H, dd, J 9.0 Hz, 2.5 Hz, H-7). 
CHN Anal. Calcd for C, 61.16; H, 4.15; N, 6.79. Found: C, 61.10; H, 3.98; N, 6.65%.
2-(3,4-Dimethoxyphenyl)-l-methylsulfonylbenzimidazole (41)
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OMe
Q \
Me
C16H16N20 4S, MW: 33237
Prepared from (6 ) and methylsulfonyl chloride (60% yield), *H NMR (CDCI3): 6  2.97 
(3H, s, Me), 3.96 (3H, s, OMe), 3.98 (3H, s, OMe), 7.01 (1H, d, J  8.5 Hz, H-5’), 7.34- 
7.57 (4H, m, H -Ar), 7.83 (1H, dd, J  2.0 Hz, 8.5 Hz, H-6 ’), 8.04 (1H, d, J  2.0 Hz, H-2’). 
,3C NMR (CDCI3): 6  41.61,55.98,56.09,110.36,113.94,114.73,120.43,121.63,124.2 
3,125.55,125.58,133.86,142.47,148.36,151.34,153.70. CHN Anal. Calcd for C, 
57.82; H, 4.85; N, 8.42. Found: C, 57.70; H, 4.76; N, 8.32%.
2-(3,4-Dimethoxyphenyl)-N-phenylsulfonylbenzimidazole (42)
OMe
C21H18N20 4S, MW: 394.44
Prepared from (6 ) and phenylsulfonyl chloride (55% yield), NMR (CDCI3): 6  3.90 
(3H, s, OMe), 4.00 (3H, s, OMe), 6.96 (1H, d, J  8.0 Hz, H-5’), 7.12 (1H, d, J2.0 Hz, H- 
2’), 7.25 (1H, dd, J  8.5, 2.0 Hz, H-6 ’), 7.28-7.53 (7H, m, Ar-H), 7.73 (1H, d, J  8.0 Hz, 
Ar-H), 8.24 (1H, d, J8.0 Hz, Ar-H), 13CNMR (CDCI3): 6  56.01, 56.01,110.17,113.95, 
115.40,120.21,121.99, 124.46,125.40,125.42, 126.95, 126.95,129.00,129.00,134.13,
134.27,138.00,142.53,148.11,151,14,154.12.
2-(3,4-Dimethoxyphenyl)-l-tosylbenzimidazole (43)
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OMe
Me
C^HUN^S, MW: 408.47
Prepared from (6) and p-toluene sulfonyl chloride (42% yield), 1H NMR (DMSO): 6 
2.30 (3H, s, Me), 3.77 (3H, s, OMe), 3.88 (3H, s, OMe), 7.10 (1H, d, J  8.5 Hz, H-5’), 
7.19 (2H, m, Ar-H), 7.30 (2H, d, J  8.5 Hz, H-3” , H-5”), 7.39 (2H, d, J 8.5 Hz, H-2” , H- 
6”), 7.47 (2H, m, Ar-H), 7.70 (1H, d, J  8.0 Hz, H-5’), 8.08 (1H, d, J  8.0 Hz, Ar-H). 13H 
NMR (DMSO): 6 21.01,55.58,55.62,110.70, 113.93, 114.05, 114.87, 118.91, 119.98, 
123.88, 125.37, 125.42, 126.51, 126.51, 130.12, 130.12, 134.80, 135.52, 141.51, 146.02, 
153.30, 154.12.
2-(3,4-Dimethoxyphenyl)-5-fIuoro-N-methylbenzimidazole (50)
OMe
Me
C16H15FN20 2, MW: 28630
Prepared from (4) and iodomethane (67% yield), NMR (CDC13): 6 3.72 (3H, s, Me), 
3.85 (3H, s, OMe), 3.88 (3H, s, OMe), 6.92 (2H, m, Ar-H), 7.13 (2H, m, Ar-H), 7.28 (1H, 
d, J  2.0 Hz, H-2’), 7.40 (1H, dd, .79.5 Hz, 2.5 Hz, H-4). CHN Anal. Calcd for C, 67.12; 
H, 5.28; N, 9.78. Found: C, 66.93; H, 5.36; N, 9.72%.
2-(3,4-Dimethoxyphenyl)-6-fluoro-l-methylbenzimidazole (51)
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OMe
1 \
Me
C16H15FN20 2, MW: 28630
Prepared from (4) and iodomethane (54% yield), *H NMR (CDCI3): 6  3.78 (3H, s, Me), 
3.82 (3H, s, OMe), 3.89 (3H, s, OMe), 6.92 (1H, d, J  8.5 Hz, H-5’), 7.02 (2H, m, Ar-H), 
7.18 (1H, dd, J  8.5 Hz, 2.0 Hz, H-6 ’), 7.29 (1H, d, J  2.0 Hz, H-2’), 7.68 (1H, dd, J  2.5 
Hz, 9.5 Hz, H-7). CHN Anal. Calcd for C, 67.12; H, 5.28; N, 9.78. Found: C, 66.99; H, 
5.26; N, 9.80%.
5.2.4, N-substituted phenyl indoles:
Compounds (52) and (53) were prepared using the procedure described above for the 
synthesis of N-substituted benzimidazoles.
2-(3,4-Dimethoxyphenyl)- 5-fluoro-l-methyl-indole (52)
OMe
Me
C17H16FN02, MW: 28531
Prepared from (18) and iodomethane (51% yield), *H NMR (DMSO-dg): 6  3.74 (3H, s, 
NMe), 3.80 (3H, s, OMe), 3.85 (3H, s, OMe), 6.52 (1H, s, H-3), 7.01 (1H, dt, J2.5 Hz,
9.5 Hz, H-6 ), 7.12 (3H, m, H-2’, H-5’, H-6 ’), 7.30 (1H, dd, J2.5 Hz, 10.0 Hz, H-4), 7.49 
(1H, dd, J  4.5 Hz, 9.0 Hz, H-7). CHN Anal. Calcd for C, 71.56; H, 5.65; N, 4.91. Found: 
C, 71.94; H, 5.87; N, 4.62%.
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2-(3,4-Dimethoxyphenyl)-l-methylindole (53)
OMe 
OMe 
Me
C17H17N02, MW: 26732
Prepared from (20) and iodomethane (66% yield), 'H NMR (DMSO-d*): 6  3.73 (3H, 
s, NMe), 3.80 (3H, s, OMe), 3.85 (3H, s, OMe), 6.55 (1H, s, H-3), 7.01-7.22 (5H, m, Ar- 
H), 7.46 (1H, d, J  2.0 Hz, H-2’), 7.58 (1H, d, 8.5 Hz, H-5’). 13C NMR (DMSO-d6): 
6  31.11, 56.02, 56.08,101.14,109.53, 111.17,112.83, 119.85, 120.31, 121.52, 121.97,1 
25.58, 127.97, 138.19, 141.52, 149.05. 150.03.
2-(3,4-Dimethoxyphenyl)-3-chloro-l-methylsulfonyl-indole (54)
Cl OMe
OMe 
Me
C17H16C1N04S, MW: 36533
From (20) and methylsulfonyl chloride as a side product (28% yield). *H NMR (CDCI3): 
6  2.85 (3H, s, Me), 3.93 (3H, s, OMe), 3.98 (3H, s, OMe), 7.00 (1H, d, J  8.0 Hz, H- 5’), 
7.10 (1H, d, J 2.0 Hz, H-2’), 7.14 (1H, dd, J8.0, 2.0 Hz, H-6 ’), 7.49-7.52 (2H, m, H-Ar), 
8.22 (1H, d, J  7.5 Hz, 2.0 Hz, Ar-H), 8.32 (1H, d, J  8.0, 2.0 Hz, Ar-H). I3C NMR 
(DMSO-</6): 6  42.19,55.81, 56.21,107.11,110.12,114.63,114.84, 116.18,119.06,124. 
61,126.54,131.50, 136.18,145.00,149.91,151.80,157.65.
2-(3,4-Dimethoxyphenyl)-3-chloro-5-fluoro-l-methyIsulfonyl-indoIe (55)
96
Chapter Five Experimental
Cl OMe
Me
C ,7Hi5ClFN0 4S, MW: 383.82.
From (20) and methylsulfonyl chloride as a side product (50% yield), 1H NMR (DMSO- 
d6): 6  3.03 (3H, s, Me), 3.74 (3H, s, OMe), 3.84 (3H, s, OMe), 7.05 (1H, dd, J 2.5 Hz, 8.5 
Hz, H-6 ’), 7.14 (1H, m, Ar-H), 7.23 (1H, m, Ar-H), 7.42 (1H, m, Ar-H), 7.83 (1H, m, Ar- 
H), 8.12(1H, dd, J  4.5 Hz, 9.0 Hz, H-7).
2-(4,5-Dimethoxyphenyl)-3-chloro-l-methylsulfonylindole (56)
Cl OMe
Me
C23H20CINO4S, MW: 441.9
From (18) and p-toluenesulfonyl chloride as a side product (57% yield), NMR
(CDCI3): 6  2.46 (3H, s, Me), 3.92 (3H, s, OMe), 3.99 (3H, s, OMe), 6.99 (1H, d, J  2.0 
Hz, H-2’), 6.98 (1H, d, J  8.0 Hz, H-5’), 7.04 (1H, dd, J  8.0, 2.0 Hz, H-6 ’), 7.09 (2H, d, J
8.0 Hz, H-3”, H-5”), 7.30 (2H, d, J  8.0 Hz, H-2”, H-6 ”), 7.41-7.47 (2H, m, Ar-H), 7.53 
(1H, d ,y 8.0 Hz, Ar-H), 8.38 (1H, d, J8.5 Hz, Ar-H). 13C NMR (CDC13): 6  21.59, 55.87,
55.96, 105.03, 109.99, 114.85, 116.51, 118.61, 121.38, 124.40, 124.68, 126.02, 126.96,
126.96, 128.53, 129.35, 129.35, 134.71, 135.83, 136.23, 144.94, 147.93, 149.81.
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2-(3,4-Dimethoxyphenyl)- 3-chIoro-5-fluoro-l-phenylsulfonyl-indole (57)
Cl OMe
C22H17CIFNO4S, MW: 445.89
Prepared from (20) and phenylsulfonyl chloride as a side product (55% yield), *H NMR 
(DMSO-</6): 6  3.76 (3H, s, OMe), 3.87(3H, s, OMe), 6.95 (1H, d, J2.5 Hz, H-2’), 7.01 
(1H, dd, J  8.0 Hz, 2.0 Hz, H-6 ’), 7.10 (1H, d, J  8.0 Hz, H-5’), 7.35-7.65 (7H, m, H-Ar), 
8.24 (1H, dd, J  9.0 Hz, 4.5 Hz, H-7).
2-(3,4-Dimethoxyphenyl)-l-methylsulfonylindoIe (58)
OMe
Me
C17H17N 0 4S, MW: 33139
Prepared from (18) and methylsulfonyl chloride (52% yield) !H NMR (CDCI3): 
6  2.75 (3H, s, Me), 3.92 (3H, s, OMe), 3.96 (3H, s, OMe), 6.71 (1H, s, H-3), 6.94 (1H, d, 
J  8.0 Hz, H-5’), 7.28 (2H, m, Ar-H), 7.39 (2H, m, Ar-H), 7.60 (1H, dd, J  8.0 Hz, 2.0 Hz, 
H-6 ’), 8.16 (1H, d,y 8.0 Hz, Ar-H). 13C NMR (CDCI3): 6  39.31, 55.87, 56.02, 110.29,
112.59, 114.08, 115.97, 120.83, 122.49, 124.54, 124.94, 129.68, 131.96, 138.03, 141.96, 
148.11,149.79.
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2-(3,4-Dimethoxyphenyl)- 5-fluoro-l-methylsulfonyl-indole (59)
OMe
Me
C17H16FN04S, MW: 34938
Prepared from (20) and methylsulfonyl chloride (59% yield), *H NMR (DMSO-^): 
6 3.08 (3H, s, Me), 3.78 (3H, s, OMe), 3.82 (3H, s, OMe), 6.82 (1H, s, H-3), 7.02 (dd, J
2.5 Hz, 8.0 Hz, H-6’), 7.11-7.26 (3H, m, Ar-H), 7.46 (1H, d, J  8.5 Hz, H-5’), 7.97 (1H, 
dd, 74.5 Hz, 9.0 Hz, H-7).
2-(3,4-Dimethoxyphenyl)-l-pheny!sulfonylindole (60)
OMe
CaHpNC^S, MW: 393.46
Prepared from (18) and phenylsulfonyl chloride (47% yield), *H NMR (CDCI3): 
6 3.91 (3H, s, OMe), 3.97 (3H, s, OMe), 6.53 (1H, s, H-3), 6.92 (1H, d, J  8.5 Hz, H-5’), 
7.01-7.03 (2H, m, Ar-H),7.22-7.46 (8H,m, Ar-H), 8.35 (1H, d,7 8.5 Hz, Ar-H).13CNMR 
(CDCI3): 5 55.92, 55.99,110.17,113,03,114.26, 116.68,120.98,122.87,124,39,124.72,
124.75,126.78,126.78,128.98,128.98,130.51,133.48,137.76,138.29,142.00,147.91, 
149.65.
2-(3,4-Dimethoxyphenyl)-l-tosylindole (61)
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OMe
Me
CoHnNOA MW: 407*48
Prepared from (18) and p-toluenesulfonyl chloride (52% yield), 1H NMR (DMSO-dij): 
6 2.26 (3H, s, Me), 3.79 (3H, s, OMe), 3.84 (3H, s, OMe), 6.74 (1H, s, H-3), 7.04-7.10 
(3H, m, Ar-H), 7.22-7.38 (6H, m, Ar-H), 7.50 (1H, d, J  8.0 Hz, Ar-H), 8.15(1H, d, J  8.5 
Hz, H-Ar). 13C NMR (DMSO-</6): 6 20.92, 55.54, 55.54, 110.85, 113.24, 114.01, 
116.08, 120.81, 122.54, 124.29, 124.53, 124.68, 126.26, 126.26, 129.60, 129.60, 130.36,
133.60, 137.50, 141.86, 144.97, 147.62, 149.32.
2-(3,4-Dimethoxyphenyl)- 5-fluoro-l-phenylsulfonylindole (62)
OMe
C22H18FN04S, MW: 411.45
Prepared from (20) and phenylsulfonyl chloride (40% yield), NMR (DMSO-d^): 
6 3.79 (3H, s, OMe), 3.85(3H, s, OMe), 6.75 (1H, s, H-3), 7.04-7.05 (3H, m, Ar-H), 7.22 
(1H, dt, J  2.5 Hz, 9.5 Hz, H-6), 7.32-7.49 (6H, m, Ar-H), 8.14 (1H, dd, J  9.0, 4.5 Hz, H-
7). CHN Anal. Calcd for C, 64.22; H, 4.41; N, 3.40. Found: C, 63.91; H, 4.51; N, 3.37%.
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6.1. Protein-protein interactions as a target in cancer drug discovery
The last decade was the genomics era with massive quantities of data generated in this 
field, especially through the successful decoding of the human genome.1 However, this 
scientific endeavour has recently shifted toward the field of proteomics where the main 
focus is changed from looking for which genes encode which proteins into how proteins 
interact with each other. Due to their vast structural diversity, proteins often undergo a 
complex network of interactions to exert several effects including the fine control of 
protein localisation, substrate-processing activity and their tagging for destruction and 
recycling. Moreover, these protein-protein interactions play a major role in the well-tuned 
signal transduction between cells caused by neighbouring environmental stimuli leading 
to the appropriate set of responses.
There is currently growing interest in targeting the different protein-protein interactions 
for therapeutic purposes. Because of their desired pharmaceutical properties in terms of 
convenience of administration through the oral route, it is ideally hoped to be able to have 
small drug-like molecules to target specific protein-protein interactions. However, this 
task is very challenging since the interface area between the interacting proteins is often 
very large (1,500-3,000A2) compared to typically less than a third of that in the case of 
well-studied protein-small molecule interactions (300-1000 A2).2,3 Moreover, these 
surfaces of interactions are generally flat lacking grooves or pockets where small 
molecules usually bind.4 However, there is much evidence indicating that only a small 
subset of the interface residues contribute most of the free energy of binding leading to 
what are termed as “hot spots”. 5,6 These hot spots are usually found at the centre of 
contact interfaces and they constitute less than half of the interaction interface. Therefore, 
efforts can be directed into designing inhibitory molecules that target these relatively 
small areas but this in itself poses another challenge, which lies in the ability to identify 
these hot spots.
Hanahan and Weinberg have defined and described six hallmarks (aquired capabalities) 
for most cancers which have been descrbied in detail previously (Chapter l).7 It is
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believed that cancer cells have the ability to develop their own growth signalling 
pathways and evade inhibitory signals and apoptosis. They also acquire the ability of 
unlimited replicative potential, angiogenesis and metastasis. Table 1 lists some potential 
protein-protein targets for each of these hallmarks which can be explored as potential 
target pathways for developing and designing novel treatments.7’8
6.1.1. The human protein double minute (HDM2) binders: an example o f successful 
targeting o f protein-protein interactions
Despite the fact that targeting protein-protein interactions is undoubtedly a very 
challenging task, several small-molecule inhibitors with significant potency to dismpt 
such interactions have been identified. One of the most interesting and best-characterised 
examples in the area of oncology is the successful targeting of the p53-HDM2 
interactions although an inhibitor in this area has yet to reach clinical trials.9
The tumour suppressor protein p53 otherwise known as the guardian of the genome plays 
an essential role in the DNA-damage response. It is estimated that more than 50% of 
cancers have a malfunctioning p53.10 One of the key functions of p53 is inducing 
apoptosis (programmed cell death) as a result of genomic stress and the complete 
mechanism involved is still being investigated. Under normal conditions, cellular levels 
o f p53 are very low due to p53-HDM2 protein-protein interactions whereby HDM2 
catalyses the binding of ubiquitination to p53 resulting in its proteosomal degradation. 
Therefore, it follows that the protection of p53 from this proteosomal degradation process 
by disrupting the p53-HDM2 interactions leads to an increased p53 activity, which in
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Acquired capability Example of mechanism Protein-protein target
Self-sufficiency in growth signals Overexpression of growth-factor receptors (e.g. Her2/«ew) ESX-Sur-2, Bcl-2 family
Insensitivity to anti-growth signals
Overexpression of c-myc, inactivation of retinoblastoma 
protein
p-catenin-T cell factor
Evading programmed cell death 
(apoptosis)
Inactivation of p53, overexpression of anti-apoptotic proteins
Bcl-2 family, MDM2-p53, XIAP- 
caspase
Limitless replicative potential Activation of telomerase -
Sustained angiogenesis Induction of vascular endothelial growth factor -
Tissue invasion and metastasis Alteration of cell adhesion and motility Rac-Tiaml
Table 1: Hallmarks of cancer anc protein-protein targets (adapted from reference 8).
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turn is associated with an antitumour activity. Investigation of the p53-HDM2 interface 
revealed that only three amino acid residues of p53 (Leu26, Trp23 and Phel9) contribute 
most of this interaction in the hydrophobic binding interface (hot-spot area of 300 Ao2).n 
In a search for a small molecule inhibitor of the p53-HDM2, high-throughput screening 
(HTS) led to the discovery of a series of tetra-substituted dihydroimidazoles which 
become known as Nutlins (research was carried out in Nutley-New Jersey, Hoffmann-la 
Roche laboratories). Structural optimisation of these molecules led to the identification of 
an even more potent inhibitor NUTLIN 3 (Figure 1) which disrupts the p53-MDM2 (the 
mouse homologue of HDM2) complexes with an IC50 of 90 nM.12 It was also found that 
Nutlin-3 has a potent p53-blocking activity in vitro against human tumour xenografts in 
vivo)2
In a competing project at Johnson & Johnson, a series of benzodiazepinediones were 
identified as HDM-2 binders as a result of parallel screening of a library of 338,000 
compounds using thermostability assays.13 Further structural optimisation studies on this 
compound series led to the identification of a benzodiazepinedione (Figure 1) with high 
binding affinity to HDM-2 {K<j = 67 nM, IC50 = 420 nM).14 In cells overproducing 
HDM2, these benzodiazepinediones were found to block p53-MDM2 complexes and 
promote their rapid dissociation.15
Most intriguing was the finding that the discovered small-molecule HDM2 binders 
(Nutlins and benzodiazepinediones) with remarkable differences in their structural 
scaffolds have a similar binding mode. X-ray crystallography studies showed that Nutlins 
and benzodiazepinediones disrupt the HDM2-p53 interactions by mimicking the key p53 
amino residues in the interaction hot spot.12,13 These compounds bind to the same 
binding region of p53 in the HDM2 and their aromatic or aliphatic moieties extend into 
HDM2 pockets which bind the key residues of p53 (Leu26, Trp23 and Phel9).
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MDM2 MDM2
Nutlin
p53 p53
Trp
Phe
Antitumour effectp53 degradation
Nutlin-3Benzodiazepinedione
Figure 1. An illustrative diagram o f p53-MDM2 protein-protein interaction and its 
disruption by a Nutlin inhibitor (adapted from reference 9). The chemical structures o f  
Nutlin-3 and one o f  the benzodiazepinedione compound series are also shown.
6.2. T he W n t signalling  pa thw ay
The current understanding o f  the Wnt-dependent signaling pathways is mainly derived 
from several studies using various model organisms including, Xenopus, Drosophila 
melanogaster, Caenorhabditis elegans and mammals. These studies have established that 
Wnt-dependent signaling pathways consist o f  a complex network o f  proteins, which play
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a major role in controlling many events during embryonic development and regulating 
cell proliferation, morphology, motility as well as cell fate.16
The Wnt-dependent signaling pathways consist of three different molecular pathways 
downstream of Wnt/Fz interaction; the canonical pathway, the planar cell polarity (PCP) 
pathway and the Wnt/Ca2+ pathway. Most of the published research in the area of Wnt 
signaling has focused on the Wnt/p-catenin pathway referred to as the “canonical” Wnt 
pathway (Figure 2), which plays a key role in regulating cell proliferation by means of 
gene expression control. The other two pathways, the Wnt/Ca2+ and Wnt/polarity are 
known as the “non-canonical pathways” and their components have only been recently 
identified.16,17 It is believed that the Wnt/Ca2+ signalling leads to transient increases in 
cytoplasmic free calcium which results in the activation of protein kinase C (PKC) and 
Ca2+ -calmodulin dependent protein kinase II.18 On the other hand, the Planar Cell 
Polarity signalling regulates remodeling of the cytoskeleton and changes in cell adhesion 
and motility. This effect is mediated via the activation of the small GTPases RHOA 
(RAS homologue gene-family member A) and RAC1.19
The discrimination between the three Wnt pathways is made at the receptor level. While 
the common initial step in Wnt signalling is the binding of Wnt ligand to the seven- 
transmembrane Frizzled (Fz) receptor, signal transduction downstream thereafter differ in 
each of these three pathways depending mostly on which Wnt ligand and Fz receptor are 
activated. Wnt/Fz mediated interactions are associated with a wide range of responses as 
19 different human Wnt factors and 10 different transmembrane receptors of the Frizzled 
receptor family have been identified so far.16
The Wnt/p-catenin pathway, which controls the cytosolic concentration of the 
oncoprotein p-catenin has been extensively studied in various vertebrate and invertebrate 
model systems. The activation of this canonical pathway and signal transduction require 
the hetero-dimerisation of Fz and the co-receptor LRP5 or LRP 6 (low-density 
lipoprotein receptor related protein).20 A detailed representation of the several events, 
which take place during Wnt/p-catenin pathway activation is represented in Figure 2.
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In the absence of Wnt ligand, APC, Axin and GSK-3 normally function as part of a p-
catenin turnover complex, which targets P-catenin for ubiquitin-mediated proteosomal
degradation. It follows that p-catenin is captured by APC and Axin within this
destruction complex leading to the phosphorylation of a set of conserved serine and
threonine residues sequentially in the amino terminus by the kinases C K l-a and GSK- 
13 p. The phosphorylated p-catenin binds to a component of an E3 ubiquitin ligase 
complex; p-TRCP (P-Transducin Repeat Containing Protein) leading to its 
ubiquitinylation and subsequently is directed into the proteosomal degradation 
machinery. As a consequence, cytosolic p-catenin levels are maintained at low levels 
allowing the TCF/LeF (T-cell factor/ Lymphoid enhancer) proteins to interact with other 
co-repressors and bind to Wnt target genes to block their transcription.
On the other hand, the binding of a Wnt ligand to a Fz receptor and its LRP 5 or LRP 6 
c-receptor, induces the formation of Fz-Dvl complex which facilitates the relocation of 
axin to the cell membrane causing the inactivation and dissociation of p-catenin turnover 
complex. The unphosphorylated p-catenin escapes ubiquitinylation leading to its 
cytosolic accumulation and subsequent entry to the nucleus. Once in the nucleus, P- 
catenin activates Wnt target gene transcription by associating with nuclear TCF/LeF 
transcription factors. It is worthy to note that many of the transcriptional targets of the 
Wnt pathway (e.g. c-myc, cyclin D1 and survivin) are also oncogenes and may in part 
explain the tumour-promoting consequences of mutations to Wnt signalling components.
110
Chapter Six___________________________________________________________________Introduction
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Axin
Axin
P-TRCP
CSK3p
Protea somal 
degradation
PYG^
■fBCL9
Repression ActivationC roucho
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Figure 2: An overview o f the Wnt signaling pathway (reproduced from reference 8). In the absence o f  active Wnt (left), (3-catenin is 
degraded and Tcf/Lef transcription factors act as repressor. On the other hand, when a Wnt signal is present (right), P-catenin 
accumulates in the cytoplasm, enters the nucleus, and activates transcription together with Tcf/Lef transcription factors.
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6.3. Wnt signaling pathway and cancer
The link between the Wnt pathway and cancer dates back to the initial discovery of this 
signalling pathway when the first Wnt (Wnt-1) was found as a protooncogene activated 
by the integration of the mouse mammary tumour virus in murine breast cancer.22 The 
following studies in this area and the subsequent identification of downstream 
components of this pathway have all come to confirm and provide further evidence for 
the role of Wnt signalling in oncogenesis and cancer development (Table 2).7,16,17
Multiple mechanisms are involved in the aberrant activation of the Wnt signalling 
pathway in cancer (Figure 3). Oncogenic mutations to the intracellular Wnt signalling 
components, p-catenin, APC and Axin are found in a large number of human tumours 
including colon cancers, hepatocellular carcinomas and melanomas.16,17 Oncogenic 
mutations that prevent p-catenin turnover lead to the activation of TCF-dependent 
transcription in the absence of Wnt ligands.
Alternative mechanisms that inappropriately activate the Wnt pathway include the
O'Xoverexpression of Wnt ligands or loss of soluble Wnt antagonists. The creation of 
autocrine Wnt-secretion / Wnt response loops have been shown to stimulate tumour cell 
proliferation and to prevent apoptosis in a number of human cancers.24"27 Reduction of 
Wnt-induced signalling by treatment of cells with Wnt antibodies or soluble Wnt 
inhibitory proteins (SFRP) blocked cell proliferation and induced apoptosis in head and 
neck and colorectal cancer cell lines.28 Additional yet-to-be identified mechanisms have 
been hypothesised to account for the presence of stabilised p-catenin and the activation of 
TCF-dependent transcription in several tumour types including breast and prostate 
cancer.29,30 In several tissues Wnt ligands maintain the undifferentiated state of stem 
cells, raising the possibility that deregulated signalling may reactivate stem cell pathways
29,30m cancer. ’
In tumour cell lines, the replacement of wild type APC and Axin reduced levels of TCF- 
dependent transcription and reversed a range of oncogenic readouts leading to increased
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Figure 3: An illustrative depiction o f some routes to aberrant activation in Wnt signaling in cancer cells (reproduced from reference
7).
J r t t r - C H d t s c t i o r t
Pathway component Observed alterations Disease
Wnt ligands Increased expression Colon cancer; breast cancer; melanoma; 
head & neck cancer^non-small-cell lung 
cancer; gastric cancer; mesothelioma
Frizzled receptors Increased expression Colon cancer; breast cancer; head & neck 
cancer; gastric cancer; synovial sarcomas
Dishevelled family members
Increased expression Mesothelioma; non-small-cell lung cancer; 
cervical cancer
APC
Loss-of-function mutations/reduced 
expression
Colon cancer
p-catenin Gain-of-function mutations Colon cancer; gastric cancer; hepatocellular 
cancer, hepatoblastoma; Wilm's tumour; 
endometrial ovarian cancer; adrenocortical 
tumours
Axin 1 Loss-of-function mutations Hepatocellular cancer
Axin 2/Conductin Loss-of-function mutations Colon cancer; hepatocellular cancer
SFRP family members
Reduced expression Colon cancer; breast cance; gastric cancer; 
mesothelioma; non-small-cell lung cancer; 
Barrett's oesophagus; leukaemia
WIF family members Reduced expression Colon cancer; breast cancer; prostate cancer; 
lune cancer: bladder cancer
Table 2: The different cancers linked to t le aberrant activation of Wnt signalling pathway (adapted from reference 8).
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apoptosis.31 In addition, expression of dominant negative forms of TCF in colon cancer 
cells blocked cell proliferation and induced enterocytic differentiation, regardless of the 
presence of additional (e.g. p53) mutations.31 These studies support the idea that tumours 
require ongoing TCF-dependent transcription and identify Wnt/TCF-dependent signalling 
as a molecular therapeutic target.
6.4. The Frizzled-Dishevelled (Fz-Dvl) protein-protein interaction as a 
target for small synthetic anti-cancer molecules.
The aberrant activation of the Wnt signalling pathways have been implicated in different 
types of cancer as well as several other diseases. Therefore, many components of this 
signaling pathway have attracted interest as exciting targets for drug discovery research 
efforts from both academia and industry. Frizzled-Dishevelled (Fz-Dvl) interactions play 
a central role in relaying the Wnt signal to downstream components. Therefore, 
disrupting this protein-protein interaction could block signal transduction at the Dvl level 
and interfere with Wnt signaling events that contribute to disease states.
Dvl proteins (~ 700 amino acid residues) are essential components in Wnt signalling 
pathways and play a key role in tumourgenesis as described above.32 There are three 
homologues, Dvl 1, Dvl 2 and Dvl 3, which were identified in mammalians. These Dvl 
proteins are highly conserved throughout the animal kingdom. The Dvl protein consists 
of three domains; N-terminal DIX domain, a central PDZ (Post-synaptic density-95/Discs 
large/Zonula occludens-l) domain and a C-terminal DEP domain. Protein-protein 
interactions involving Dvl protein are mediated by the PDZ domain, which therefore 
plays a major role in the Wnt signalling pathway. Studies have established that the Dvl 
PDZ domain directly interacts with a conserved sequence (KTXXXW) of Fz, which 
begins two amino acids after the seventh transmembrane domain.
Compounds that target the Dvl PDZ domain would be expected to act only against 
tumours that are dependent on Wnt ligands or Dvl overexpression. However, autocrine 
Wnt signalling was shown to be required for cell proliferation in colorectal cancer cells 
with mutant (3-catenin and APC.24,34,35 This suggests that constitutive Wnt signalling may
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be required to complement APC / P-catenin mutations during the progression of 
colorectal cancers and that the targeting of receptor-proximal signalling may have 
therapeutic potential in many genetic backgrounds. Taken together, the available 
evidence suggests that targeting the Dvl PDZ domain in cancer cells will suppress their 
growth and trigger apoptosis through up-regulation of caspase activity.
Indeed, Fujii and co-workers targeted this Dvl-Fz protein-protein interaction and they 
were able to show that an indole-2-carbinol based compound (FJ9, Figure 4) displaced 
the Fz C-terminus from the Dvl PDZ domain, resulting in the induction of apoptosis in 
tumour cell lines and inhibition of tumour growth in xenograft models.36 Further studies 
by the same group indicate that the indole-2-amide scaffold bearing a small hydrophobic 
group on the 2-amide (Figure 4) can be used to antagonize the Dvl PDZ domain, down- 
regulating Tcf activation of transcription and inducing caspase activation and subsequent 
apoptosis.37 Notably caspase activation was not observed in /fTE^T-immortalised normal 
human foreskin fibroblasts, suggesting that down-regulation of Tcf-induced transcription 
may induce apoptosis selectively in cancer cells.37,38
Using receptor-based virtual screening of the NCI (National Cancer Institute) library, 
Shan and co-workers identified a Dvl PDZ domain peptidomimetic inhibitor 
(NSC668036, Figure 4). NSC668036 was found to act as a Wnt antagonist with a binding 
affinity of 237 pM to inhibit signalling induced by Wnt3A in Xenopus.39,40,41 The same 
group has also recently reported a new small-molecule inhibitor (3289-8625, Figure 4) of 
Dvl PDZ with a low micromolar affinity (Kd = 10.6 pM) using the same approach 
(structure-based virtual screening) but extending it to include the Chemical Diversity Inc. 
(ChemDiv, San Diego, CA) library.42 This compound was shown to effectively block 
Wnt signalling in both in vitro and in vivo using a Xenopus testing system and prostate 
cancer PC-3 cells.42
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Figure 4: Chemical structures of small-molecule inhibitors of the Fz-Dvl protein-protein 
interactions.
6.5. Aims and objectives
Recent progress and success in the development of inhibitors of protein-protein 
interactions has opened the door and paved the way for developing drugs with novel and 
selective mechanisms. Our understanding of how the deregulation of Wnt signaling 
activity occurs has made major advances in the past few years providing a solid platform 
from which promising drug discovery and development programs targeting this pathway 
in cancers can be launched.
As described above, the PDZ domain of the intracellular Dvl PDZ protein binds directly 
to the transmembrane Fz protein to relay Wnt signals to downstream components of the 
beta-catenin degradation complex. Therefore, it is anticipated that an inhibitor of the Dvl 
PDZ domain would effectively block oncogenic Wnt signalling as exemplified by the
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initial success of the identified inhibitors (Figure 4). Moreover, both NSC668036 and FJ9 
provide a structural basis for the rational design of high-affinity inhibitors of the Dvl- Fz 
interactions.
The aim of this project is to combine the robust molecular modelling tools and protein- 
protein interaction assays for the identification of novel small molecule inhibitors of the 
Dvl PDZ domain. The work would be based on exploiting the available crystal structure 
of the Dvl PDZ domain to rationalize the inhibitory activity of the reported Dvl-Fz7 
interaction inhibitors and closely related anlogues. * Having established the main 
molecular contacts and key residues mediating Dvl-Fz7 interaction, virtual compound 
library screening combined with structure-activity studies will be performed to 
successfully select promising candidate molecules. Biochemical binding assays and 
mechanistic studies could then determine the ability of the identified molecules to alter 
cell proliferation or induce apoptosis by blocking the Wnt signalling in cancer cells.
118
Chapter Six Introduction
References
1. International Human Genome Sequencing Consortium. Finishing the euchromatic 
sequence of the human genome. Nature 2004,431, 931-45.
2. Jones, S.; Thornton, J. M. Principles of protein-protein interactions. Proc. Natl 
Acad. Sci. 1996,93,13-20.
3. Cheng, A. C.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Cafffey, D. R.; 
Salzberg, A. C .; Huang, E. S. Structure-based maximal affinity model predicts 
small-molecule druggability. Nat. BiotechnoLlWXl, 25, 71-75.
4. Hopkins, A. L.; Groom, C. R. The draggable genome. Nature Rev. Drug. Discov. 
2002, 1, 727-730.
5. Clackson, T.; Wells, J. A. A hot spot of binding energy in a hormone-receptor 
interface. Science 1995,267, 383-386.
6. Moreira, I. S.; Fernandes, P. A.; Ramos, M. J. Hot spots: a review of the protein- 
protein interface determinant amino-acid residues. Proteins. 2007, 68, 803-812.
7. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell, 2000,100, 57-70.
8. Clevers, H.; Barker, N. Mining the Wnt pathway for cancer therapeutics. Nat. 
Rev. Drug. Discov. 2006, 5, 997-1014.
9. White, A. W.; Westwell, A. D.; Brahemi, G. Protein-protein interactions as 
targets for small-molecule therapeutics in cancer. Exp. Rev. Mol. Med. 2008, 10, 
1-14.
10. Levin, A. J. p53, the cellular gatekeeper for growth and division. Cell. 1997, 88, 
323-331.
11. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; 
Pavletich, N. P. Crystal structure of the MDM2 oncoprotein bound to 
thetransactivation domain of the p53 tumor suppressor. Science. 1996, 274, 948- 
953.
12. Vassilev, L. T.; et al. In vivo activation of the p53 pathway by small-molecule 
antagonists of MDM2. Science. 2004, 303, 844-848.
119
Chapter Six Introduction
13. Grasberger, B. L. et al. Discovery and cocrystal structure of benzodiazepinedione 
HDM2 antagonists that activate p53 in cells. J. Med. Chem. 2005,48, 909-912.
14. Parks, D. J. et al. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists 
of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett. 
2005,15, 765-770.
15. Koblish, H. K. et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex 
suppress human tumor cell proliferation in vitro and sensitize tumors to 
doxorubicin in vivo. Mol. Cancer Ther. 2006, 5,160-169.
16. Janssens, N.; Janicot, M.; Perera, T. The Wnt-dependent signaling pathways as 
target in oncology drug discovery. Invest. New. Drugs. 2006,24,263-280.
17. Dev, K. K. Making protein interactions draggable: targeting PDZ domains. Nat. 
Rev. Drug Discov. 2004,1047-1056.
18. Kuhl, M.; Sheldahl, L.C.; Malbon, C. C.; Moon, R. T. Ca (2+)/calmodulin- 
dependent protein kinase II is stimulated by Wnt and Frizzled homologs and 
promotes ventral cell fates in Xenopus. J  Biol Chem. 2000, 275:12701-12711.
19. Habas, R.; Dawid, I. B.; He, X. Coactivation of Rac and Rho by Wnt/Frizzled 
signaling is required for vertebrate gastralation. Genes Dev. 2003,17:295-309.
20. Wehrli, M.; Dougan, S. T.; Caldwell, K.; O’Keefe, L.; Schwartz, S.; Vaizel- 
Ohayon, D.; Schejter, E.; Tomlinson, A.; DiNardo, S. Arrow encodes an LDL- 
receptor-related protein essential for Wingless signalling. Nature. 2000, 407:527- 
530.
21. Ding, Y.; Dale, T. Wnt signal transduction: kinase cogs in a nano- machine? 
Trends Biochem S ci. 2002,27:327-329.
22. Nusse, R.; Varmus, H.E. Many tumors induced by the mouse mammary tumor 
virus contain a provirus integrated in the same region of the host genome. Cell. 
1982,31,99-10.
23. Mazieres, J.; He, B.; You, L.; Xu, Z.; Jablons, D.M. Wnt signaling in lung cancer. 
Cancer letters. 2005, 222, 1-10.
24. Bafico, A.; Liu, G.; Goldin, L.; Harris, V.; Aaronson, S. A. An autocrine 
mechanism for constitutive Wnt pathway activation in human cancer cells. 
Cancer. Cell, 2004,6,497-506.
120
Chapter Six Introduction
25. Mazieres, J.; You, L.; He, B.; Xu, Z.; Lee, A.Y.; Mikami, I.; McCormick, F.; 
Jablons, D. M. Inhibition of Wnt 16 in human acute lymphoblastoid leukemia cells 
containing the t(l;19) translocation induces apoptosis. Oncogene 2005, 24, 5396- 
5400.
26. You, L.; He, B.; Uematsu, K.; Xu, Z.; Mazieres, J.; Lee, A.; McCormick, F.; 
Jablons, D. M. Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin- 
deficient mesothelioma cells. Cancer research 2004, 64, 3474-3478.
27. You, L.; He, B.; Xu, Z.; Uematsu, K.; Mazieres, J.; Mikami, I.; Reguart, N.; 
Moody, T. W.; Kitajewski, J.; McCormick, F. et a l Inhibition of Wnt-2-mediated 
signaling induces programmed cell death in non-small-cell lung cancer cells. 
Oncogene 2004,23, 6170-6174.
28. Rhee, C. S.; Sen, M.; Lu, D.; Wu, C.; Leoni, L.; Rubin, J.; Corr, M.; Carson, D. 
A. Wnt and frizzled receptors as potential targets for immunotherapy in head and 
neck squamous cell carcinomas. Oncogene 2002,21, 6598-6605.
29. Sato, N.; Meijer, L.; Skaltsounis, L.; Greengard, P.; Brivanlou, A. H. Maintenance 
of pluripotency in human and mouse embryonic stem cells through activation of 
Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004, 10, 
55-63.
30. Willert, K.; Brown, J. D.; Danenberg, E.; Duncan, A. W.; Weissman, I. L.; Reya, 
T.; Yates, J. R.; Nusse, R. Wnt proteins are lipid-modified and can act as stem cell 
growth factors. Nature 2003,423, 409-414.
31. van de Wetering, M.; Sancho, E.; Verweij, C.; de Lau, W.; Oving, I.; Hurlstone,
A.; van der Horn, K.; Batlle, E.; Coudreuse, D.; Haramis, A.P. et al. The beta- 
Catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal 
cancer cells. Cell 2002 111, 241-250.
32. Malbon, C. C.; Wang, H. Y. Dishevelled: A mobile scaffold catalyzing
development. Curr. Top. Dev. Biol. 2006, 72, 153-166.
33. Wong, H-C.; Bourdelas, A.; Krauss, A. Lee, H. J.; Shao, Y.; Mlodzik, M.; Shi, D.
L.; Zheng, J. Direct binding of the PDZ domain of Dishevelled to a conserved 
internal sequence in the C-terminal region of Frizzled. Mol. Cell. 2003, 12, 1251- 
1260.
121
Chapter Six Introduction
34. He, B.; Reguart, N.; You, L.; Mazieres, J.; Xu, Z.; Lee, A. Y.; Mikami, I.; 
McCormick, F.; Jablons, D. M. Blockade of Wnt-1 signaling induces apoptosis in 
human colorectal cancer cells containing downstream mutations. Oncogene. 2005, 
24, 3054-3058.
35. Suzuki, H et al. Epigenetic inactivation of SFRP genes allows constitutive WNT 
signaling in colorectal cancer. Nat Genet. 2004, 36, 417-422.
36. Fujii, N.; You, L.; Xu, Z.; Uematsu, K.; Shan, J.; He, B.; Mikami, I.; Edmondson, 
L. R.; Neale, G.; Zheng, J.; Guy, R.K.; Jablons, D.M. An antagonist of 
dishevelled protein-protein interaction suppresses P-catenin-dependent tumor cell 
growth. Cancer Res. 2007, 67, 573-579.
37. Mahindroo, N.; Punchihewa, C.; Bail, A. M.; Fujii, N. Indole-2-amide based 
biochemical antagonist of Dishevelled PDZ domain interaction down-regulates 
Dishevelled-driven Tcf transcriptional activity. Bioorg. Med. Chem. Lett. 2008, 
18, 946-949.
38. You, L.; Xu, Z.; Punchihewa, C.; Jablons, D. M.; Fujii, N. Evaluation of a 
chemical library of small-molecule Dishevelled antagonists that suppress tumor 
growth by down-regulating Tcf-mediated transcription. Mol. Cancer. Ther. 2008. 
1633-1638.
39. Shan, J.; Shi, D. L.; Wang, J.; Zheng, J. Identification of a specific inhibitor of 
the Dishevelled PDZ domain. Biochem. 2005,44, 15495-15503.
40. Shan, J.; Zheng, J. J. Optimizing Dvl PDZ domain inhibitor by exploring 
chemical space. J. Comput. Aided. Mol. Des. 2009, 23: 37-47.
41. Wang, N. X.; Lee, H. J.; Zheng, J. J. Therapeutic use of PDZ protein-protein 
interaction antagonism. Drug. News. Perspect. 2008,21,137-142.
42. Grandy, D.; Shan, J.; Zhang, X.; Rao, S.; Akunuru, S.; Li, H.; Zheng, Y.; Alpatov, 
I.; Zhang, X. A.; Lang, R.; Shi, D. L.; Zheng, J. J. Discovery and characterization 
of a small molecule inhibitor of the PDZ domain of Dishevelled. J. Biol. Chem. 
2009,284,16256-16263.
122
Chapter Seven The design of Dvl-Fz small molecule inhibitors
7. The design of Dvl-Fz protein-protein interaction 
small molecule inhibitors
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7.1. Computer-assisted drug design studies
Molecular modelling can be defined as the science or art of representing molecular 
structures numerically using computational chemistry programs through the application 
of quantum and classical physics.1 These programs enable the simulation of the 
behaviour, geometries, energy, bulk, electronic, spectroscopic and the other properties of 
molecules.1 Nevertheless, experimental data as well as the chemist’s expertise and 
intuition are essential in guiding the molecular modelling work and interpreting the 
obtained data. The field of study, which is concerned with the application and use of 
these molecular modelling programs in research and drug development has become 
known as computer assisted drug design (CADD).
Over the past few years, there have been massive advances in the development of tools 
and products dedicated to computer assisted drug design. Of such computational 
products, the programs which were mainly used in this project include; Molecular 
Operating Environment (MOE, 2008.10),2 SYBYL 7.0 (Tripos SYBYL, 7.0)3 and 
LigandScout (Inte:Ligand).4 These modelling programs allow the use of several 
approaches for the design of novel small molecule inhibitors of the disheveled PDZ 
domain.
7.1.1. The use of structure-based virtual screening
Virtual screening has experienced a growing interest in its application in the drug 
discovery process over the recent years. It is considered as a complementary approach to 
high throughput screening (HTS) which when combined with robust structural biology 
techniques, has the potential to enhance the drug discovery process. This computational 
methodology encompasses the rapid in silico assessment and evaluation of large virtual 
libraries of chemical structures in order to identify those potential structures with high 
affinity for binding to a given target.5 There are two main categories of this technique 
namely ligand-based and structure-based virtual screening.
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A. Ligand-based virtual screening:
Ligand-based virtual screening focuses on building a pharmacophore model based on a 
set of structurally diverse ligands which are proven to bind to a certain receptor or target. 
Then, candidate ligands can be screened against this generated pharmacophore model in 
order to determine their compatibility and hence their potential binding.6
B. Structure-based virtual screening:
Structure-based virtual screening estimates the affinity of binding of candidate 
compounds to a protein target by docking these compounds into a pharmacophore model, 
which is derived from the available target structure.7
Fortuitously, the crystal structure of the Dvl PDZ domain bound to its ligand peptide 
Dapper is available in the Protein Data Bank (PDB: 1L60).8’9’10 This makes structure- 
based virtual ligand screening the more appropriate choice to identify potential ligands 
with the ability to inhibit the Fz-Dvl protein-protein interactions. Moreover, this 
approach was successfully implemented by Shan et al in the identification of a specific 
PDZ domain antagonist despite its low binding affinity (Ki= 237 pM ).11
7.1.1.1. Structure-based virtual screening of potential Dvl PDZ domain ligands
Generally speaking, a structure-baSed virtual screening process consists of several steps 
as illustrated in Figure 1. The success of the process depends on the careful and thorough 
implementation of various computational techniques in each step.
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Figure 1: A description o f the workflow o f  the different steps involved in structure-based 
virtual screening process (modified from reference 5)
A. Database and target preparation:
A .I. Target preparation: The crystal structure o f  Dvl PDZ bound to its natural peptide 
(8 amino acid residues) ligand dapper was retrieved as PDB file from the protein data 
bank (PDB entry 1 L 6 0 ).9,10 The active site, which is the set o f  residues that mediate the 
binding interactions with Dapper was identified using “Site Finder” function in MOE.
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Site function is a feature, which allows location and identification o f  the different 
hydrophobic cavities in a target, which can form a potential binding site. This was further 
confirmed by the fact that Dapper as a natural ligand is known to bind at the same Dvl 
PDZ site o f  interaction with F z .10
Dvl PDZ is a modular protein interaction domain, which has two a-helices and six 13- 
sheets (Figure 2-A). One o f  the a  helices and p-sheets together with the preceding loop 
form a peptide binding cleft where Dapper binds as shown in Figure 2-B
Figure 2: A: Ribbon diagram o f the PDZ domain structure (a-helices are shown in red 
while P-sheets are shown in yellow). B: The binding site (active site) o f  the Fz7 peptide 
represented using MOE “Site finder” feature.
A.2. Pharmacophore query design: A pharmacophore is the collection or set o f  steric 
and electronic features o f  specific functional groups and their spatial placement, which 
are required to elicit a specific biological response.12
The main interactions between Dvl PDZ and Dapper (Figure 3) were analyzed in terms o f  
the main residues contributing to these interactions.
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Figure 3: The complex structure o f Dvl PDZ domain bound to its natural ligand Dapper 
is shown on the left panel while the right one shows a 2D depiction o f  the main hydrogen 
bonds mediating this interaction.
The analysis o f  Dvl PDZ-Dapper complex structure reveals that their interaction is 
mainly mediated by the hydrogen bonds formed with residues Leu 265, Gly 266, lie 267 
and lie 269 in the P-B sheet.
A pharmacophore query was built using “pharmacophore query” which is a function in 
MOE which enables derivation o f a pharmacophore from complex structures. The query 
generated consists o f  5 main features as illustrated in Figure 4.
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Figure 4: The generated pharmacophore query from the Dvl PDZ-Dapper complex using 
MOE. FI, F2: (Cyan colour) Acc & Don (acceptor and donor) correspond to the 
carboxylic acid moiety; F3, F4: Acc, Don respectively which correspond to the amide 
bond linking threonine and methionine. The black spheres (mainly in the panel on the left 
side) represent the exclusion volume to prevent steric clash. The yellow spheres represent 
the inclusion volume, which represent deeper hydrophobic cavities in the binding cleft 
where ligand occupation enhances interaction with the Dvl PDZ domain.
Having successfully identified the active site, which mediates Dvl-Fz protein-protein 
interactions and derived a pharmacophore query, the next step was to prepare a database 
o f  virtual compounds to run a virtual screening assay.
B. Database preparation: Virtual compound libraries are a collection o f  chemical 
compounds, which are readily accessible synthetically or commercially in sufficient 
quantities to run the required biological assays. Examples o f such libraries include but 
are not limited to the Zinc database (> 4,500,000 m olecule),13 the NCI library (450,000 
m olecule),14 Enamine (20,000 m olecule),15 and Maybridge (56,000 m olecule)16. These 
databases are freely available in ready-to-dock, 3D format and were successfully 
downloaded.
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Nevertheless, it is most important to prepare the chosen libraries before the screening 
process. By preparing, it is meant to have virtual compounds with drug-likeness 
properties via the use of physical and chemical filters. Drug-likeness is most often 
evaluated by the Lipinski’s rule of five, which is one of the most frequently used 
empirical rules.17 This rule describes molecular properties and pharmacokinetics, which 
account for ADME (absorption, distribution, metabolism and excretion). In fact, drug- 
likeness is usually considered before the construction of these virtual compound libraries.
Nevertheless, out of the above downloaded libraries, the lead-like Zinc subset library 
database has the largest number of compounds (1,000,000 compound). This library subset 
was downloaded as an SD file. Then, it was imported to the MOE database viewer 
module whereby it was prepared by removing any multiple fragment entries, 
deprotonating strong acids and protonating strong bases and accounting for Lipinski’s 
rule filters. Then, they were energy minimized. The 3D conformations of these 
compounds were generated to account for the flexibility and rotations around bonds.
C. In Silico screening: The next step in the structure-based virtual screening is to run 
the virtual compounds against the pharmacophore generated. The “Pharmacophore 
query” module in MOE allows executing this process with flexible and variable criteria 
in that it allows a partial search where only some of the features are considered. It follows 
that the more restrictions accounted for, the fewer hit compounds will be generated. For 
instance, when the search process was applied to account for the five features mentioned 
above, no hits were obtained. Therefore, the screening was run again including 4 features 
only with FI, F2 and F4 as essential. This led to the generation of a small database of 
compounds, which fulfill the set criteria, and the compounds generated are represented in 
Figure 5.
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Figure 5: The main potential hits obtained from structure-based virtual screening process 
using Zinc lead-like database.
7 .1 .1 .2 . Pharmacophore query based on using LigandScout:
LigandScout: is a molecular modelling program which allows creation of 3D 
pharmacophores from protein-ligand complex structures which can be exported to MOE 
to be used for virtual screening process.18’ 19 Moreover, there are many examples of the 
successful application of this strategy.20,21 The pharmacophore derived is represented in 
Figure 6.
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Figure 6: Dvl PDZ-Dapper complex structure based pharmacophore using LigandScout. 
The hydrogen bond acceptors (red arrows), hydrophobic interactions (yellow spheres), 
hydrogen bond donors (green arrows) are indicated.
From Figure 6, it appears that the LigandScout derived pharmacophore accounts for more 
features than the previous one. However, it is important to mention that only the terminal 
4 residues (Met-Thr-Thr-Val) o f Dapper (8 amino acid residues) are known to be 
involved in the interaction with Dvl PDZ.8,10 On the other hand, even when only 
considering these 4 amino acid residues, the newly derived pharmacophore still accounts 
for more hydrophobic interactions.
Nevertheless, using this pharmacophore the same structure-based virtual screening 
process described above was implemented. The only modification was that the database 
o f  compounds used was a combination o f  the Zinc-lead like subset, NCI database, 
Maybridge and Enamine databases. The 8 potential hits obtained using this modified 
protocol are shown in Figure 7.
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Figure 7: The main potential hits obtained from the modified structure-based virtual
screening protocol.
7.1.2. Similarity search
Fujii and co-workers reported the indole carbinol (FJ9) as the first small molecule 
inhibitor of Dvl PDZ.22 The same group later went on to report a derivative for this 
structure which has even more potent activity (Figure 8).
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Figure 8: The indole carbinol (FJ9) and its derivative as known Dvl PDZ inhibitors.
The “Similarity Search” function in MOE enables a search in a virtual database for 
molecules, which are structurally similar to a query compound. It follows that a 
fingerprinted database and a query molecule are required in order to run a similarity 
search.
A. Query molecule: the modified structure of FJ09 was used as the query molecule since 
it was reported to have more potent inhibition of the Dvl-Fz protein-protein interaction.
B. Fingerprinted database: a molecular database for which fingerprints already have 
been pre-calculated for all of the molecule entries. Molecular fingerprints otherwise 
known as structural keys or signatures represent a set of the core features derived from 
the structure of a molecule. It follows therefore that molecules can be compared by 
measuring and defining the extent to which their calculated set of features may match or 
overlap. Once fingerprints are derived for molecular database, a metric is necessary to 
compare these fingerprints with die ones of the query model. In MOE, Tanimoto 
Coefficient (TC) is the most common and widely used similarity metric. TC can be 
considered as the number of common features between the pair of compounds divided by 
the number of total features of both fingerprints. Therefore, TC can take a value between 
1 and 0 ranging from most to least similar and is calculated by comparing the fingerprints 
between any pair of molecules.
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There are several fingerprint systems implemented in MOE, which can be used. Of these 
systems, the fingerprint system “FPrMACCS” which contains a total of 166 structural 
keys corresponding to various groups present in organic compounds was chosen. The 
first step was to calculate the FPrMACCS for the previously prepared ZINC lead-like 
database as well as for the modified structure of FJ09. TC ;> 0.85 which is the default 
criterion (in MOE) for considering two molecules to be similar was applied. However, 
when running a similarity search with this default criterion no hits were obtained. 
Therefore, it was necessary to reduce the TC threshold but no hits were obtained until TC 
was set as 0.5.
Nevertheless, the similarity search approach was stopped and not investigated any further 
as having hits with 50% similarity to the active compound is not sufficient since the 
active compound has low micromolar activity in the first place. However, it is important 
to note that this approach could have been improved by employing a bigger and more 
diverse molecular database or by considering a different set of fingerprints.
7.1.3. The use of high-throughput docking:
Docking is the computational simulation process to predict the preferred orientation of a 
ligand candidate when bound to its target.24 Because of the flexibility of the ligand and 
target, the docking process aims to achieve an optimized best-fit conformation of the 
complex with minimum overall energy of the system. The strength and affinity of binding 
between the ligand and its target is often predicted in terms of scoring functions which 
mainly account for the number of favorable intermolecular interactions in terms of 
hydrogen bonds and hydrophobic interactions.25
7.I.3.I. High-throughput docking using GFscore:
GFscore is a general nonlinear consensus scoring function for high-throughput docking 
reported by Betzi et al recently.26 This methodology extends the principle of consensus 
scoring in a non-linear neural network manner by combining the five scoring functions 
(FlexX Score, G_Score, D_Score, ChemScore, PMF Score) found in the Cscore package
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from Tripos inc. It follows that a neural network has been trained on the scoring results to 
combine the 5 scoring functions and generate this Generalist Function score, GFscore. 
This was achieved by selecting a diverse database (1420 compounds of the NCI Diversity 
database) and a set of diverse protein-ligand complexes to train this neural network. 
Among the 200 protein-ligand dataset complexes, FlexX was able to generate 78 
complexes with an accurate RMSD (< 2A).26 GFscore is reported to distinguish true 
negatives from false negatives in a given compound database and eliminate up to 75% of 
molecules with a confidence rate of 90%.26 This in turn enriches the list of potential hits 
to be investigated for biological activity by considering only 25% of molecules.
This methodology was successfully applied by the same group to identify a small 
molecule inhibitor of the HIV-1 Nef protein-protein interactions with a submicromolar 
activity (K<i= 0.3 pM ).27
The following steps were followed in the application of GFscore:
1. The FlexX/Cscore docking experiment needs to be run on the diversity database 
used to train the GFscore neural network. Therefore, the NCI diverse database 
was first downloaded from the GFscore server’s website ( http://gfscore.cnrs- 
mrs.fr/) and then docked using FlexX in the Dvl PDZ domain.
2. The obtained docking results were exported in ASCII file format using the comma 
separator.
3. Virtual screening experiment was performed on the Zinc lead-like database and 
the results were exported similarly (ASCII file).
4. The two exported files were uploaded to the GFscore calculation webpage 
mentioned above and a list of potential hits was obtained.
Having followed this process, a list of potential PDZ inhibitors was obtained. The next 
step was to further filter these hits. Therefore, a pharmacophore model was generated 
(MOE). This pharmacophore model was superimposed with the docking database pose 
(same 3D coordinates) during the MOE pharmacophore search using the option "use 
absolute position". This query enabled the selection of fewer compounds. This number
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was further filtered by visual inspection of the chemical and geometrical properties of the 
ligand pose to give the potential hits, which were put forward for synthesis (Figure 9).
HO
HO
OMe
MeO
Figure 9: The 2 main structural scafolds obtined from the Gfscore high-throughput 
docking studies.
7.13.2. High-Throughput docking using Plants:
PLANTS (Protein-Ligand ANT System) is a docking algorithm based on ant colony 
optimisation (ACO), which is a class of stochastic optimisation algorithms.28 During the 
docking process, an artificial ant colony is employed to identify ligand conformations 
with the lowest energy of binding to the target active site. The concept of this docking 
algorithm stems from the behaviour of real ants in finding the shortest path to food 
sources from their colony whereby they release pheromones to mark the paths they 
follow during their search. It follows therefore that high levels of pheromones determine 
path choice. Similarly, ACO algorithms imitate this behaviour by associating numerical 
values with each possible solution.28
PLANTS encompasses two empirical scoring functions; PLANTSplp and 
PLANTSchemplp-29 While the former accounts mainly for the steric complementarity 
between the ligand and the protein target, the latter accounts for the hydrogen bonding 
formed between the ligand-target complex.29
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The ChemBridge lead-like database was chosen for high throughput docking with 
PLANTS as any potential hits can easily be purchased in sufficient quantities to run 
biological assays. The ChemBridge lead-like library is freely available for download 
from the website of ChemBridge corporation after simple registration procedure.30 This 
database contains more than 450,000 compounds with diverse structures. Database 
preparation and pre-processing was performed as described above for the other databases 
used previously. Energy minimization and conformational analysis were performed using 
the implemented MMFF94X forcefield in MOE.
This database of compounds was docked using PLANTS V-1.06 in the PDZ domain 
active site identified earlier with the docking site limited to a 12A radius sphere centered 
in this active site. The number of conformations was set to no more than 10 for each 
ligand.
The obtained docking results were saved as mol2 file type and then exported to MOE 
Database Viewer to enable better visual analysis of the docked confirmations in the PDZ 
domain. The docked compound candidates were ranked using PLANTS in-built scoring 
functions (PLANTSplp and PLANTSchemplp)-
The top-ranked ligand confirmations were then visually inspected using MOE. A 
particular interest was drawn into piperazine (HTS00568) as it adopts a conformation, 
which resides deep into the PDZ binding site as shown in Figure 10. The interactions of 
this ligand with PDZ domain are also depicted in 2D format.
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Gly266
Figure 10. The conformation adopted by the piperazine (HTS00568) when docked into 
the active site o f  Dvl PDZ domain using PLANTS is shown in the panel on the left. The 
panel on the right represents a 2D depiction o f  the main hydrogen bonds mediating this 
interaction.
This hit confirmation adopts a favorable binding position with the medium size 
hydrophobic cyclopentane group residing deep into the hydrophobic cleft forming 
favorable hydrophobic interactions. This hit also shows hydrogen bonding with the side 
chain o f  the amino acid lie 269 (note it is one o f  the hydrogen bonds that the N o f  
dapper forms with lie 269). On the other hand, one o f the phenyl groups (hydrophobic) is 
exposed to the water surface (hydrophilic) leading to unfavorable interactions. Therefore, 
the structure o f  this hit was modified by removing one o f  the phenyl rings and 
introducing a methyl group to further enhance hydrophobic interactions (Scheme 1).
OHOH
Scheme 1
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The modified hit structure was then re-docked using PLANTS and following the same 
process described above. The obtained structure for the binding o f this hit with Dvl PDZ 
is illustrated in Figure 11 as well as a 2D depiction o f  the main interactions involved.
Gly266
a
L eu 2 6 5
Leu
Llle267
Figure 11. The conformation adopted by the modified structure o f  the piperazine 
(HTS00568) when docked into the active site o f  Dvl PDZ domain using PLANTS is 
shown in the panel on the left. The panel on the right represents a 2D depiction o f  the 
main hydrogen bonds mediating this interaction (lie 267).
Indeed, the new piperazine compound adopts a more favorable binding mode when 
docked into Dvl PDZ domain. The carboxylic acid group o f  this compound is in closer 
proximity to lie 267 leading to the formation o f  hydrogen bonding.
The promising results o f the docking o f the modified structure o f  HTS00568 encouraged 
further attempts for structural modifications (Scheme 2). The piperazine group is 
substituted with a /7-aminoaniline and the methylphenyl group is replaced with the more 
hydrophobic group (cyclohexyl group).
Scheme 2.
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The new structural modifications resulted in better hydrogen bonding interactions o f  the 
carboxyl group with lie 267, Gly 266 and Leu 265 while still adopting an extended 
binding pose along the active site as shown in Figure 12.
Leu
269Arg
J29.
Figure 12: The binding mode o f the modified structure as a result o f  PLANTS docking 
into the Dvl PDZ domain shown in the panel on the left whereas the panel on the right 
represents a 2D depiction o f the main hydrogen bonds mediating this interaction.
Nevertheless, the following two hits (Figure 13) were selected for synthesis and 
subsequently for biological testing as potential Dvl PDZ inhibitors.
Figure 13. The 2 hits obtained from PLANTS docking studies, which were chosen for 
synthesis.
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8.The synthesis and biological evaluation of the 
designed Dvl PDZ domain inhibitors
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8.1.Chemistry
Initial efforts focused on establishing suitable synthetic routes toward the preparation of 
the hits, which were obtained from the performed molecular modelling studies (Chapter 
7). These efforts were also directed into ensuring access to the required starting materials 
either commercially or through robust synthetic procedures with good yields.
8.1.1. Synthesis of structure-based virtual screening hits:
The following 2 hits (Figure 1) represent the main structural scaffolds obtained by the 
virtual screening approach as outlined in Chapter 7.
Figure 1: The 2 potential hits obtained via structure-based virtual screening.
8.I.I.I. Synthesis of (lS)-2-(4-methoxyphenyl)-2-oxoethyl-5-oxopyrrolidine-2-carboxy 
late (64)
The synthesis of 5-2-(4-methoxyphenyl)-2-oxoethyl 5-oxopyrrolidine-2-carboxylate (64) 
was achieved by heating under reflux a mixture of 1S'-2-pyrrilidonecarboxylic acid and 2- 
bromo-4’-methoxyacetophenone in acetone. Both of these substrates were commercially 
available. The reaction took a few hours to give the desired product as shown is Scheme 
1. The use of column chromatography enabled isolation of (64) in analytically pure form 
and relatively good yield (60%).
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OH
OMe OMe
Reagents and conditions:acetone, reflux, 3hrs.
Scheme 1
8.1.1.2. Synthesis of 2-(4-methoxyphenyl)-2-oxoethyl-6-oxo-l,6-dihydropyridine-3- 
carboxylate (67)
The same procedure was employed for the synthesis of 2-(4-methoxyphenyl)-2-oxoethyl 
6-oxo-1,6-dihydropyridine-3-carboxylate(67) from 6-oxo-1,6-dihydropyridine-3-
carboxylic acidand 2-bromo-4’-methoxyacetophenone (Scheme 2) in a comparable yield 
(64%).
* 0II *1 0T  | BrS / \ / \  ----------► HN. ^# L . o v J L /i TI 0
67
Reagents and conditions:Acetone, reflux, 3hrs.
Scheme 2
Subsequently, because of the ease of synthesis and mild conditions, this synthetic 
procedure was further employed for the preparation of other structurally related 
analogues starting with differently substituted acids and bromoacetophenones as shown 
below in Figure 2. The newly synthesised compounds included the (R) isomer of (5)-2- 
(4-methoxyphenyl)-2-oxoethyl-5-oxopyrrolidine-2-carboxylate (65). Overall, relatively 
good yields (50%-70%) were obtained for the preparation of these products.
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Figure 2. The synthesised derivatives of the 2 potential hits obtained from the structure-
based virtual screening.
8.1.2. The synthesis of structure-based virtual screening hits (LigandScout 
approach):
The modified structure-based virtual screening approach led to the identification of the 
following hits as potential Dvl PDZ inhibitors (Figure 3).
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Figure 3. The structures of the potential hits obtained via structure-based virtual 
screening using LigandScout.
8.1.2.1. Synthesis of ($-N(l-(4-methoxyphenyl)ethyl)-4-methylbenzamide (68)
The synthesis of (68) was easily achieved through the substitution reaction between the 
two commercially available substrates; p-toluoyl chloride and 4-methoxy-a- 
methylbenzylamine. The p-toluoyl chloride is added dropwise to a stirring mixture of the
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amine and TEA in DCM at 0°C. Once the p-toluoyl chloride is fully added, the reaction is 
left stirring at room temperature as shown in Scheme 3 to afford compound (68)in 
excellent yield (85%).
68
Reagents and conditions: TEA, 0°C, lhr; RT, 12 hrs.
Scheme 3.
8.1.2.2. Synthesis of (S)-2-(l-(4-methoxyphenyl)ethylamino)-2-oxoethyl-4- 
methylbenzoate (70)
This compound (70) was prepared from 4-methoxy-a-methylbenzylamine and 2-(4- 
methylbenzoyloxy)acetic acid. While the former substrate is commercially available, the 
latter had to be prepared.
8.1.2.2.L Synthesis of2-(4-methylbenzoyloxy)acetic acid (69)
1st attempt: for the synthesis of 2-(4-methylbenzoyloxy)acetic acid, p-toluoyl chloride 
was added dropwise to a stirring solution of glycolic acid in DCM in the presence of 
slightly access of TEA (Scheme 4-A). The yield obtained was relatively low (<20%) and 
the reaction was taking a long time. Given that this particular type of reaction was going 
to be used for the preparation of other starting materials required in the synthesis of some 
of the obtained hits, it was essential to explore an alternative procedure with better yields.
2nd attempt: the same reaction was repeated but this time by stirring the components in 
pyridine overnight. This led to the formation of the desired product in relatively good 
yield (60%) (Scheme 4-B).
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69
Reagents and conditions: A: TEA, DCM, 24 hrs (15% yield) or
B: Pyridine, 12 hrs (60% yield).___________ ________
Scheme 4
The compound (70)was then synthesised from the coupling of 4-methoxy-a- 
methylbenzylamine and the prepared compound (69)using the coupling agent 
carbonyldiimidazole (CDI)as represented below (Scheme 5). It follows that CDI reacts 
first with the carboxylic acid 2-(4-methylbenzoyloxy) acetic acid and activates it by 
making it more susceptible to the nucleophilic attack of the amine (4-methoxy-a- 
methylbenzylamine). One of the main advantages of using this procedure is that the final 
product can be isolated by precipitating from ice-cold water. This precipitate can be 
sufficiently purified by a thorough washing with water.
70
Reagents and conditions: CDI, DMF, 0°C, 1 hr; rt, 12 hrs.___________________
Scheme S
8.1.2.3. Synthesis of 2-(l-(benzo[</][l,3]dioxol-5-yl)ethylamino)-2-oxoethyl-4-methyl 
benzoate (72).
This compound was prepared from 2-(4-methylbenzoyloxy)acetic acid and 1- 
(benzo [</] [ 1,3 ]dioxol-5 -yl)ethaneamine following the same synthetic procedure described 
for the previous hit (S-2-(l-(4-methoxyphenyl)ethylamino)-2-oxoethyl-4- 
methylbenzoate). 2-(4-Methylbenzoyloxy)-acetic acid was already prepared from p- 
toluoyl chloride as described above while l-(benzo[c/][l,3]dioxol-5-yl)ethanamine had to 
be synthesised.
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8.1.2.3.1. Synthesis o f l-(benzo[d][l,3]dioxol-5-yl)ethanamine (71)
1 -(benzo[d] [ 1,3 ]dioxol-5 -yl)ethanamine is not commercially available and had to be 
prepared. Therefore, efforts were focused on deriving this desired amine from the 
commercially available ketone (l-(benzo[d][l,3]dioxol-5-yl)ethanone) through reductive 
animation reaction which involves the conversion of the ketone carbonyl group into the 
amino functionality.
For the reductive animation reaction, treatment of ketones with ammonia in ethanol and 
titanium(IV) isopropoxide, followed by in situ reduction with sodium borohydride was 
reported to give their primary amine derivatives in excellent yields in a one-pot 
procedure.1 This procedure was successfully applied to the synthesis of the racemic 
product(71)and afforded a relatively moderate yield ( 50%) of product.(Scheme 6).
NH
Reagents and conditions: NH3. EtOH, Ti(Q'Pr)4, RT, 6hr; NaBFLt, RT, 3hr.
Scheme 6
Having prepared the required starting substrates, 2-( 1 -(benzo [d] [ 1,3 ]dioxol-5 - 
yl)ethylamino)-2-oxoethyl-4-methylbenzoate (72) was prepared following the procedure 
described for (70) as outlined in Scheme 7.
69 71 72
Reagents and conditions: CDI, DMF, 0°C, 1 hr; RT, 16 hr._____________________
Scheme 7
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8.1.2.4. Synthesis of 2-(4-methoxybenzylamino)-2-oxoethyibenzofuran-2-carboxylate 
(75)
Compound (75) was synthesised using benzofuran-2-carbonyloxy-2-acetic acid(74) and 
4-methoxybenzylamine. However, the acid had first to be prepared from benzofuran-2- 
carbonyl chloride(73).
8.1.2.4,1. Synthesis o f benzofuran-2-carbonyl chloride (73):
It was required to convert the carboxylic acid (benzofuran-2-carboxylic acid) into its acyl 
chloride derivative as the acyl chloride is more readily reactive in substitution reactions 
(Scheme 8).
1st attempt: thionyl chloride (SOCI2) is widely used to convert carboxylic acids into acyl 
chlorides. It is a preferred reagent since the formed side products namely HC1 and SC^are 
gaseous and hence they are easily removed from the reaction media. Thus, benzofuran- 
carboxylic acid was dissolved in thionyl chloride and heated under reflux overnight 
leading to the formation of benzofuran-2-carbonyl chloride but the yield was not 
satisfactory (25%).
2nd attempt: this procedure was slightly modified by adding a drop of DMF (catalyst) 
and the reaction proceeds smoothly giving high yields (70%) within 5 hours.
iPCXV( ---------------- CCMS^ ^ - 0  OH
73
Reagents and conditions: A: SOCI2, Reflux, 12 hrs (yield, 25%)
B: SOCI2 , DMF (ldrop), reflux, 5hrs(yield, 70%)
Scheme 8
8.1.2.4.2. Synthesis ofbenzofuran-2-carbotiyloxy-2-acetic acid (74):
This reaction is similar to the synthesis of (69)which is described above and therefore, the 
same procedure was employed whereby benzofuran-2-carbonyl chloride and glycolic
153
Chapter Eight Synthesis and biological evaluation
acid were stirred overnight in pyridine giving relatively good yield of product (60%) 
(Scheme 9).
j -
Reagents and conditions s: Pyridine, 12 hrs.
Scheme 9
In the final step for the preparation of (75), the previously used procedure for the 
preparation of(70) was employed (Scheme 10).
OH
Hitl
Reagents and conditions: CDI, DMF, 0°C, 1 hr; rt, 12 hr.
Scheme 10
8.I.2.5. Synthesis of 2-(benzylthio)-Ar-(2,4-dimethoxyphenyl)acetamide (76)
The synthesis of (76) was easily achieved using the commercially available S- 
benzylthioglycolic acid and 2,4-dimethoxyaniline following the procedure described for 
preparation of (70)in an excellent yield (83%)as outlined in Scheme 11.
Reagents and conditions: CDI, DMF, 0 C, 1 hr; RT, 12 hr.
Scheme 11
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8.I.2.6. Synthesis of methyl 3-(2-(3-fluorobenzoyloxy)acetamido)-4-methylbenzoate 
(77)
This product was prepared from 2-(3-fluorobenzoyloxy) acetic acid and methyl-3-amino- 
4-methylbenzoate as described for (70) (Scheme 12) in a relatively good yield (66%). 
The substrate (2-(3 -fluorobenzoyloxy)acetic acid) was prepared from 3- 
fluorobenzoylchloride and glycolic acid (detailed synthesis in Chapter 10).
NH
Reagents and conditions: A: Pyridine, ON, B:CDI, DMF, 0°C, 1 hr; rt, ON.
Scheme 12
8.1.2.7. Synthesis of methyl 5-methyl-4-(l-(4-methylbenzoyloxyimino)ethyl)isoxazole 
-3-carboxylate (82)
The synthesis of methyl 5-methyl-3- (l-(4-methylbenzoyloxyimino)ethyl)isoxazole-4- 
carboxylate (82) was achieved in a four-step process as represented in the following 
scheme (Scheme 13). It started with the synthesis of methyl 2-chloro-2- 
(hydroxyimino)acetate(79) which was cyclised to methyl 4-acetyl-5-methylisoxazole-3- 
carboxylate(80)and then reacted with hydroxylamine to give the corresponding 
oxime(81). This latter was reacted with p-toluoyl chloride to provide the desired 
compound (48%).
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(B),N-OH
(C)
HOCD)
Reagents and conditions: A: 2eq HC1, -5°C; 2eq aq NaNC>2 ; 0°C, 12 hrs.
B :Acetylacetone,NaOEt, EtOH, 2hrs.
C: NH2OH.HCl, TEA, lhr; EtOH, 80 °C. 
____________________ D: p-toluoyl chloride,TEA, 0°C-lhr; RT, 12 hrs.
Scheme 13
8.1.2.7.1. Synthesis o f methyl 2-chloro-2- (hydroxyimino) acetate (79)
(79) was prepared from the consecutive diazotization and reduction of the commercially 
available glycine methyl ester hydrochloride in acidic media using sodium nitrate 
(Scheme 13-A).
8 .1 .2 .7.2. Synthesis o f methyl 4-acetyl-5-methylisoxazole-3-carboxylate (80)
1st attempt: methyl 4-acetyl-5-methylisoxazole-3-carboxylate was reported to be easily 
accessed from the one-step condensation of nitro malonyl and acetyl acetone at high 
temperature (170 °C) in high yields.3 Moreover, the products were reported to be isolated 
in sufficient purity via distillation. However, when these conditions were attempted, poor 
yields were obtained and laborious purification was needed since different side products 
were formed.
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2ndattempt: the synthesis of methyl 4-acetyl-5-methylisoxazole-3-carboxylate was 
successfully achieved from the previously prepared chloro-hydroxyliminoacetate and 
acetylacetone using conditions reported by Giovannoni and co-workers4 (scheme 13-B).
8.1.2.7.3. Synthesis o f methyl 4-(l-(hydroxyimino)ethyl-5-methylisoxazole-3-
carboxylate (81)
The synthesis of the oxime (81) was achieved in a straightforward method by treating 
compound (80) with hydroxylamine hydrochloride in a refluxing ethanol in the presence 
of TEA for a couple of hours (scheme 13-C).
$.1.2.1 ASynthesis o f methyl 5-methyl-4- (l-(4methylbenzoyloxyimino)ethyl)isoxazole 
-3-carboxylate (82)
This final step encompasses the acylation reaction between the previously prepared 
intermediate; (81) and p-toluoyl chloride (yield 48%). (Scheme 13-D).
Overall, 8  hits were successfully prepared in pure form and good quantities to conduct 
the necessary biological assays (Figure 4). Of these hits, compound (83) was 
commercially obtained. A 5 mg of this compound was purchased from Maybridge 
screening library as it was anticipated that any attempts for its preparation in the lab 
would be labor intensive and time consuming since several synthetic steps are required.
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Figure 4: The structures of the synthesised potential hits obtained from the structure-
based virtual screening studies (modified approach).
8.1.3.Synthesis of high throughput docking hits:
8.1.3.1. GFscore hits: The following 2 hits (Figure 5) represent the main structural 
scaffolds obtained from the molecular modelling studies using GFscore approach. While 
the synthesis of the first hit (isoindoline derivative) proved to be straightforward in one 
step from commercially available substrates, the second hit (isatin derivative) required a 
multi-step synthesis.
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HO
Figure 5: the hits obtained using GFscore approach.
8.I.3.I.I. Synthesis of methyl (lS)-2-(l-methoxy-5-methyl-l-oxahexan-2-yl)-l,3-dioxo- 
isoindoline-5-carboxylic acid (84)
1st attempt: for the synthesis of (84), 1,2,4-benzenetricarbocyclic acid anhydride and L- 
leucine methyl ester hydrochloride were heated under reflux in acetic acid overnight.5 
This procedure led to the formation of the desired product but in a very low yield (<15%) 
and thus a different synthetic route was investigated.
2 nd attempt: it was reported that when using pyridine instead, the reaction gives better 
yields and proceeds smoothly (Scheme 17).6 The same starting materials were employed 
and the use of pyridine in this case led to the formation of the desired product(84) in a 
very good yield (> 75%). Moreover, it was possible to purify the product through a 
straightforward column chromatography.
HO.HO.
Reagents and conditions: Pyridine, Reflux, 12 hr.
Scheme 17
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8.1.3.1.2. Synthesis of 6-methoxy-2-oxo-3-(2-tosylhydrazono)indoline-5-carboxylic 
acid (8 6 )
The preparation of (8 6 ) was achieved over 2 main steps (Scheme 19).7 The first step 
included the preparationof 6-methoxy-2,3-dioxoindoline-5-carboxylic acid (isatin) from 
methyl-4-amino-2-methoxybenzoate. This known as Sandmeyer isonitrosoacetanilide 
isatin synthesis, which involves cyclyzing the condensation product of the aniline, chloral 
hydrate and hydroxylamine in sulfuric acid at 90°C (yield 70%). This was accompanied 
by the hydrolysis of the methyl-ester to its corresponding carboxylic acid. In the second 
step, the isatin intermediate was reacted with p-toluenesulfonylhydrazide in a refluxing 
ethanol for 3 hours to give the title compound (40%).8
85 8 6
Reagents and conditions: A: C2H3CI3O2, NH2OH.HCI, sodium sulfate, aq HC1, 55 °C,
1 2  hrs; H2SO4, 90°C, 45mins.
B: EtOH, reflux, 3hrs._________________________________________________
Scheme 19
Using these established synthetic routes, a further 2 indoline derivatives and 1 more isatin 
derivative were prepared.
8.I.3.I.3. Synthesis of methyl (S)-2-(l-hydroxy-4-methylthio)butan-2-yl)-l,3- 
dioxoindoline-5-carboxyIic acid (87) and methyl 2-(4-methylphenylsulfonamido)-l, 
3-dioxoisoindoline-5-carboxylic acid (8 8 )
Both of these compounds were prepared as described above for(84)and as shown in 
Scheme 20.(87)was prepared from 1,2,4-benzenetricarbocyclic acid anhydride and S-
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methioninol while (8 8 ) was prepared from 1,2,4-benzenetricarbocyclic acid anhydride 
and p-toluenesulfonylhydrazide.
OH
HO.
HO N-NHHO
Reagents and conditions: Pyridine, Reflux, ON.
Scheme 20
8.1.3.1.4. Synthesis of 7-methyl-2-oxo-3-(2-tosylhydrazono)indoline-4-carboxylic 
acid (90)
Compound(90) was prepared from 7-methyl-2,3-dioxoindoline-4-carboxylic acid and p- 
toluenesulfonylhydrazide following the procedure described for the synthesis of (8 6 )
(yield 24 %) as represented in the following scheme (scheme 21).
HO^^O HOv .  vCr0
s^NHa JL J  J O '
°  1 X - rY>o b » r
^  J ' W  ^
89 90
Reagents and conditions: A: C2H3CI3O2, NH2OH.HCI, sodium sulfate, aq HC1, 55 °C,
12 hrs; H2SO4, 9 0 °C, 45mins.
B: EtOH, reflux, 3hrs.
Scheme 21
Overall, the main compounds prepared based on GFscore modelling studies are 
represented in Figure 5.
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OHHOHO
Oil*
S —
HOHO
HO.
Figure 5: The compounds, which were synthesised based on GFscore modelling studies.
8.I.3.2. PLANTS hits:
The following 2 potential hits (Figure 6 ) were derived from high- throughput docking 
using PLANTS.Generally speaking, it can be said that these 2 hits have relatively similar 
structures and hence, efforts were focused on devising a synthetic route, which enables 
access to both structures in good yields.
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'O
Figure 6 : the 2 hits obtained via high throughput docking with PLANTS approach.
8.I.3.2.I. Synthesis of 2-(l-(2-(4-(4-methyIbenzyl)piperazin-l-yl)-2oxoethyl)cyclo 
pentyl)acetic acid
Compound(92)was synthesised by preparingp-methylbenzylpiperazine(91)first and then 
reacting it with 3,3-tetramethyleneglutaric anhydride as illustrated in scheme 22.
Reagents and conditions: A: THF, reflux, 2hrs; B: Dioxane, reflux, 5hrs.
Scheme 22
p-Methylbenzylpiperazine(91) was prepared by reacting p-methylbenzylchloride with an 
excess of piperazine (2eq) (Scheme 22-A). The piperazine is first dissolved in THF and 
the temperature is reduced to 0°C. Methylbenzylchloride was then added and the solution 
was then heated under reflux for 2 hrs leading to the formation of (91), which was 
obtained in a pure form and good yield (79%) using column chromatography.
(91)
(B)
(92)
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The synthesised piperazine (91)was then heated under reflux with the commercially 
available anhydride (3,3-tetramethyleneglutaric anhydride) in dioxane. The electron lone 
pair of the piperazine attacks the anhydride at one of the carbonyls leading to the opening 
of the ring and a free carboxylic acid. The crude product obtained was further purified 
using column chromatography using a mixture of hexane and ethylacetate (1:9) as eluent 
to give the desired compound (yield 6 6 %)
8.1.3.2.2. Synthesis of 2-(l-(2-(4-(cyclohexanecarboxamido)phenylamino)-2-
oxoethyl)cyclopentyl)acetic acid (95)
As mentioned before, the structure of this hit is mostly similar to the previously prepared 
compound (92) and therefore, a similar synthetic route was followed (Scheme 23).
♦ H rf i-Q -N o , - m  »  q A n X X
m )
NO*
 (B)
o V ^  < A ^ * o JtO-
^  (94) <*>
Reagents and conditions: A: DMF, reflux, 115°C.
B: Fe, AcOH:EtOH, H2O,reflux, 40 mins.
C: Dioxane, reflux, 5hrs.
NH
Scheme 23
The synthesis consists of three main steps. It starts by reacting the /?-nitrophenylaniline 
with cyclohexanecarbonyl chloride in refluxing DMF under inert gas conditions to obtain 
N-(4-nitrophenyl)cyclohexanecarboxamide in excellent yield (82%). This nitro 
compound was subsequently, reduced to its amino counterpart (N-(4-
aminophenyl)cyclohexanecarboxamide). There are many reported reagents and methods
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for the reduction of nitro compounds. The most common ones are the catalytic 
hydrogenation over Pd/C or Raney nickel and the use of LAH, SnCh or metal iron 
(Fe) . 9,10 For this synthesis, the use of Fe in acidic media was chosen as the procedure 
requires mild conditions and highly tolerable to wide range of functional groups. It 
follows that N-(4-nitrophenyl)cyclohexanecarboxamide was heated under reflux in a 
mixture of EtOH:acetic acid (1 : 1) in the presence of excess amounts of Fe for 40 
minutes (TLC monitored) to give N-(4-aminophenyl)cyclohexanecarboxamide in good 
yield (75%).
The third and final step was the formation of the amide bond as it was the case with the 
previous compound (92) by heating under reflux a mixture of N-(4- 
aminophenyl)cyclohexanecarboxamide with 3,3-tetramethyleneglutaricanhydride in 
dioxane to obtain the crude (95) .This latter was further purified using column 
chromatography (yield 54%).
8.2. Biology
8.2.1. Biochemical Binding Assays
The biochemical binding assays were carried out in the laboratories of our collaborators 
in St. Jude Children’s Research Hospital under the supervision of Prof Jie Zheng. They 
use NMR based experiments (15N HSQC chemical-shift perturbation) to derive binding 
affinities (K d) of PDZ ligands. A detailed description of the protocol followed is reported 
in previous publications by this research group. 11,12
Compounds (82) and (90), which showed promising activity in cell based assays as well 
as compounds (92)and (95)(good docking results) were chosen for testing using these 
assays.
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8.2.2. Results
The main findings obtained from the NMR based experiments are illustrated in Figure 8 .
• (82) was not tested due to solubility problem (not soluble in buffer or in 
20%DMSO).
• Both compounds (92)and (90) showed no obvious binding to the Dvl PDZ domain 
in the !H-15N HSQC titration experiments.
• The hit compound (95) showed specific binding to the peptide-binding site of the 
Dvl PDZ domain with binding affinity in the low micromolar range as it is the 
case with compound (3289-8625), which is the most potent Dvl PDZ inhibitor 
reported so far. 13
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Figure 8: l5N-HSQCspectra PDZ domain titrated with compounds (90), (92) and (95). 
Spectra are colored by the protein to ligand ratios: black (1:0), red (1:1), green 
(1:3),yellow (1:5), cyan (1:9) and magneta (1:15).
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9. The design and synthesis of analogues for 
the hit compound (95)
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The biochemical binding assays showed that one of the potential hits obtained from 
molecular modelling studies namely 2-(l-(2-(4-(cyclohexanecarboxamido)phenylamino)- 
2-oxoethyl)cyclopentyl)acetic acid (95) (Figure 1) binds to the Dvl PDZ domain. 
Therefore, the next step was to implement a molecular dynamic (MD) simulation to 
explore the mode of binding of this compound, which in turn enables the synthesis of 
structural analogues with better binding affinity.
HO
NH
Figure 1: the chemical structure of (95)
9.1. Molecular modelling studies
Molecular dynamics (MD) is a sub-discipline of molecular modelling, which is centered 
on computationally simulating the motion of atoms, and molecules. 1,2 MD is widely used 
in different fields and frequently in the study of proteins and biomolecules. During MD 
simulation, molecules and atoms are allowed to interact for a period of time in an effort 
to generate a conformational search in space, or trajectory, under specified 
thermodynamic conditions such as constant temperature or constant pressure. This 
trajectory is important for two main reasons. The first is the fact that it allows calculation 
of the thermodynamic properties of a system by providing configurational and 
momentum information for each atom. The second reason is that it represents an 
exploration of the conformation space available to a particular system.
Short-running MD studies of the complex between the Dvl PDZ domain and (95) were 
performed using MOE to further investigate their interaction.3 The starting structures of
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ligand-protein complexes were prepared using the output from the PLANTS docking 
studies. The partial charges were calculated and the energy o f the molecular system was 
minimized to RMS gradient o f  0.1. Using the dynamics panel, constant volume (NVT) 
ensemble simulations were carried out.
Figure 2 shows the conformation o f  the complex ((95) -Dvl PDZ) with the lowest free 
energy o f  binding.
Figure 2: the conformation o f the complex (Dvl PDZ- ligand 95) with the lowest free 
energy o f  binding from the performed MD simulations.
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The main finding of this short-running MD simulation is that (95) adopts an extended 
binding pose along the active site of the Dvl PDZ domain, which supports the docking 
results, obtained by PLANTS. The carboxylic acid group of (95) is in close proximity 
with residues lie 267, Gly 266 and Leu 265. On the other hand, while the cyclopentane 
part of (95) structure resides deeply in a hydrophobic cavity of the active site, the 
cyclohexane part is more exposed to the solvent.
9.2. Chemistry
Based on the docking and molecular dynamic simulations of the interactions between 
(95) and Dvl PDZ domain, several potential structural modifications can be introduced to 
further optimize the activity of this ligand as illustrated in Figure 3.
1-Hydrophobic2-Hydrophobic
Figure 3: The potential areas of structural modifications to ligand (95) to optimize its
activity.
1. Changing the size of hydrophobic group (cyclopentane) by using bigger 
(cyclohexane) or smaller groups (dimethyl) to study the effects on the binding to 
PDZ domain.
2. Changing the size of hydrophobic group (cyclohexane) by incorporating bigger 
(methylbenzene) or smaller (methyl) hydrophobic groups.
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3. The linker group: the aniline group acts as a linker group connecting both 
hydrophobic parts (cyclopentane side and cyclohexane) of the structure. Hence, 
any change in this linker will force the molecule into adopting a different binding 
mode. The main aim of varying this group is to achieve another hydrogen bonding 
with residue Ile269 of the PDZ domain as seen for Dapper bound Dvl PDZ (refer 
to Figure 3, Chapter 7).
4. Ester derivatives: the docking as well as MD studies showed that the carboxylic 
acid moiety is essential for mediating the interaction between the Dvl PDZ and 
ligand (95). Nevertheless, by masking the carboxylic acid moiety of the 
compound, the ester derivatives are more likely to be taken into cells by crossing 
membranes.
The preparation of these novel analogues with the desired structural modifications can 
mainly be achieved using the same synthetic steps followed in the synthesis of (95) as 
represented in Scheme 1. It is worthwhile to mention that this synthesis was discussed in 
detail in the previous chapter (Chapter 8 ).
Reagents and conditions: A: DMF, reflux, 115 °C.
B: Fe, AcOHrEtOH, H2O, reflux, 40 mins. 
C: Dioxane, reflux, 5hrs.
Scheme 1
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Nevertheless, key changes to this synthetic route in the preparation of (95) analogues will 
be discussed for each of the potential four areas of structural modifications highlighted 
above.
1: The hydrophobic moiety (cyclopentane): The main modifications to this part of the 
structure involved the use of dimethyl or the cyclohexane groups as replacement for 
cyclopentane. These two groups were mainly introduced by the use of the appropriate 
anhydride; 3,3-dimethylglutaric anhydride or cyclohexylglutaric anhydride (3- 
oxaspiro[5,5]undecane-2,4-dione) which when reacted with the corresponding aniline 
leads to the opening of the cyclic anhydride ring and subsequently formation of the 
desired product as shown in Scheme 2. The overall yields were comparable to those 
obtained for (95) (yield 52-61 %). The chemical structures of compounds prepared 
using this procedure are shown in Figure 4).
HO
NH;
OH
NH
Reagents and conditions: Dioxane, Reflux, 5hrs.
Scheme 2
2: The hydrophobic moiety (cyclohexane): The use of smaller hydrophobic group in 
the form of methyl can be easily achieved by the use of acetyl chloride instead of 
cyclohexanecarbonyl chloride used in the synthesis of (95). However, it was more cost 
and time effective to purchase JV-(4-aminophenyl)acetamide and react it directly with the 
anhydride to give the final product in a one step process (Scheme 3). This resulted in 
excellent yields (> 80 %) as this procedure overcomes the need for the formation of a 
nitro substrate and its subsequent reduction.
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Reagents and conditions: Dioxane, Reflux, 5hrs. 
Scheme 3
In addition to the use of methyl group, a methylbenzene (toluene) moiety was 
successfully introduced to the structure as a replacement for the cyclohexane. This work 
will be discussed within the next category of structural modifications, which is concerned 
with changes of linker group.
3: The linker group (benzene-1,4-diamine): The first change was simply to use the meta 
derivative of the diamine (benzene-1,4-diamine) linker. Hence, the same synthetic 
procedure was repeated with the only difference being the use of 3-nitroaniline as a 
starting substrate. For instance, the preparation of the structural isomer of (95) is shown 
in Scheme 4.
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Reagents and conditions: A: DMF, reflux, 115 °C.
B: Fe, AcOH:EtOH, H2O, reflux, 40 mins.
C: Dioxane, reflux, 5hrs.
Scheme 4
The other modification to the linking group was to use p-nitrobenzoylchloride instead of 
benzene-1,4-diamine. The two linking groups are similar in that they have the nitro group 
which has to be reduced before undergoing a condensation reaction with the anhydride. 
The only difference is that p-nitrobenzoylchloride acts initially as an electrophile because 
of the presence of the highly reactive carbonyl chloride. This allows the use of different 
nucleophiles to introduce a hydrophobic moiety replacement to the cyclohexane (second 
area of modifications). For instance, the preparation of (iS)-4-amino-Ar-( 1 -p- 
tolylethyl)benzamide is illustrated in Scheme 5. The same reagents and conditions used 
in the synthesis of (95) are applied in this procedure. It follows that p-tolylethanamine is 
reacted with a slight excess of p-nitrobenzoylchloride to give a nitro intermediate which 
is subsequently reduced to , the corresponding amine (S)-4 -amino-7V-( 1 -p- 
tolylethyl)benzamide )This latter was then reacted with different glutaric anhydrides to 
give novel (95) derivatives as shown in Scheme 6 .
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Reagents and conditions: A: DMF, reflux, 115 °C.
____________________ B: Fe, AcOH:EtOH, H2O, reflux, 40 mins.
Scheme 5
NH; 101100
OH
NH.
102100
,OH
^  ^  nh2 v  J  ' o
100
Reagents and conditions: Dioxane, reflux, 5hrs.
103
Scheme 6
Overall, considering these three potential areas of structural modifications, the following 
(95) analogues were successfully prepared (yield 50-70%) (Figure 4).
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= O
„Aj>CxOH
103 H
HxXfrb
104
X^X ixlo, XXXXxA
H H
105 106
OH
OH
I J H I I H
107 108
X XHN ^ ^  NH
c r ^ ^ r
OH
H
x c r r S
109 110
Figure 4: The synthesised novel analogues of (95).
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4. The synthesis of ester derivatives
The simplest ester derivatives of these compounds are their methylester counterparts. 
These ester derivatives can be obtained through esterification of the already prepared 
carboxylic acid compounds (Figure 2). There are many esterification methods using 
different reagents and under different conditions described in literature.
4.1. The synthesis of methyl 2-(l-(2-(4-(cyclohexanecarboxamido)phenylamino)-2- 
oxoethyl)cyclopentyl)acetate:
1st attempt: l,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) was reported as an effective 
nucleophilic catalyst for carboxylic acid esterification with dimethyl carbonate (DMC) . 4 
Excellent yields (> 90%) were reported for various carboxylic acids to be obtained from a 
simple aqueous work-up and acid washings. It is thought that that DBU reacts with DMC 
forming an unstable carbamate, which acts as a highly effective methylating agent for the 
carboxylic acid.
The procedure involves the addition of 1 equivalent of DBU to 10% solution of (95) in 
DMC and heating under reflux for 8  hours (Scheme 7). Upon completion (TLC 
monitored), the reaction was cooled to room temperature and diluted with EtOAc and 
H2O. The organic layer was then washed with H2O, twice with 2M HC1 and twice with 
NaHCC>3 and twice with H2O once more. Then, it was dried over MgSCU, filtered and 
concentrated in vacuo. The crude product showed a mixture of components and needed 
further purification in form of column chromatography but the overall yield was poor (< 
15%).
OH
111
Reagents and conditions: DBU, DMC, 90 °C, reflux.
Scheme 7
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2 nd attempt: this time, the carboxylic acid was heated under reflux in methanol in the 
presence of trimethylsilyl chloride (Scheme 8 ) .5 After the reaction is completed (TLC 
monitored), the solvent was removed in vacuo giving the crude product in sufficient 
purity and good yields (78 %).
OH
111
Reagents and conditions: TMSC1, MeOH, 69°C, reflux.
Scheme 8
This synthetic route was then used for the preparation of other methylester derivatives as 
shown in Figure 5.
I l l
X r
113
Figure 5: The chemical structures of the prepared methylester derivatives.
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9.3. Biology
The new series of the synthesised (95) analogues were sent to our collaborators in the 
Netherlands under the supervision of Prof Jan Paul Medema (University of Amsterdam) 
to study their inhibition of the Wnt signaling pathway using specific cell lines developed 
for this purpose. Based on the cell line data, the most promising compounds will be sent 
for biochemical binding assays (Prof J Zheng, St. Jude Hospital, University of 
Tennessee).
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10.1. General experimental details
Melting points were measured on a Griffin apparatus and are uncorrected. All 
commercially available starting materials used were purchased from Aldrich without 
further purification. All glassware was oven dried at 60°C for several hours or overnight.
Chromatography
Thin Layer Chromatography (TLC) was performed using precoated, aluminum backed 
silica gel plates (TLC Silica gel 60 F254-Merck) and an ultra-violet (UV) lamp was used 
for visualisation (254nm). For column chromatography, silica gel (Silica 60A particle 
size 35-70 micron, Fisher Scientific) was used.
NMR spectroscopy
]H, and 13C NMR were recorded on a Bruker Avance 500 spectrometer with operating 
frequencies of 500, and 125 MHz respectively. The following abbreviations are used in 
the assignment of NMR signals: s (singlet), d (doublet), t (triplet), m (multiplet). J  
coupling constants were calculated on the Topspin program and are reported Hertz (Hz).
Mass Spectroscopy
Mass spectra were determined under electroscopy conditions on a Bruker MicroTOF LC 
instrument at the Welsh School of Pharmacy, Cardiff, or at the Chemistry Department, 
Cardiff University.
CHN Analysis
CHN analysis was carried out by MED AC. The data were recorded on a Carlo-Erba EA 
1108 element analyser, PC based data system, Eager 200 for Windows and a Sartorius 
Ultra Micro balance 4504MP8.
186
Chapter Ten________________________________________ Experimental section
10.2. Synthesised compounds:
General procedure 1:
A mixture of pyrrolidinonecarboxylic acid or hydroxynicotinic acid (3.88 mmol), 
(substituted) 2-bromoacetophenone (3,88 mmol) and TEA (l.lmL) in acetone (20 mL) 
was heated under reflux for 3 hours. After completion of the reaction (monitored by 
TLC), the solvent was evaporated and the residue was extracted using EtOAc, dried over 
MgSC>4 and concentrated in vacuo. The obtained residue was purified by column 
chromatography (90% EtOAc/10% Hexane) to give the title compound as a white solid. 
The following compounds were prepared using this procedure.
(5)-2-Oxo-2-phenylethyl-5-oxopyrrolidine-2-carboxylate (63)
O
C13H13NO4, MW: 247.25
Prepared from ($-2-pyrrolidinonecarboxylic acid and 2-bromoacetophenone (yield 
63%). *H NMR (CDCI3): S 2.41-2.53 (4H, m, H-3, 4), 4.45 (1H, m, H-2), 5.43 (2H, s, 
CH2), 6.23 (1H, bs, NH), 7.52 (2H, m, Ar-H), 7.64 (1H, m, Ar-H), 7.91 (2H, m, Ar-H). 
13C NMR (CDC13): 5 25.11, 29.17, 55.24, 66.65, 127.73, 127.73, 128.99, 128.99, 
133.84,134.19, 171.80,177.94,191.25. ESI MS m/z 270.06 [M+Na+].
(S>2-(4-Methoxyphenyl)-2-oxoethyl-5-oxopyrroIidine-2-carboxylate (64)
O
OMe
Ci4H15N 05, MW: 277.27
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Prepared from (S)-2-pyrrolidinonecarboxylic acid and 2-bromo-4’-methoxyacetophenone 
(yield 61%). *H NMR (CDCfe): 6  2.41-2.53 (4H, m, H-3, 4), 3.91 (3H, s, OCH3), 4.46 
(1H, m, H-2), 5.42 (2H, s, CH2), 6.14 (1H, bs, N-H), 6,98 (2H, d, 79.0 Hz, H-3’, 5’), 7.90 
(2H, d, 79.0Hz, H-2’, 6 ’). l3CNMR(CDCfe) : 6  25.10,28.98, 55.17,55.57,66.30,114.21 
114.21,126.82,130.04, 130.04,164.32, 172.12,177.96,189.70. ESI MS m/z 300.06 
[M+Na+],
(/?>-2-(4-Methoxyphenyl)-2-oxoethyl-5-oxopyrrolidine-2-carboxylate (65)
C14H15NO5, MW: 277.27
Prepared from (^-2-pyrrolidinonecarboxylic acid and 2-bromo-4’-methoxyacetophenone 
(yield 67 %). *H NMR (CDC13): 6  2.41-2.53 (4H, m, H-3, 4), 3.91 (3H, s, OCH3), 4.45 
(1H, m, H-2), 5.42 (2H, s, CH2), 6.14 (1H, bs, N-H), 6,98 (2H, d,79.0 Hz, H-3’, 5’), 7.90 
(2H, d, 7 9.0 Hz, H-2’, 6 ’). UC NMR (CDCfe): 6  25.11,29.02,55.23,55.56, 66.29, 
114.20,114.20,126.83,130.04,130.04,164.30,171.85,177.92,189.64. ESI MS m/z 
300.06 [M+Na+],
2-(4-Methoxyphenyl)-2-oxoethyl-2-oxo-l,2-dihydropridine-3-carboxyIate (6 6 )
OMe
C15H13NO5, MW: 287.27
Prepared from 2-hydroxynicotinic acid and 2-bromo-4’-methoxyacetophenone (yield 52 
%). *H NMR (DMSO-d<): 6  3.89,(3H, s, OCH3), 5.74 (2H, s, CH2), 6.81 (1H, t, 77.0 Hz, 
H-5), 7.14 (2H, d,79.0 Hz, H-3’, 5’), 8.07 (2H, d,79.0 Hz, H-2’, 6 ’), 8.20 (1H, dd,72.0
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Hz, 7.5 Hz, H-6 ), 8.47 (1H, J  2.0 Hz, 7.5 Hz, H-4). 14.21 (1H, s, N-H). 13C NMR 
(DMSO-rf*): 5 55.70, 55.76, 108.26, 114.28, 114.28, 116.40, 126.95, 130.51, 130.51, 
145.93,146.02,163.42,163.97,164.59,189.93. ESI MS m/z 300.06 [M+H*!
2-(4-Methoxyphenyl)-2-oxoethyl-6-oxo-l,6-dihydropridine-3-carboxylate (67)
OMe
C15H13NO5, MW: 287.27
Prepared from 6 -hydroxynicotinic acid and 2-bromo-4’-methoxyacetophenone (yield 64 
%). *H NMR (DMSO-rf<): 6  3.89 (3H, s, OCH3), 5.74 (2H, s, CH2), 6.81 (1H, t, J  7.0 Hz, 
Ar-H), 7.14 (2H, d, J  8.5 Hz, H-3’, 5’), 8.07 (2H, d, J  8.5 Hz, H-2’, 6 ’), 8.20 (1H, dd, J
2.0 Hz, 6.5 Hz, Ar-H), 8.47 (1H, dd, J  2.0 Hz, 7.5Hz, Ar-H), 14.19 (1H, s, N-H). ,3C 
NMR (DMSO-dt): 6  55.68, 55.74, 108.25, 114.28, 114.28, 116.41, 126.95, 130.50, 
130.50,145.93,146.00,163.42,163.98, 164.59, 189.92. ESI MS m/z 300.06 [M+H*].
(S)-Ar-(l-4-Methoxyphenyl)ethyl)-4-methylbenzamide (6 8 ):
C17H19NO2, MW: 269.34
/7-Toluoyl chloride (0.3mL, 2.2mmol) was added dropwise to a stirring solution of 4- 
methoxy-a-methylbenzylamine (0.29mL, 2mmol) and TEA (0.42mL, 3mmol) in 15 mL 
DCM at 0°C under nitrogen. The reaction was then stirred further at room temperature 
over night. Upon the completion of the reaction, the solvent was evaporated and the 
residue was extracted using ethyl acetate, dried over MgSC>4 and concentrated in vacuo. 
The obtained residue was further purified with column chromatography (EtOAc-Hexane)
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(yield 83 %). *H NMR (CDClj): 8 1.61 (3H, s, CH3), 2.41 (3H, s, CH3), 3.82 (3H, s, 
OCHj), 5.31 (1H, m, H -l”), 6.21 (1H, bs, NH), 6.91(2H, d, J 7.0 Hz, H-3’, 5’), 7.23 (2H, 
d, J  8.0 Hz, H-2’, 6’), 7.35 (2H, d, J  7.0 Hz, H-3, 5). 7.67 (2H, d, 8.5 Hz, H-2, 6). ,3C 
NMR (CDC13): 8 21.41, 21,61, 48.56, 55.32, 114.10, 114.10, 126.88, 126.88, 127.48, 
127.48, 129.18, 129.18, 133.00, 140.96, 141.08,158.43, 167.10. ESI MS m/z 292.12 
[M+Na+],
General procedure II:
To a stirring solution of glycolic acid (7.5 mmol) in pyridine (6 mL), p-toluoyl chloride 
(6.50 mmol) is added dropwise and stirred over night. Upon completion of the reaction 
(TLC monitored), the solvent was evaporated and the resultant residue was extracted 
using ethyl acetate (3 x 30mL), dried over MgSC>4 and concentrated in vacuo. The 
obtained residue was purified by column chromatography.
2-(4-Methylbenzoyloxy) acetic acid (69)
O
Prepared from p-toluoyl chloride and glycolic acid using general procedure II (yield 59 
%). *H NMR (DMSO-dtf): 6 2.37 (3H, s, CH3), 4.78 (2H, s, CH2), 7.37 (2H, d, J9 .0  Hz, 
H-3, 5), 7.96 (2H, d, .79.0 Hz, H-2, 6), 12.83 (1H, s, OH).
General procedure III :1
A mixture of the acetic acid (lmmol) and carbonyl diimidazole (lmmol, leq) in DMF 
(5mL) was stirred at 0 °C for 1 hour. (Substituted) amine (lmmol, leq) was dissolved in 
DMF (2 mL) and added. The reaction was then stirred at 0 °C for another 1 hour, allowed 
to warm to room temperature to be kept stirring overnight. Once the reaction is
completed (TLC monitored), the mixture was poured into a beaker containing ice-cold
/
water. This immediately led to the formation of a precipitate, which was collected by
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filtration and washed thoroughly with water to yield the desired product. No further 
purification was required.
(S)-2-(l-(4-Methoxyphenyl)ethylamino)-2-oxoethyl-4-inethylbenzoate (70)
C19H22NO4, MW: 327.37
Prepared from 2-(4-methylbenzoyloxy)acetic acid and 4-methoxy-a-methylbenzylamine 
using general procedure III (65 % yield). *H NMR (CDCI3): 6  1.53 (3H, m, CH3), 2.37 
(3H, s, CH3), 3.81 (3H, s, CH30), 4.81 (2H, s, CH2), 5.21 (1H, m, H-l”), 6.32 (1H, bs, 
NH), 6.89 (2H, d, J  7.0 Hz, H-3’, 5’), 7.27 (4H, m, H-3, 5, H-2’, 6 ’), 7.94 (2H, d, 77.0 
Hz, H-2, 6 ). I3C NMR (CDCI3): 6  21.65, 21.71, 47.96, 55.30, 63.38, 114.13, 114.13, 
126.25, 127.29, 127.29, 129.40, 129.40, 129.76, 129.76, 134.71, 144.59, 158.99, 165.27, 
166.29. ESI MS m/z 350.12 [M+Na+],
l-(Benzo[d]|l,3]dioxol-5-yl)ettaananiine (71)2
A mixture of the ketone (10 mmol), titanium(IV) isopropoxide (6.0 ipL, 20 mmol) and 
ammonia in absolute ethanol(2 M, 25 mL, 50 mmol) was stirred under nitrogen in a well 
sealed flask at room temperature for 6  hrs. Sodium borohydride (0.6 g, 15 mmol) was 
then added and the resulting mixture was stirred at room temperature for an additional 3 
h. The reaction was then quenched by pouring it into ammonium hydroxide (2 M, 25 
mL), the resulting precipitate was filtered off, and washed with ethyl acetate (25 mL). 
The organic layer was separated and the remaining aqueous layer was extracted with 
ethyl acetate (25 mL). The combined organic solution was next extracted with 
hydrochloric acid (1 M, 30 mL) to separate the neutral materials. The acidic aqueous
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extracts were washed with ethyl acetate (50 mL), then treated with aqueous sodium 
hydroxide (2 M) to a basic pH (10-12), and extracted with ethyl acetate (50 mL><3). The 
combined organic extracts were washed with brine (50 mL), dried (MgS0 4 ), and 
concentrated in vacuo to afford the title compound (yield 49 %). *H NMR (CDCI3): 6
1.43 (3H, m, CH3), 5.08 (1H, m, H -l’), 6.01 (2H, s, O-CH2 -O), 6.40 (2H, bs, NH2), 6.94-
7.35 (3H, m, Ar-H).
2-(l-(Benzo [d] [1,3] dioxol-5-yl)ethyIamino)-2-oxoethyl-4-methylbenzoate (72)
C19H19NO5, MW: 341.36
Prepared from 2-(4-methylbenzoyloxy)-acetic acid and (71) using general procedure III 
(yield 57 %). *H NMR (CDCI3): 6 1.52 (3H, m, CH3 ), 2.45 (3H, s, CH3), 4.81 (2H, s, 
CH2), 5.15 (1H, m, H -l”), 5.96 (2H, s, 0-CH2-0), 6.28 (1H, bs, NH), 6.78 (2H, m, H- 
Ar), 7.29 (2H, J  8.0 Hz, H-3, 5), 7.96 (2H, J  8.0 Hz, H-2, 6), 8.02 (lH,m, H-Ar). 13C 
NMR (CDCI3): 6 21.72, 21.83, 48.37, 63.37, 106.78, 108.18, 108.38, 119.31, 129.21, 
129.42, 129.42, 129.78,129.78, 130.23, 144.26, 144.63, 147.94, 166.34, 171.11.
Benzofuran-2-carbonyloxy-2-acetic acid (74)
O.
k OH
o- 7
O O
H
Benzofuran-carboxylic acid was dissolved in 5 ml thionyl chloride and a drop of DMF 
was added and the reaction mixture was heated under reflux for 5 hours. Once the 
reaction is completed (TLC monitored). The solvents were removed in vacuo. The 
resultant residue was used with glycolic acid as described above for the synthesis of 2-(4-
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methylbenzoyloxy) acetic acid (yield 57 %). *H NMR (DMSO-^): 6  5.01 (2H, s, CH2),
7.05 (1H, m, H-2), 7.42-7.51 (3H, m, Ar-H), 7.78 (1H, m, Ar-H), 13.10 (1H, bs, COOH).
2-(4-MethoxybenzyIamino)-2-oxoethylbenzofuran-2-carboxylate (75)
2' 3'
6
C19H17NO5, MW: 339.34
Prepared from benzofuran-2-carbonyloxy-2-acetic acid and 4-methoxybenzylamine using 
general procedure III (yield 56 %). 'H NMR (CDCI3): 6  3.81 (3H, s, OCH3), 4.56 (2H, s, 
CH2), 4.94 (2H, s, CH2), 6.51 (1H, bs, NH), 6.87 (2H, J  8.0 Hz, H-3’, 5’), 6.91 (1H, m, 
Ar-H), 7.37 (1H, m, Ar-H), 7.51 (1H, m, Ar-H), 7.57 (2H, J  8.0 Hz, H-2’, 6 ’), 7.73 (1H, 
m, Ar-H), ,3C NMR (CDCI3): 843.16, 55.27, 63.42, 112.42, 113.25, 113.25, 115.45,
119.88, 123.03, 124.12, 124.12, 127.08, 128.30, 129.89, 143.10, 153.95, 158.63, 159.20, 
167.82. ESI MS m/z 362.08 [M+Na+],
Synthesis of 2-(benzylthio)-Ar-(2,4-dimethoxyphenyI)acetamide (76)
OMe
MeO
NH
S
C17H19NO3S, MW: 317.40
This compound was prepared from benzylthioglycolic acid and 2,4-dimethoxyaniline 
using general procedure III (yield 82 %). *H NMR (CDCI3): 6  3.30 (2H, s, CH2), 3.82 
(2H, s, CH2), 3.83 (3H, s, OCH3j, 3.91 (3H, s, OCH3), 6.51 (2H, m, Ar-H), 6.91(2H, d,
7.0 Hz, Ar-H), 7.25-7.34 (5H, d, 8.0 Hz, Ar-H), 8.20 (1H, d, 8.5 Hz, Ar-H), 8.96 (1H, bs,
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NH), l3C NMR (CDCI3): 5 36.36, 37.00, 55.57, 55.78, 98.69, 103.76, 120.71, 127.42, 
128.65, 128.65, 129.08, 129.08, 129.10, 138.12, 149,78, 156.73, 168.55. ESI MS m/z 
340.08 [M+Na4].
2-(3-Fluorobenzoyloxy)acetic acid.
O
Prepared from 3-fluorobenzoylchloride and glycolic acid using general procedure II 
(yield 52 %). *H NMR (DMSO-tfc): 6  5.08 (2 H, s, CH2), 7.48 (1H, m, Ar-H), 7.57 (1H, 
m, Ar-H), 7.66 (1H, m, Ar-H), 7.78 (1H, m, Ar-H), 13.23 (1H, bs, COOH).
Methyl 3-(2-(3-fluorobenzoyloxy) acetamido)-4-methylbenzoate (77)
OMe
CigHifiFNOs, MW: 345.32
Prepared from 2-(3-fluorobenzoyloxy)acetic acid and methyl-3-amino-4-methylbenzoate 
using general procedure III (yield 6 6  %). *H NMR (CDCI3): 8  2.32 (3H, m, CH3 ), 3.92 
(3H, s, OCH3), 5.03 (2H, s, CH2), 7.28 (1H, d, J  8.0 Hz, Ar-H), 7.37 (1H, m, Ar-H), 7.52 
(1H, m, Ar-H), 7.82 (3H, m, Ar-H), 7.94 (1H, d, J  8.0 Hz, Ar-H), 8.51 (1H, bs, NH). ESI 
MS m/z 368.09 [M+Na+].
Methyl 2-chloro-2-(hydroxyimino)acetate (79) 3
O
M e O ^ Y ^ O h l
Cl
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Glycine methyl ester hydrochloride (5g, 0.08 mol) was dissolved in H2O (15 mL) and 
HC1 (4mL) was added. The mixture was cooled to -5 °C and a solution of NaNCh (leq) in 
H2O (lOmL) was added dropwise. A second equivalent of HC1 and NaNCb were added 
inthe same way. The mixture was left in the fridge over night leading to the formation of 
a precipitate, which was collected. 13C NMR (CDCI3): 6  54.11,132.63,159.22.
Methyl 3-acetyl-5-methylisoxazole-4-carboxylate (80)4
O
To a cooled (5 °C) and stirred solution of sodium ethoxide (2.42mL, 3M), a solution of 
acetyl acetone (0.74mL, 7.27mmol) was slowly added under nitrogen. A solution of 2- 
chloro-hydroxyliminoacetate in dry ethanol (lOmL) was then added dropwise and the 
mixture was stirred for 2 hours. The mixture was neutralized with 6 N HC1, extracted 
with ether, dried (MgS0 4 ) and concentrated in vacuo. The resultant residue was purified 
by column chromatography (hexane, ethyl acetate) to yield the titled compound (59 %). 
*H NMR (DMSO-rf*): 6  2.43 (3H, s, CH3), 2.68 (3H, s, CH3), 3.91 (3H, s, OCH3)
Methyl 3- (l-(hydroxyimino) ethyl-5-methylisoxazole-4-carboxylate (81)
HO
N—
OMe
Triethylamine (6 mL) was added to a mixture of methyl 3-acetyl-5-methylisoxazole-4- 
carboxylate and hydroxylamine hydrochloride (0.3g, 4.36mmol) in ethanol (15mL) and 
heated under reflux for 3 hours. Once the reaction is completed (TLC monitored), the 
mixture was evaporated, and the obtained residue was extracted with ether, dried
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(MgSC>4) and the evaporation of the solvent produces the desired product (77 %) in 
sufficient purity. 'H  NMR (DMSO-rf«): 5 2.47 (3H, s, CH3), 2.59 (3H, s, CH3), 3.84 (3H, 
s, OCH3), 11.40 (lH ,s, OH).
Methyl 5-methyl-3- (l-(4-methylbenzoyloxyimino) ethyl) isoxazole-4-carboxylate 
(82)
o y  yy^-OM e
^ V N
C i6H i6N 0 5, MW: 316.31
p-Toluoyl chloride (1.5 mmol) was added dropwise to a stirring solution of methyl 3- (1- 
(hydroxyimino)ethyl-5-methylisoxazole-4-carboxylate (1 mmol) and pyridine in DCM 
(15 mL) at 0 °C. The reaction was allowed to warm to room temperature and stirred over 
night. Upon the completion of the reaction, the solvent was evaporated and the resultant 
residue was extracted with ethyl acetate, dried over MgSC>4 and concentrated in vacuo. 
The obtained compound was further purified with column chromatography (EtOAc- 
Hexane) (yield 46 %). ‘H NMR (DMSO-4,): 5 2.41 (3H, s, CH3 ), 2.43 (3H, s,
CH3), 2.53 (3H, s, CH3), 3.95 (3H, s, OCH3 ), 7.42 (2H, d, J  8.0 Hz, H-3, 5), 8.02 (2H, d, 
J  8.0 Hz, H-2, 6). UC NMR (DMSO-rf6): 6 11.75, 17.04, 21.22, 53.14, 125.36, 129.37, 
129.37, 129.60,129.60,144.41,157.51,165.20,166.80,167.74, 169.55, 173.07. ESI MS 
m/z 339.11 [M+Na*]. CHN Anal. Calcd for C, 60.76; H, 5.10; N, 8.85. Found: C 60.54; 
H, 5.24; N, 8.79 %.
General procedure IV:5
To a stirring solution of a (substituted) amine (lOmmol) in pyridine (lOmL), 1,2,4- 
benzenetricarbocyclic acid anhydride (lOmmol, leq) was added and the reaction mixture
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was heated under reflux over night. Upon the completion of the reaction, the solvent was 
evaporated and the residue was extracted using ethyl acetate, dried over MgSC>4 and 
concentrated in vacuo. The obtained compound was further purified with column 
chromatography (EtOAc-Hexane).
Methyl (iS)-2-(l-methoxy-5-methyl-l-oxahexan-2-yI)l,3-dioxoisoindoline-5carboxylic 
acid (84)
HO
OMe
Ci6H17N0 6, MW: 319 .31
Prepared from L-leucine methyl ester hydrochloride and 1,2,4-benzenetricarbocyclic acid 
anhydride using general procedure IV (yield 80 %). !H NMR (DMSO-ck): 6 0.88 (6H, 
m, 2 x CH3), 1.51 (1H, m, H-4’), 188 (1H, m, H-3’), 2.12 (1H, m, H-3’), 3.65 (3H, s, 
OCH3), 4.95 (1H, m, H-2’), 8.04 (1H, dd, J  8.0 Hz, 0.5 Hz, H-7), 8.28 (1H, dd, J  2.0, 0.5 
Hz, H-4), 8.41 (1H, dd, J  8.0, 1.5 Hz, H-6), 12.59 (1H, bs, COOH). 13C NMR (DMSO- 
</*): 6 20.80, 22.90, 24.30, 36.73, 50.09, 52.63, 123.53, 123.92, 131.35, 134.11, 135.74, 
136.79, 165.61, 166.43, 166.47, 169.53.
Methyl (S)-2-(l-hydroxy-4-mettiylthio)butan-2-yl)-l,3 dioxoisoindoline-5-carboxylic 
acid (87)
O n
HO
O S—-
C14H15NO5S, MW: 309 .34
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Prepared from' S-methioninol and 1,2,4-benzenetricarbocyclic acid anhydride using 
general procedure IV (yield 52 %). *H NMR (DMSCM„): 8 1.99 (1H), 2.02 (3H, s, 
CH3),2.09 (1H, m), 2.43 (2H, m), 2.45 (3H, s, CH3), 3.61 (1H, m),3.83 (1H, t, J8.0 
Hz), 4.30 (1H, m), 7.96 (1H, dd, J  8.0, 0.5 Hz, H-7 ), 8.21 (1H, d, J  2.5, 0.5 Hz, H-4),
8.36 (1H, dd, J  8.0, 2.5 Hz, H-6 ), 13.65 (1H, bs, COOH). 13C NMR (DMSO- 
d6y. 8  14.55, 27.24, 30.16, 53.38, 60.62,122.86, 123.26, 132.01, 134.88, 135.13, 136.10, 
165.84,166.43,167.56.
Methyl 2-(4-methylphenylsulfonamido)-l,3-dioxoisoindoline-5-carboxylic acid (88)
HO
C16H12N2O6S, MW: 360.34
Prepared from p-toluenesulfonylhydrazide and 1,2,4-benzenetricarbocyclic acid 
anhydride using general procedure IV (yield 8 6 %). ’H NMR (DMSO-*/*): 6  2.48 (3H, s, 
CH3), 7.39 (2H, d, J 8.0 Hz, H-3’, 5’), 7.74 (2H, d, J 8.0 Hz, H-2’, 6 ’), 8.03 (1H, dd, J 8.0 
Hz, 0.5 Hz, H-7), 8.24 (1H, dd, J  2.0 Hz, 0.5 Hz, H-4), 8.40 (1H, dd, J  8.0 Hz, 1.5 Hz, H- 
6 ), 11.05 (1H, bs, NH), 13.82 (1H, bs, COOH). I3C NMR (DMSO-</«): 6  21.06, 123.73, 
124.24, 127.44, 127.44, 127.56, 129.55, 129.55, 132.35, 135.91, 136.91, 136.93, 143.86, 
163.71,163.76,165.54. ESI MS m/z 361.04 [M+H+].
General procedure V:6
Chloral hydrate (1.47g, 8 .8 8 mmol) was added to a 250mL round-bottomed flask 
containing a suspension of hydroxylamine hydrochloride (1.85g, 26.6mmol), sodium 
sulfate (8.4g, 59mmol), and methoxybenzoate (17.4mmol) in water (50 mL) and 2M
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aqueous HC1 (2.5mL). The mixture was then heated to 55 °C overnight with stirring. 
After cooling to room temperature, a precipitate is formed which was collected by 
filtration and washed thoroughly with water and left to be air-dried. This intermediate 
was then added in small portions to a 100 mL flask containing concentrated sulfuric acid 
(5 mL), which had been heated to 70 °C. The resulting deep red solution was heated to 
90°C for 40 minutes and then cooled to room temperature. After that, the mixture was 
added rapidly to a vigorously stirred mixture of ice water (50 mL) and ethyl acetate (20 
mL). The organic phase was separated and the aqueous phase was further extracted 
thoroughly with ethyl acetate the combined organic phases were dried over MgSC>4, 
concentrated in vacuo to give the desired isatin with accepted purity to pursue the next 
step.
6-Methoxy-2,3-dioxoindoline-5-carboxylic acid (85)
HO
MeO
Prepared from methyl-4-amino-2-methoxybenzoate using general procedure V (yield 70 
%). 'H NMR (DMSO-rf«): 6  3.91 (3H, s, OCH3), 6.56 (1H, s, H-7), 7.76 (1H, s, H-4),
11.43 (1H, s, NH), 12.56 (1H, bs, COOH).
7-Methyl-2,3-dioxoindoline-4-carboxylic acid (89)
HO
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Prepared from methyl-3-amino-4-methylbenzoate using general procedure V (yield 54 
%). *H NMR (DMSO-</*): 6  2.22 (3H, s, CH3), 7.14 (1H, d, J  8.0 Hz, H-6;, 7.37 (1H, d, 
J  8.0 Hz, H-5;, 11.35 (1H, s, NH), 13.10 (1H, bs, COOH).
General procedure VI: 7
The prepared isatin using general procedure V (0.65mmol) and p- 
toluenesulfonylhydrazide (0.65mmol, leq) were added to a 10 mL round bottom flask 
containing ethanol (20 mL) and the reaction mixture was heated under reflux for 3 hours. 
The solution was left to cool to room temperature leading to the formation of the desired 
compound as a yellow precipitate, which was collected by vacuum filtration and dried.
6-Methoxy-2-oxo-3-(2-tosylhydrazono) indoline-5 -carboxylic acid (8 6 )
HO
MeO
C17Hi5N30 6S, MW: 389.38
Prepared from (85) and p-toluenesulfonylhydrazide using general procedure VI (36 %). 
*H NMR (DMSO-rfd): 5 2.38 (3H, s, CH3), 3.86 (3H, s, OCH3), 6.58 (1H, s, H-7), 7.45 
(2H, d, J 8.0 Hz, H-3’,5’), 7.73 (1H, s, H-4), 7.87 (2H, d, J 8.0Hz, H-2’,6 ’), 11.41 (1H, 
s, NH), 12.35 (1H, bs, NH), 12.53 (1H, bs, COOH). ,3C NMR (DMSO-rf*): 6  21.02, 
56.23, 95.68, 110.98, 113,35, 114.48, 123.88, 127.65, 127.65, 128.89, 128.89, 135.06, 
144.37,147.12, 162.40,162.55,166.10. ESI MS m/z 390.06 [M+H+],
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7-Methyl-2-oxo-3-(2-tosylhydrazono)indoline-4-carboxylic acid (90)
5'
HO
C17H15N3O5S, MW: 373.38
Prepared from (89) and p-toluenesulfonylhydrazide using general procedure VI (yield 24 
%). 'H NMR (DMSO-*): 6  2.22 (3H, s, CH3), 2.39 (3H, s, CH3), 7.12 (1H, d, J  8.0 Hz, 
H-5), 7.25 (1H, d, J  8.0 Hz, H-6 ), 7.44 (2H, d, J  8.0 Hz, H-3’,5’), 7.83 (2H, d, J  8.0 Hz, 
H-2’,6 ’), 11.44 (1H, s, NH), 12.82 (1H, s, NH), 13.20 (1H, bs, COOH). ,3C NMR 
(DMSOwfc): 6  16.02, 20.99, 121.73, 122.40, 122.93, 123.41, 124.77, 127.71, 127.71, 
129.69, 129.69, 132.46, 137.60, 141.24, 144.53, 161.99, 167.14. ESI MS m/z 374.05 
[M+H*].
N-(3-(3-Acetamidophenoxy)propyl)-3-(3-pyridin-2-yl)-l,2,4-oxadiazoI-5 
yl)propanamide (83)
Purchased from Maybridge corporation Ltd. 13C NMR (DMSO-</*): 
6  21.97, 24.03, 28.84, 31.06, 35.53, 60.19, 64.96, 69.79, 72.31,105.44,108.77,11.23,12 
3.15,125.94,129.33,137.59,140.41,145.81,150.23,158.73,167.51,168.24,169.90,18
0.28.
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The following general procedure were used in the synthesis o f (95) and its analogues.
General procedure VII: to a stirring mixture of nitroaniline (lOmmol) in DMF (10 mL) 
at room temperature, an acyl chloride (lOmmol) was added under inert gas conditions. 
The reaction was then heated to 110 °C and left stirring until completion (5-6 hrs) (TLC 
monitored). Once completed, the mixture was poured into ice cold H2O (20 mL) and the 
product precipitates. The precipitate was further washed with cold H2O, then collected by 
vacuum filtration and dried.
QGeneral procedure VIII: a mixture of the nitro compound (0.05 mol), reduced iron 
(30g), EtOH (40mL), H2O (lOmL) and HC1 (10M, 0.5mL) was heated for 40 minutes. 
The iron is removed by filtration through a celite and washed with hot EtOH (3X lOmL). 
The filtrate and washings are collected and evaporated to dryness to give a crude product. 
Purification was accomplished by recrystallisation from methanol.
General procedure IX: the reduced nitro compound (2 mmol) was added to an 
equivalent amount of the glutaric anhydride (2 mmol) in refluxing (90 °C) dioxane 
(20mL) and the reaction mixture was kept stirring for 5-7 hours. After completion of the 
reaction (monitored by TLC), the solvent was evaporated and the residue was extracted 
using EtOAc, dried over MgSCU and concentrated in vacuo. The obtained residue was 
purified by column chromatography (85% EtOAc/15% Hexane) to give the title 
compound as a white solid.
General procedure X:9 Chlorotiimethylsilane (0.3 mol) was added slowly to a stirring 
mixture of the obtained acid (0.1 mol) in methanol (10 mL) and the resulting mixture was 
heated under reflux for 2-3 hours. After completion of the reaction (monitored by TLC), 
the reaction mixture was concentrated on a rotary evaporator to give the ester product. 
Purification was accomplished by a straightforward column chromatography (yield 60- 
72%).
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l-(4-Methylbenzyl)piperazine (91)
(91) was prepared from p-methylbenzylchloride and piperazine. The piperazine (140 
mg, 1 mmol) is first dissolved in THF (20 mL) and the temperature is reduced to 0°C. 
Methylbenzylchloride (173mg, 2mmol) was added and the reaction mixture was then 
heated under reflux for 2 hrs (TLC monitoring). The crude product was isolated and 
further purified using column chromatography eluting with DCM to afford (91) in a good 
yield (79%). 'H NMR (DMSO-rf*): 5 2.20- 2.42 (8H, s, H-l, 2,3,4), 2.56 (3H, s, CH3), 
3.02 (1H, bs, NH), 3.40 (2H, s, CH2), 7.05 (2H, d, J8.5 Hz, H-3’, 5’), 7.15 (2H, d, J 8.5 
Hz, H-2’, 6’).
2-(l-(2-(4-(4-Methylbenzyl)piperazin-l-yl)-2-oxoethyl)cycIopentyl)acetic acid
(92)
OH
N
T
7" 2'
C21H30N2O3, MW: 3 5 8 .4 7
Prepared from (91) and 3,3-tetramethyleneglutaric anhydride using general procedure IX 
(yield 66 %). *H NMR (DMSO-//*): 6 1.53-1.55 (8H, m, H-4, 5, 6, 7), 2.26- 2.31 (11 H, 
m, H-l’, 2’, 3’, 4’, CH3), 2.45 (2H, s, CH2), 2.51 (2H, s, CH2), 7.12 (2H, d, J  8.0 Hz, H- 
4”, 6”), 7.18 (2H, d, J  8.0 Hz, H-3”, 7”), 12.10 (1H, bs, COOH). 13C NMR (DMSO-</*): 
6 20.69, 23.51,37.46, 38.72,39.03, 40.09, 40.08,41.70, 43.01,45.31,52.37, 52.77, 61.59 
, 128.74,128.74,128.83,128.83,134.70,135.98,169.54,173.48. CHN Anal. Calcd for 
C, 70.36; H, 8.43; N, 7.81. Found: C 70.26; H, 8.48; N, 7.79 %.
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jV-(4-Nitrophenyl)cyclohexanecarboxaiiiide (93)
NO
Prepared from 4-nitroaniline and cyclohexanecarbonyl chloride using general procedure 
VII (yield 82%). *H NMR (DMSO-rf,,): 8 1.08-1.70 (10H, m, H-2-6), 2.45 (1H, m, H-l), 
7.34 (2H, d, J8.0 Hz, H-2’, 6’), 8.29 (2H, d, J 8.0 Hz, H-3’, 5’), 10.45 (1H, s, NH).
Ar-(4-aminophenyl)cyclohexanecarboxamide (94)10
NH
Prepared from (93) using general procedure VIII (yield 75%). !H NMR (DMSO-^): 
6 1.08-1.70 (10H, m, H-2-6), 2.31 (1H, m, H-l), 4.80 (2H, s, NH2), 6.50 (2H, d, J8.0 
Hz, H-3’, 5’), 7.34 (2H, d, J8.0 Hz, H-2’, 6’), 9.35 (1H, s, NH).
2-(l-(2-(4-(Cyclohexanecarboxamido)phenylamino)-2-oxoethyl)cyclopentyl)acetic 
acid (95)
OH
C22H30N2O4, MW: 386.48 
Prepared from (94) and 3,3-tetramethyleneglutaric anhydride using general procedure IX 
(yield 54 %). m.p. 204-206 °C, 'H NMR (DMSO-</d): 8 1.16-1.40 (6H, m, H-4”, 5”, 6”),
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1.54- 1.75 (12H, m, H-4, 5, 6, 7, 3”, 7”), 2.31 (1H, m, H-2”), 2.48 (4H, s, 2 x CH2), 7.45- 
7.51 (4H, m, H-l’, 2’, 3’,4’), 9.68 (1H, s, NH), 9.74 (1H, s, NH), 12.03 (1H, bs, COOH). 
13C NMR (DMSO-rf*): 6 23.66, 23.66, 25.22, 25.22, 25.39, 29.13,29.13, 37.15, 37.16, 
42.15,43.04,43.76,44.74, 119.34,119.34, 119.52, 119.52, 134.30,134.81, 169.80, 173.38
173.89. CHN Anal. Calcd for C, 68.37; H, 7.82; N, 7.24. Found: C 68.19; H, 7.91; N, 
7.22%.
jV-(3-Nitrophenyl)cyclohexanecarboxamide (96)
NO;
Prepared from 3-nitroaniline and cyclohexanecarbonyl chloride using general procedure 
VII (yield 86%). NMR (DMSO-rf*): 6 1.20-2.02 (10H, m, H-2-6), 2.47 (1H, m, H-l), 
7.14 (1H, m, Ar-H), 7.51 (1H, m, Ar-H), 8.36 (1H, m, Ar-H), 8.72 (1H, m, Ar-H), 10.49 
(1H, s, NH).
7V-(3-Aminophenyl)cyclohexanecarboxamide (97) 10
Prepared from (96) using general procedure VIII (yield 75%). *H NMR (DMSO-^): 
6 1.20-1.98 (10H, m, H-2-6), 2.45 (1H, m, H-l), 5.12 (2H, s, NH2), 6.22 (1H, t, J  8.0 Hz, 
Ar-H), 6.75 (1H, d, J  8.0 Hz, Ar-H), 6.80-6.93(2H, m, 78.0 Hz, Ar-H), 9.49 (1H, s, NH).
(5)-4-Nitro-V-(l-p-tolylethyl)benzamide (99)
o
Prepared from (S)-1 -p-tolylethanamine and 4-nitrobenzoylchloride using general 
procedure VII (yield 73%). *H NMR (DMSCMs): 6 1.52 (3H, s, CH3), 2.25 (3H, s,
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CH3), 5.11 (1H, m, H-l”), 7.17 (2 H, d, J 8.0 Hz, H-3” , 4”), 7.25 (2 H, d, J 8.0 Hz, H- 
2” , 5”), 8.16 (2 H, d ,J 8.0 Hz, H-2’, 3’), 8.35 (2 H, m, H-l’, 4’), 9.10 (1H, s , NH).
6S)-4-Amino-iV-(l-p-tolylethyl)benzamide (100)
o
Prepared from (99) using general procedure VIII (yield 68%). *H NMR (DMSO-^): 6 
1.38 (3H, s, CH3), 2.22 (3H, s, CH3), 5.06 (1H, m, H-l” ), 5.55 (2H, bs, NH2), 6.51 (2 H, 
d, J 8.0 Hz, H-l’, 4’), 7.06 (2 H, d, J8.0 Hz, H-3” , 4”), 7.25 (2 H, d,78.0 Hz, H-2’, 3’), 
7.53 (2 H, m, H-2” , 5”), 8.21 (1H, s, NH).
6S)-3,3-Dimethyl-5-oxo-5-(4-(l-p-tolylethylcarbamoyl)phenylamino)pentanoic acid 
(101)
= o
C23H28N2O4, MW: 396.48 
Prepared from (100) and 3,3-diamethylglutaric anhydride using general procedure IX 
(yield 53%). *H NMR (DMSO-</*): 6 1.10 (6H, s, 2 x CH3), 1.44 (3H, m, CH3), 2.26 
(3H, s, CH3), 2.38 (4H, s, 2 x CH2), 5.13 (1H, m, 1”), 7.12 (2H, d, J  8.0 Hz, H-3”, 4”), 
7.26 (2H, d, J  8.0 Hz, H-2”, 5”), 7.67 (2H, d, J  8.5 Hz, H-l ’, 4’), 7.84 (2H, d, J  8.5 Hz, 
H-2’, 3’), 8.60 (1H, d, J8.0 Hz, NH), 10.05 (1H, s, NH), 11.95 (1H, bs, COOH).
(lS)-2-(l-(2-Oxo-2-(4-(l-/7-tolylethylcarbamoyl)phenylamino)ethyl)cyclohexyl)acetic 
acid (102)
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C26H32N2O4, MW: 436.54
Prepared from (94) and 3-oxaspiro[5.5]undecane-2,4-dione using general procedure IX 
(yield 58%). *H NMR (DMSO-tf*): 6  1.34-1.49 (13 H, m, H-4, 5, 6 , 7, 8 , CH3), 2.26 (3H, 
s, CH3), 2.50 (4 H, s, 2 x CH2 ), 5.13 (1H, m, 1”), 7.11 (2H, d, J  8.0 Hz, H-3”, 4”), 7.26 
(2H, d, J  8.0 Hz, H-2”, 5”), 7.67 (2H, d, J  8.5 Hz, H-l’, 4’), 7.83 (2H, d, J  8.5 Hz, H- 
2 \ 3’), 8.59 (1H, d, J  8.0 Hz, NH), 10.06 (1H, s, NH), 11.99 (1H, bs, COOH). 13C NMR 
(DMSO«fc):S 20.57, 21.03,22.23,23.65, 23.68, 37.22, 40.00, 41.99, 42.18,43.02,43.85, 
47.99, 118.16, 118.16,125.95,128.10, 128.10,128.68, 128.68, 128.92, 135.48, 141.98, 1 
42.11, 166.15,171.05,174.31.
6S>2-(l-(2-Oxo-2-(4-(l-/Molylethylcarbamoyl)phenylamino)ethyl)cyclopentyl)acetic 
acid (103)
C25H30N2O4, MW: 422.52
Prepared from (100) and 3,3 -tetramethyleneglutaric anhydride using general procedure 
IX (yield 48%). 'H NMR (DMSO-rf„): 6 1.14-1.63 (9H, m, H-4, 5, 6, 7, CH3), 2.26 (3H, 
s, CH3), 2.48 (4 H, s, 2 x CH2), 5.12 (1H, m, 1”), 7.12 (2H d, J  8.0 Hz, H-3”, 4”), 7.26 
(2H, d, J  8.0 Hz, H-2”, 5”), 7.65 (2H, d, J  8.5 Hz, H-l’, 4’), 7.82 (2H, d, J  8.5 Hz, H-2’, 
3’), 8.58 (1H, d, J  8.0 Hz, NH), 10.03 (1H, s, NH), 11.98 (1H, bs, COOH).l3C NMR 
(DMSOd«):6 20.57,22.21,23.61,23.64,37.20,40.01,41.99,42.16,42.98,43.84,47.97, 
118.15,118.15,125.96,128.10,128.10, 128.67, 128.67,128.82,135.48, 141.66,141.98, 
164.85,170.50,173.38.
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2-(l-(2-(4-Acetamidophenylamino)-2-oxoethyl)cyclopentyl)acetic acid (104)
OH
A
H
C17H22N2O4, MW: 358.47
Prepared from iV-(4-aminophenyl)acetamide and 3,3-tetramethyleneglutaric anhydride 
using general procedure IX (yield 54 %). m.p. 198-199°C, NMR (DMSO-^): 6 1.57- 
1.63 (8H, m, H-4, 5, 6, 7), 2.01 (3H, s, CH3), 2.48 (4H, s, 2 x CH2 ), 7.47 (4H,s , H-l’,2\ 
3’,4’), 9.75 (1H, s, NH), 9.83 (1H, s, NH), 11.99 (1H, bs, COOH). 13C NMR (DMSOrf*): 
6 23.65,23.65,23.82, 37.15,42.14,43.05,43.75, 66.32, 119.28, 119.28, 119.59, 119.59, 
134.40, 34.64,67.88,169.83,173.39. CHN Anal. Calcd for C, 64.13; H, 6.96; N, 8.79. 
Found: C 64.28; H, 7.03; N, 8.89 %
5-(4-(Cyclohexanecarboxamido)phenylamino)-3,3-dimethyl-5-oxopentanoic acid 
(105)
C20H28N2O4, MW: 360.45
Prepared from (94) and 3,3-dimethylglutaric anhydride using general procedure IX (yield 
65%). m.p. 184-186°C, *H NMR (DMSO-</*): 6 1.08 (6H, s, 2 x CH3), 1.09- 1.40 (6H, 
m, H-4”, 5”, 6”), 1.65-1.78 (4H, m, H-3”, 7”), 2.29 (1H, m, H-2”), 2.33 (4H, s, 2 x CH2), 
7.45-7.52 (4H, m, H-l’,2’, 3’,4’), 9.69 (1H, s, NH), 9.75 (1H, s, NH), 11.99 (1H, bs, 
COOH). ,3CNMR (DMSO-</5): ,6 25.22, 25.22, 25.38, 27.23, 27.23, 29.13,29.13, 32.53,
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44.74,45.17,47.14,119.35,119.35, 119.65, 119.65, 134.24,134.86, 169.40,172.99, 173. 
90. CHN Anal. Calcd for C, 66.64; H, 7.83; N, 7.77. Found: C 66.38; H, 7.76; N, 7.84%.
5-(4-Acetamidophenylamino)-3,3-dimethyl-5-oxopentanoic acid (106)
C15H20N2O4 , MW: 292.33
Prepared from N-(4-aminopheny 1)acetamide and 3,3-dimethylglutaric anhydride using 
general procedure IX (yield 66%). m.p. 187-188 °C, NMR (DMSO-*/*): 8 1.10 (6H, 
s, 2 x CH3), 2.12 (3H, s, CH3), 2.37 (4H, s, 2 x CH2 ), 7.45 (4H, s, H -l’,2 \ 3’,4’), 9.76 
(1H, s, NH), 9.81 (1H, s, NH), 11.99 (1H, bs, COOH). I3C NMR (DMSO- 
d6y. 823.83,23.28,27.23,32.54,45.19,47.16,119.28,119.28, 119.62, 119.62,134.35,1 
34.70, 167.86,169.42,172.99. CHN Anal. Calcd for C, 61.63; H, 6.90; N, 9.58. Found: 
C 61.38; H, 6.90; N, 9.57 %.
5-(3-(Cyclohexanecarboxamido)phenylamino)-3,3-dimethyl-5-oxopentanoic acid 
(107)
2 '
o
C20H28N2O4 , MW: 360.45
Prepared from (97) and 3,3-dimethylglutaric anhydride using general procedure IX (yield 
71%). m.p. 113-115 °C, 'H NMR (DMSO-d«): 8 1.09 (6H, s, 2 x CH3), 1.19-1.41 (6H, 
m, H-4”, 5”, 6”), 1.63-1.79 (4H, m, H-3”, 7”), 2.34 (1H, m, H-2”), 2.36 (4H, s, 2 x CHa), 
7.16 (1H, m, Ar-H), 7.21 (1H, m, Ar-H), 7.29 (1H, d, J  8.0 Hz, Ar-H), 7.96 (1H, m, H-
H 2
209
Chapter Ten Experimental section
4’), 9.76 (lH,~s, NH), 9.81 (1H, s, NH), 12.05 (1H, bs, COOH). 13C NMR (DMSO- 
d6y. 6 22.02,25.20,25.38, 27.21, 29.10, 29.10, 32.55,44.75,45.14,47.19,110.31, 113.94, 
114.03, 128.56,128.56,139.26, 139.68, 169.72, 173.01, 174.24.
2-(l-(2-(4-(Cyclohexanecarboxamido)phenylamino)-2-oxoethyl)cyclohexyl)acetic 
acid (108)
OH
C2 3H3 2N2 O4 , MW: 360.45
Prepared from (94) and 3-oxaspiro[5.5]undecane-2,4-dione using general procedure IX 
(yield 54%). m.p. 221-223°C, NMR (DMSO-fifc): 6 1.07-1.51 (16H, m, H-4, 5, 6, 7, 
8, 4”, 5”,6”), 1.63-1.79 (4H, m, H-3”, 7”), 2.26 (1H, m, H-2”), 2.47 (4H, m, 2 x CH2), 
7.49 (4H, m, H -l’, 2 \  3’,4’), 9.68 (1H, s, NH), 9.75 (1H, s, NH), 11.98 (1H, bs, COOH). 
13C NMR (DMSOrf*): 6 21.05,25.22,25.22,25.39, 25.57, 29.13, 35.07, 35.18,40.00,41 
.12,43.03, 44.74, 56.00,119.34,119.34,119.54, 119.54, 134.24, 134.86, 169.60, 173.24,
173.89. CHN Anal. Calcd for C, 68.97; H, 8.05; N, 6.99. Found: C 68.56; H, 7.97; N,
7.06 %.
2-(l-(2-(3-(Cyclohexanecarboxamido)phenylamino)-2-oxoethyl)cyclopentyl)acetic 
add (109)
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2 '
HN NH
OH
C2 2H3 0N2 O4 , MW: 386.48
Prepared from (97) and 3,3-tetramethyleneglutaric anhydride using general procedure IX 
(yield 43%). m.p. 142-143°C, *11 NMR (DMSO-</*): 5 1.25-1.41 (6 H, m, H-4”, 5”, 6 ”), 
1.55- 1.79 (12H, m, H-4, 5, 6 , 7, 3”, 7”), 2.50 (1H, m, H-2”), 2.51 (4H, m, 2 x CH2), 7.16 
(1H, t, J  8.0 Hz, Ar-H), 7.19 (1H, m, Ar-H), 7.28 (1H, d, J  8.0 Hz, Ar-H), 7.95 (1H, m, 
H-4’), 9.76 (1H, s, NH), 9.80 (1H, s, NH), 12.01 (1H, bs, COOH). 13C NMR (DMSO- 
d6): 6  23.60, 23.66,25.20, 25.38,29.10,37.15, 37.14, 40.00, 42.10, 43.04,43.77,44.75,1 
10.28, 113.90, 113.97, 128.56,128.56, 139.31, 139.67, 170.12, 173.39,174.23.
2-(l-(2-(4-acetamidophenylamino)-2-oxoethyl)cyclohexyl)acetic acid (110)
OH
1 H
O 2
A
H
C18H2 4N2 O4 , MW: 332.39
Prepared from Ar-(4-aminophenyl)acetamide and 3-oxaspiro[5.5]undecane-2,4-dione 
using general procedure IX (yield 72%). m.p. 213-215 °C, NMR (DMSO-</*): 6  1.36- 
1.49 (10H, m, H-4, 5, 6 , 7, 8 ), 2.01 (3H, s, CH3), 2.51 (4H, s, 2 x CH*), 7.48 (4H,s , H- 
r,2’, 3’,4’), 9.76 (1H, s, NH), 9.82 (1H, s, NH), 11.96 (1H, bs, COOH).l3CNMR 
(DMSO-rf«): 6  18.51,21.05,21.05,23.82,35.08,35.18,41.12,43.04,56.00,119.28,119. 
.28, 119.60, 119.60,134.34,134.70,167.86,169.62,173.24. CHN Anal. Calcd for C, 
65.04; H, 7.28; N, 8.42. Found: C 64.85; H, 7.35; N, 8.46 % .
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Conclusion
This project was divided into two main parts and the findings can be briefly 
summarised as the following:
Part I: The synthesis and biological evaluation o f novel benzimidazole and indole 
based antitumour compounds
• A new series of (substituted) 2-phenylbenzimidazols and indoles bearing 
oxygenated substituents on the phenyl ring has successfully been synthesised.
• The new compounds were less active than the former benzothiazole series
when tested in vitro against four human cancer cell lines.
• Incorporation of sulfonyl substituents enhanced the activity of these series.
• The most active compounds in the N-substituted benzimidazole and indole
series (shown below) exhibit low and sub-micromolar GI50 values 
respectively.
OMeOMe OMe
OMeOMe OMe
MeMe Me
Part II: The design and synthesis o f novel small molecule inhibitors of the 
Dishevelled PDZ domain for use as selective antitumour agents
• Different molecular modelling studies were performed and the potential hits 
were successfully synthesised.
• Biochemical binding assays shows that one of the hit compounds binds to Dvl 
PDZ.
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Further structural optimisation studies of the identified hit compound were 
carried out based on molecular dynamic simulations to identify more potent 
inhibitors and the biological testing are underway.
